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Summary          V  
Summary 
The ability of Streptococcus pyogenes to adapt to different host environments represents a key 
feature during the infection process of this important human pathogen. Two-component 
regulatory systems (TCS) act as sensors and communicators of environmental changes, and 
their contribution to streptococcal pathogenesis has so far been poorly investigated. 
Therefore, the main objective of this thesis was the identification and characterization of these 
systems in S. pyogenes with respect to their potential role as contributors to streptococcal 
virulence. 
Genome analysis of a sequenced S. pyogenes strain revealed the presence of thirteen putative 
TCS. Five streptococcal mutants with deletions in two-component systems were constructed 
and investigated for different virulence behaviour in comparison to the parental strain. The 
mutants deficient in the TCS FasCA, TCS09, TCS07, or TCS13 were less resistant to killing 
by human phagocytic cells, indicating a role in virulence. The two most attenuated deletion 
mutants, deficient in TCS07 and TCS13, respectively, were characterized in more detail. 
The TCS07 mutant showed a loss of virulence in a mouse model of skin infection, expressed 
by survival of infected animals, development of smaller skin lesions, and a rapid clearing of 
the mutant from systemic organs and bloodstream in comparison to the wildtype strain. On 
the molecular level, the mutant lacked transcription of two major antiphagocytic virulence 
factors: M-protein and streptococcal inhibitor of complement (SIC). As expected, absence of 
M protein was accompanied by the loss of fibrinogen binding capability of the mutant.  
Additionally, the mutant failed to induce encapsulation with hyaluronic acid under in vivo 
conditions as it was observed for the wildtype strain. 
The mutant deficient in TCS13 exhibited a reduced virulence in the investigated mouse skin 
model, as well, seen by survival of infected mice and clearing of bacteria from systemic 
organs and bloodstream when compared to the parental strain. Using a mouse model of 
intraperitoneal infection, the enhanced killing of this mutant within murine 
polymorphonuclear leukocytes (PMNs) could be demonstrated. Molecular analysis showed a 
reduced ability of this mutant to bind fibrinogen, which was found to be due to a release of 
the N-terminal part of the streptococcal M protein from its surface. Additionally, as with the 
TCS07 deletion strain, in vivo-induction of hyaluronic acid encapsulation did not occur in the 
TCS13 mutant. Thus, it was demonstrated that the two-component systems TCS07 and 
TCS13 of S. pyogenes are involved in regulation and posttranslational alterations of major 
streptococcal virulence factors and are required for full virulence of S. pyogenes in vivo. 
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1. Introduction 
Streptococcus pyogenes (Lancefield Group A streptococcus, GAS) is a gram-positive, 
extracellular human pathogen. The name already describes its characteristic appearance of 
long chains (Fig. 1A): ‘streptos’ is the Greek word for “twisted”; ‘coccus’ means “berry”. 
From the metabolic side, S. pyogenes belongs to the group of homofermentative lactic acid 
bacteria, generating this acid as main product. Furthermore, it is non-spore-forming, immotile, 
aerotolerant, and catalase-negative. A characteristic feature of S. pyogenes is the ability to 
lyse erythrocytes, a phenomenon called haemolysis. When grown on blood agar plates, this 
results in a clear zone surrounding growing colonies, also referred to as β-haemolysis (Fig. 
1B). This β-haemolysis of S. pyogenes can clearly be distinguished from the α-haemolysis 
produced by S. pneumoniae, which induces colony-surrounding greenish zones. 
 
 
  
 
 
 
 
 
 
 
 
 
S. pyogenes is an exclusive human pathogen colonizing the throat and skin. There it can cause 
infections with a wide range of severities, ranging most commonly superficial infections such 
as pharyngitis, scarlet fever, or impetigo (47), to deep and life-threatening infections, such as 
bacteraemia and cellulitis, streptococcal toxic shock syndrome (STSS), and necrotizing 
fasciitis (56). Nonsuppurative autoimmune sequelae, such as rheumatic fever (RF) and 
glomerulonephritis can also develop following infections with S. pyogenes (47, 206) and are 
of major concern in developing countries. Annually, over 10 million GAS infections occur, 
most of them are non-severe throat and skin infections (press release, WHO 1999). However, 
since the mid-1980s an unexplained, worldwide resurgence of severe streptococcal infections 
has been observed, including systemic diseases, as well as outbreaks of STSS (9, 42, 208). 
These incidences, especially STSS, are associated with a high mortality rate of 30 - 60% since 
A  
Figure 1. (A) Scanning electronmicroscopic photograph of a typical chain of S. pyogenes (by M. Rohde). 
(B) Clear β-haemolysic zones surrounding colonies of S. pyogenes on blood agar plate. 
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there is no true therapeutic remedy (201). In developing countries, rheumatic fever is a major 
cause of cardiovascular mortality and remains an endemic disease; from 100000 school-aged 
children, annually 100 - 200 are affected by this streptococcal sequelae (164). 
Regarding the treatment of streptococcal infections, penicillin is still the antibiotic of choice, 
and surprisingly no resistant strains have been reported up to now (96, 138). Nevertheless, 
failure to eradicate infection after penicillin-treatment has been reported in up to 25% of GAS 
pharyngitis (110, 173), suggesting that this pathogen has developed additional mechanisms to 
circumvent its effects. It has been proposed that intracellular survival of bacteria, as well as 
the degradation of this antibiotic by β-lactamase-producing coexisting commensals might be a 
reason (176, 194). 
The ability of S. pyogenes to sense and respond to environmental signals is a key component 
to streptococcal pathogenicity. During infection, streptococci gain access to different 
compartments of the host where they propagate and persist. Therefore, S. pyogenes elaborated 
a broad range of virulence functions, which contribute to colonization or invasion of the 
epithelium, evasion of the host immune system, and dissemination from the local infection 
site of infection in order to cause more severe disease (47). These virulence functions are 
regulated by complex and overlapping regulatory circuits, which confer S. pyogenes a great 
flexibility to express different sets of genes at various host sites (47, 121). So far, only few of 
the regulatory systems of S. pyogenes have been identified and characterized. Therefore, the 
main objective of this study was to gain further insights into the underlying mechanisms of 
streptococcal virulence gene regulation with the focus on two-component regulatory systems 
(TCS), which contribute to signal perception and adaptation to environmental signals (204). 
Additionally, an enhanced understanding of the role of these systems in streptococcal 
virulence at specific host sites could provide crucial information for the identification of new 
targets for therapeutic intervention.   
1.1. Virulence factors of S. pyogenes 
Upon entering the host, several steps are crucial for S. pyogenes to establish an infection. The 
first step consists of the colonization of host surfaces, mediated by bacterial adhesins binding 
to the epithelium of the human respiratory mucosa or skin. Simultaneously, S. pyogenes needs 
to circumvent the host defence mechanisms, which includes (i) the avoidance of phagocytic 
uptake, (ii) survival within phagocytic cells, and (iii) degradation of immunoglobulins of the 
acquired immune system. All these processes are carried out by regulated virulence factors 
that enable the successful colonization and survival of S. pyogenes.  
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1.1.1. Adherence and colonization factors of S. pyogenes 
Adhesion to host epithelial cells is the initial step for bacterial colonization and it protects S. 
pyogenes from being cleared by flow mechanisms of the mucosa and saliva (47). A large 
number of proteins involved in bacterial adhesion to host cells via the interaction with 
extracellular matrix proteins such as vitronectin, collagen, and laminin have been described, 
and the bacterial determinants binding either fibronectin or fibrinogen are the best 
characterized ones (107). Since S. pyogenes has a variety of adhesins, it is believed that the 
differential expression helps to colonize different niches of the host (216).  
1.1.1.1. Fibronectin binding proteins 
Fibronectin is a glycoprotein that is present in plasma, as well as in the extracellular matrix of 
epithelial cells (37). Several proteins expressed by S. pyogenes have the ability to bind 
fibronectin, such as M1 and M3 protein (46, 189; see section 1.1.2.2.), Streptococcal 
fibronectin binding protein I (SfbI) (209) and its homologue protein F1 (85), as well as PFBP 
(185), SOF (44, 119;), and the glyceraldehyde phosphate dehydrogenase (165). All of these 
proteins are surface-associated and most of them contain an LPXTG-motif, linking them 
covalently to the cell wall (161). Additionally, the fibronectin-binding region is in some of 
these proteins conserved and has homologies to fibronectin-binding repeats of other bacteria. 
Some fibronectin-binding proteins, such as SfbI and M1 protein can act as invasins and 
mediate internalization of S. pyogenes within epithelial cells (46, 157). The significance of 
this internalization process during streptococcal infection has been discussed controversially 
and the possibility that invading host cells can be used by S. pyogenes to acquire protection 
against antibiotic treatment has been hypothesized (176). 
1.1.1.2. Fibrinogen binding proteins 
Fibrinogen is a glycoprotein present in large amounts in plasma, where it is a mediator of the 
blot-clotting cascade and wound healing (37). Although a number of streptococcal 
fibronectin-binding proteins can also bind fibrinogen (e.g. FBP54 (43)), the M protein seems 
to be the major determinant of S. pyogenes involved in the fibrinogen-binding activity (37). 
Functionally, the binding of fibrinogen to the streptococcal surface renders the bacterium 
resistant to uptake by host phagocytic cells (48, 183, 227). Thus, Whitnack and Beachey (227) 
have proposed that fibrinogen-acquisition via the M protein impedes the access of 
complement proteins to streptococcal cell wall structures, therefore protecting S. pyogenes 
against opsonization by complement. Additionally, the binding of fibrinogen leads to the 
1. Introduction          4 
acquisition and activation of host plasminogen, which in turn is cleaved to plasmin by the 
streptococcal streptokinase (see section 1.1.3.3.), and might enhance bacterial invasion or 
movement of streptococci through tissue barriers (25, 38). 
1.1.2. Antiphagocytic factors 
The ability of Streptococcus pyogenes to survive and grow in whole human blood has long 
been known and is one of the most prominent features of this pathogen (126). The molecular 
basis of this resistance to phagocytosis is the expression of several factors important to 
circumvent the innate and adaptive host immune system. A number of host immune cells are 
important for the elimination of bacteria, above all macrophages, representing the first line of 
defence at early time-points of infection, and polymorphonuclear leukocytes (PMNs), which 
infiltrate infected tissues to efficiently kill invading streptococci (78, 220). The host 
complement system plays an additional essential role in host defence against streptococci and 
in the inflammatory process. Many complement proteins are involved in opsonization of 
microorganisms, rendering them susceptible to phagocytosis, killing and elimination (140). 
The major streptococcal factors responsible for resistance against uptake and killing by host 
phagocytic cells will be described in this chapter. 
1.1.2.1. Hyaluronic acid capsule 
Hyaluronic acid capsule is a surface-located polysaccharide, which is composed of repeated 
units of glucuronic acid and N-acetylglucosamine (207). S. pyogenes strains expressing large 
amounts of capsule have a mucoid phenotype on culture plates, and this high expression has 
been associated with invasive streptococcal infections (108). Recently, Dinkla et al., (51) 
identified the role of the hyaluronic acid capsule in binding of streptococci to human collagen. 
The main contribution of the capsule to virulence, however, seems to be the involvement in 
rendering GAS resistant to killing by human blood leukocytes. Mucoid strains are highly 
resistant to phagocytosis, whereas loss of the capsule by a mutation within the capsule gene 
cluster (has operon) or by enzymatic treatment results in a higher susceptibility to 
phagocytosis in vitro (48, 70). Medina et al., (152) proposed that the capsule is upregulated 
during intracellular location of S. pyogenes within PMNs, since these bacteria underwent a 
phenotypic switching from non-encapsulated to mucoid. Therefore, the upregulation of 
hyaluronic acid capsule might contribute to the ability of S. pyogenes to survive after 
phagocytosis. The role of the capsule in in vivo models of infection has also been shown, and 
a number of studies have reported encapsulated Group A streptococci to exhibit an enhanced 
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virulence (8, 104, 152, 223, 224).  
1.1.2.2. M protein   
The M protein is the best-characterized streptococcal virulence factor, and used for the 
differentiation of Group A streptococcal serotypes (125). It is covalently anchored to the 
bacterial surface by its C-terminus and is composed of four repeat blocks named A-D, all 
differing in size and sequence (95). The A-repeats are a hypervariable part of the protein, 
followed by variable B repeats and conserved C repeats. The D repeats are highly conserved 
and the proline-/glycine-rich region is with high probability located within the peptidoglycan 
layers (68) (Fig. 2). Due to a repeated periodicity of nonpolar amino acids, the M protein has 
an α-helical, coiled-coiled structure like mammalian tropomyosins, and appears as fibrils on 
the surface of Group A streptococci (172). During infection, antibodies against the N-terminal 
part of this protein are rapidly generated, leading to protection against Group A streptococcal 
infections of the same serotype (19). Consequently, the N-terminal part of the M protein is 
exposed to high selection pressure and undergoes frequent size variations, especially by 
insertion and deletions within the variable repeat regions (68).  
The contribution of the M protein to bacterial virulence is diverse and ranges from adhesion 
to and invasion into host cells (29, 46), to tissue penetration (16), and antiphagocytic activity 
toward the innate and adaptive immune response (86, 98). The antiphagocytic effect of the M 
protein is mainly due to its ability to bind fibrinogen (see section 1.1.1.2.), as well as host 
complement regulatory protein factor H, leading to an inhibition of complement function (98).  
M protein has been found to be under the regulatory control of Mga (multiple regulator of 
GAS, 1.3.2.1.), which is a single regulator controlling the transcription of several virulence-
associated genes (121). Since the M protein leads to the generation of protective antibodies 
against streptococcal infections (19), development of vaccine prototypes based on this protein 
are under investigation (49).  
 
N C
A-Repeats B-Repeats C-Repeats D-Repeats Pro/
Gly
Membrane 
Anchor
ConservedVariable
Hyper-
Variable
Wall-associated
Figure 2.  Schematic illustration of the structure of the streptococcal M-protein (based on Fischetti, 1989).  
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1.1.2.3. Streptococcal inhibitor of complement-mediated lysis (SIC) 
Protein SIC, originally described by Åkesson et al. (2), is a secreted protein that is 
predominantly present in S. pyogenes strains of the M1 serotype. This molecule exhibits a 
great polymorphism, higher than for any other streptococcal protein so far investigated (205), 
with almost 300 variants already identified (92). Such a high level of polymorphism is usually 
found in genes encoding for proteins that interact with the host environment (158). The 
function of SIC lies within its ability to bind regulators of the complement system, such as the 
human plasma proteins clusterin and HRG (histidine-rich glycoprotein) (2). This interaction 
leads to an inhibition of complement-mediated lysis of erythrocytes by incorporation of SIC 
into complement complexes (2). Additionally, SIC has an inhibitory effect towards two 
antibacterial peptides found in human neutrophils, α-defensin and LL-37 (74), as well as 
towards lysozyme and secretory leukocyte proteinase inhibitor (SLPI), which are components 
of the mucosal innate immune response (65). Hoe and colleagues (93), on the other hand, 
were able to show that the interaction of internalized SIC with the PMN component ezrin 
altered cellular processes critical for efficient bacterial internalization and killing. Therefore, 
in addition to the modulation of complement leading to evasion of the immune system, SIC is 
also capable of preventing the bactericidal activity of a number of host proteins.  
1.1.2.4. C5a-peptidase 
The streptococcal serine protease C5a peptidase (ScpA) was originally identified by Wexler et 
al. (225), who described its endopeptidase activity towards C5a, a 74-residue chemotactic 
protein of the complement (64). This streptococcal surface-bound peptidase was shown to 
remove 6 amino acids from the C terminus of C5a, rendering it unable to interact with PMN 
receptors and therefore inhibiting the recruitment of phagocytic cells to the infection site. In 
animal experiments, intraperitoneal infection of C5a peptidase lead to a delayed accumulation 
of PMNs in the peritoneal cavity of mice, stressing the relevance of this activity for 
streptococcal pathogenesis. Transcription of C5a peptidase is under control of Mga (36; see 
section 1.3.2.1.). Interestingly, C5a peptidase can also be regulated at the postranslational 
level through proteolytic cleavage by the cysteine protease SpeB (17; see section 1.1.2.5).  
1.1.2.5. Cysteine protease SpeB 
SpeB can be found as a secreted, as well as a surface-bound cysteine protease (105), and 
belongs to the streptococcal superantigens, which are further discussed in section 1.1.3.2. The 
SpeB gene is highly conserved (231), and under regulatory control of Mga (174; see 1.3.2.1.), 
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Rgg/RopB (regulation of proteinase) (135; see section 1.3.2.3.) and Pel (pleotropic effect 
locus) (130; see section 1.3.2.4.). Its transcription is induced during early stationary growth 
phase, but downregulated in the presence of glucose (32). SpeB is secreted as partially 
inactive zymogen and becomes enzymatically active after autocatalysis under reducing 
conditions (28). Functionally, this protease targets many host molecules, such as human fibrin 
(58), the antibacterial peptide LL-37 (191), IgG, as well as IgA, IgM, IgD, and IgE. The 
cleavage of IgG occurs at a defined site in the hinge region (40) and leads to a reduced 
capacity of opsonizing IgGs to kill S. pyogenes in human blood (41). The degradation of the 
other immunoglobulin-types seems to take place in a non-specific manner (40). Therefore 
SpeB seems to contribute to the resistance of S. pyogenes to phagocytosis in the presence of 
opsonizing antibodies.  
However, SpeB does not only target host factors, but also other streptococcal surface proteins, 
such as C5a peptidase (1.1.2.4) and the IgG-Fc receptor binding surface molecule, protein H 
(1). The M protein can also be a substrate for SpeB, leading to the release of two internal 
fibrinogen-binding fragments after proteolytic degradation (17). Raeder et al. (178) associated 
the cleavage of 24 amino acids of the M protein’s N-terminus by SpeB with decreased IgG 
binding properties and postulated a protective role of this action against opsonizing antibodies 
specifically recognizing this part of the M protein. Therefore, SpeB allows S. pyogenes to 
posttranslationally alter the activity of a number of its own proteins, contributing to a faster 
adaptation to different niches of the host. Additionally, modulation of host proteins necessary 
for recognition and killing of bacteria improves the ability of S. pyogenes to survive within its 
host. 
1.1.3. Other virulence factors 
1.1.3.1. Streptolysin O (SLO) and Streptolysin S (SLS) 
SLO and SLS are streptococcal exotoxins with haemolytic activities. SLO is present in nearly 
all S. pyogenes strains and is active in its reduced state, but rapid inactivation occurs in the 
presence of oxygen (3). It has high binding affinity to cholesterol, resulting in disruption of 
the eukaryotic cell membrane and subsequent lysis of the target cell (3). SLS, on the other 
hand is an oxygen-stable protein that is produced by all strains and is responsible for the β-
haemolytic activity seen on blood agar plates (195). The contribution of both streptolysins in 
streptococcal virulence using animal models of infections has been extensively demonstrated 
(20, 131). 
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1.1.3.2. Streptococcal Pyrogenic Exotoxins (SPEs) 
S. pyogenes produces pyrogenic exotoxins with high similarities to staphylococcal 
enterotoxins (146). The expression of SPEs is associated with scarlet fever, as well as with 
streptococcal toxic shock syndrome (STSS) (42, 159). The role of these superantigens in 
streptococcal virulence lies in their ability to strongly induce stimulation of T-cells, which in 
turn leads to the release of large amounts of inflammatory cytokines and capillary leakage 
(226). SpeA, B, and C are the best characterized streptococcal exotoxins and due to its 
antiphagocytic effects, SpeB is discussed in more detail in section 1.1.2.5. Whereas the gene 
encoding for SpeB is present in all strains of S. pyogenes, the presence of SpeA and SpeC is 
variable among different GAS strains since they are bacteriophage-encoded (79, 109).  
1.1.3.3. Streptokinase 
Streptokinase of S. pyogenes is a secreted plasminogen-binding protein, which is found in 
most streptococcal isolates (101). Due to the activity of this streptococcal protein, 
plasminogen is activated by its conversion to plasmin (134). The expression of streptokinase 
has been associated with the pathogenesis of acute poststreptococcal glomerulonephritis (141) 
and its contribution to streptococcal virulence and tissue invasion has been proposed (133, 
123). 
1.2. Bacterial signal transduction by Two Component Systems (TCS) 
In order to survive in diverse and changing environments, bacteria have developed efficient 
regulatory systems to sense specific signals of their environment and to adapt their gene 
expression accordingly. Most of these systems are two component systems that are 
sophisticated signalling systems found mainly in eubacteria and archae, but also in a few 
eukaryotic organisms, such as yeasts and plants (203). Environmental signals can be of 
various natures, such as temperature, osmolarity, pH, light, oxygen, or nutrients, and even 
bacteria-derived quorum-sensing molecules, allowing inter- and intra-species communication 
(87). The regulatory outcome elicited by these systems is diverse and can range from 
sporulation (122), chemotaxis (5), and nitrogen regulation (83) to competence for genetic 
transformation (171), synthesis of exoproteins (142), and resistance to chemotherapeutics 
(61). In bacteria, the number of TCS change depending of the bacterial species: there are none 
TCS present in Mycoplasma genitalium (82), about 30 in B. subtilis (118), while 31 systems 
have been described in E. coli (232), and 13 in S. pneumoniae (127). These TCS are 
composed of at least two proteins: a histidine kinase (HK), and a response regulator (RR). 
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The histidine kinase is in most cases a transmembrane protein with a conserved kinase core; it 
functions as sensor molecule. The response regulator contains a conserved regulatory domain 
and most commonly modulates the transcription of target genes. The prototypic structure of a 
bacterial TCS is depicted in Fig. 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generally, the N-terminal sensing domain of the HK is extracellularly located, or in the case 
of gram-negative bacteria, periplasmatically. The sensing domains of different TCS share 
little homologies since they respond to a variety of signals. Signals inducing activation of 
HKs are still unknown for most of the described TCS. The HKs can have two or multiple 
transmembrane helices; its C-terminus forms an independently folded domain that is located 
within the cytoplasm and comprises the kinase domain, which can bind ATP and has 
autokinase activity. Upon signal perception, it undergoes autophosphorylation at a highly 
 
Figure 3. Schematic structure of a bacterial TCS: the histidine kinase as a transmembrane protein with 
its sensing- (SD) and kinase (KD) domain. The specific environmental signal induces the 
autophosphorylation of a histidine residue within the intracellularly located KD, the phosphoryl-group 
is transferred to an aspartate within the cognate response regulator, which harbours a regulatory- (RD), 
and an effector domain (ED). Phosphorylation of the response regulator can either result in DNA-
binding, or enzymatic activity. 
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conserved histidine residue within the kinase core; a glycine-rich motif at the C-terminus is 
thought to bind the ATP needed for the phosphorylation activity. All phosphorylation steps 
require the presence of divalent cations, and it has been speculated that Mg2+ is the most 
relevant cation in vivo (203). Although different HKs do not share high sequence homologies, 
so-called homology boxes, which are named due to characteristic conserved residues, can be 
distinguished. These boxes allow the classification into different histidine kinase subfamilies.  
At least five of those homologous regions designated as H-, N, D-, F-, and G- boxes have 
been described; the first one (H) is directly involved in binding of the phosphoryl group, the 
others (N, D, F, and G) are involved in ATP-binding and kinase activity of the HK (204). 
Additionally, HKs contain an α-helical structure composed of a stretch of conserved residues 
beginning approximately 30 residues downstream of the phospho-accepting histidine, 
designated as X-region (82). The X-region seems to play an important structural role, as it 
was described for the HK EnvZ of E. coli (100). Some HKs have been shown to possess 
phosphatase activity towards their cognate RRs (203). 
After signal perception and autophosphorylation of the histidine kinase, the phosphoryl group 
is transferred to the cognate response regulator (RR), which serves as catalyst for this transfer. 
RRs usually consist of two domains: a conserved N-terminal receiver domain, and a variable 
C-terminal effector domain. The phospho-accepting residue of the RR is a conserved 
aspartate present in the receiver domain. After phosphorylation, a high-energy acyl phosphate 
is generated and presumably used as energy source for the conformational change taking 
place on the RR (203). The lifetime of these phospho-aspartates can range from seconds to 
hours (90, 106, 221), and it has also been shown that many RRs have autophosphatase 
activity, thereby decreasing the lifetime of the phosphoprotein (90, 228).  
Although RRs lack homology boxes, the presence of highly conserved single residues has 
been described (204). These include two conserved aspartates located at the N-terminal end of 
the RR, which are thought to be involved in the coordination of the magnesium ions required 
for the phosphorylation process. An additional conserved aspartate functions as phospho-
acceptor and, together with a conserved serine (also often a threonine) and lysine crucial for 
the stability of the conformational change elicited by the phosphorylation event, all five 
residues surround the active site of the regulatory protein. The majority of RRs are 
transcription factors often harbouring a helix-turn-helix (HTH) DNA-binding motif that can 
activate or repress transcription of target genes upon phosphorylation. Some RRs however, 
lack this domain; instead, their C-terminal domain can have enzymatic activities as it was 
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shown for CheB (196).  
Due to homologies within the DNA-binding domain of response regulators, TCS have been 
grouped into four different families (204). These are: (A) The OmpR family, characterized by 
the E. coli osmotic pressure sensor/regulator OmpR and EnvZ (71); (B) The AraC family, 
which was named after AraC, the arabinose operon regulatory protein of E. coli (76); (C) The 
family LuxR, their members have homologue HTH motifs to LuxR of Vibrio fischeri which 
activates the bioluminescence operon (88); and finally (D), the recently named LytTR 
(“litter”) family of response regulators (also known as “Agr”), named after LytT of Bacillus 
subtilis, and LytR of Staphylococcus aureus, which are involved in the regulation cell 
autolysis (162). Since these families have been described, a large number of further TCS have 
been identified with additional features and grouped into many newly established subfamilies, 
which are based on functional, as well as sequence similarities. However, most identified TCS 
belong to the OmpR family, and many of these systems have been shown to be involved in 
nutrient perception and metabolic adaptations (204).   
1.3. Regulatory systems of S. pyogenes 
The genome-sequencing project of Streptococcus pyogenes SF370 (66) has revealed the 
presence of 13 different ORFs with homology to two-component systems (Tab. 1, also see 
section 2.1.). Of all these systems, only the CsrRS-TCS has been characterized in great detail 
(63), two other TCS named Irr/Ihk (63) and FasBCAX (120) have been studied to a lesser 
degree. The TCS SalRK and SrtRK are sensors and regulators in the context of the 
biosynthesis of lantibiotics, which are antibacterial peptides produced by some gram-positive 
bacteria (111, 186).  
 
Tab. 1: Overview of characterized streptococcal two-component systems and regulated proteins. 
 
Besides these 13 TCS, a number of “stand-alone” regulators are also distributed throughout 
the GAS genome and, as for streptococcal TCS, only few have been characterized or shown 
Two-component 
system 
Target protein Environmental Signal Reference 
CsrRS (= CovRS) HasA, Ska, SLS, SpeMF Mg2+ 63, 129  
FasBCAX Fbp54, Mrp, unknown 120 
Irr/Ihk Unknown PMN contact 63, 219  
SrtRK Streptin-associated proteins unkown 222 
SalRK Salivaricin-associated proteins Salivaricin 214 
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to be involved in virulence (Tab. 2). The following section will give an overview on known 
regulators in S. pyogenes, as well as their impact on the expression of virulence factors.  
 
Tab. 2: Overview of characterized streptococcal single regulators and regulated proteins. 
 
1.3.1. Streptococcal TCS 
1.3.1.1. Capsule synthesis regulator/sensor (CsrRS) 
The two-component system CsrRS, also named CovRS for control of virulence genes (63) is 
by far the best characterized TCS in S. pyogenes. It belongs to the OmpR family of TCS and 
has been identified as a repressor of the capsule gene cluster (has region) in different GAS 
serotypes. The has operon is composed of three open reading frames, consisting of the has 
synthase (hasA), UDP-glucose-dehydrogenase (hasB), and pyrophosphorylase (hasC), all 
involved in the synthesis of hyaluronic acid. The response regulator CsrR has been shown to 
directly bind to a consensus element within the has promotor region (18, 129), repressing its 
transcription. This regulatory system critically influences virulence since the capsule is a 
major virulence factor contributing to the outcome of streptococcal infections (104; see 
section 1.1.2.1.). In addition to the regulation of hyaluronic acid capsule expression, CsrRS 
has also been associated with repression of streptokinase, SLS, and superantigens SpeM and F 
(63). Furthermore, genes essential for general stress responses seem to be affected by this 
regulatory system, since a CsrRS mutant was unable to grow at low pH, elevated temperature 
or osmolarity (50). Gene transcription profiling by microarray analysis of a CsrR mutant 
strain revealed that of the whole streptococcal genome, transcription of about 15% of the 
genes, including a number of virulence factors and regulatory systems such as TCS10 and 
Single Regulator Regulated proteins Environmental Signal Reference 
Mga M protein, C5a peptidase, SOF, SIC, 
Mga 
Elevated CO2, iron limitation, 
increased temperature 
168,198 
 
RofA RofA, SfbI, SLS, SpeB, Mga Temperature 69, 199  
Nra Cpa, SfbII, SpeB, SpeA, SLS, Mga unknown 175 
Rgg/RopB M protein, C5a peptidase, HasA, 
SLO, SLS, Mga, FasBCA, Irr/Ihk, 
SalRK, CsrRS 
Temperature 33,135,  
SagA/Pel Ska, SpeB unknown 130 
LuxS SLS, SpeB Autoinducer AI-2 136 
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Irr/Ihk, are affected by this mutation (80). Therefore, it was proposed that CsrRS is a part of a 
more complex regulatory network in GAS (80). The contribution of CsrRS to bacterial 
virulence was evidenced by the more severe ulcer- and lesion development in a skin infection 
model observed after in vivo infection with a strain carrying a mutation in CsrR. The more 
severe phenotype of infection seemed to be due to the higher expression of capsule and SLS 
(60). Additionally, spontaneous mutation of the CsrRS locus, resulting in higher capsule 
expression was frequently observed (59). The CsrRS system is the only TCS in GAS for 
which a molecular environmental signal has been identified. Gryllos et al. (79) observed that 
addition of Mg2+ to the growth medium resulted in repression of the capsule expression by up 
to 80 %, a phenomenon that did not occur in the mutant. However, since the phosphorylation 
events in TCS require the presence of divalent cations (203), the direct interaction of the 
sensor with the proposed stimuli still needs further investigation.  
1.3.1.2. FasBCA(X) 
Unlike the prototypic TCS illustrated in Fig. 2, the FasBCAX system is composed of two 
histidine kinases and one response regulator, suggesting that diverse signals may be needed 
for elicitation of a response. This regulatory system belongs to the LytTR- or Agr-family of 
TCS, which has been associated with the regulation of virulence genes in Staphylococcus 
aureus (167). The main effector of this system named FasX has been identified as an 
untranslated regulatory RNA (120). Disruption of FasBCA resulted in a growth-phase-
dependent reduced expression of the virulence factors streptokinase and SLS, as well as to a 
downregulation of the adhesion proteins FBP54 and MRP (120). Additionally, FasBCA 
expression seems to be influenced by the regulator Rgg (34; see 1.3.2.3). Little is known 
about the role of this TCS in streptococcal virulence. However, the high expression of the 
histidine kinase FasC observed during acute pharyngitis may suggest a putative role of this 
TCS during the infection process (218). 
1.3.1.3. Isp-adjacent RR/HK (Irr/Ihk) 
The Irr/Ihk system (named TCS13 in the work presented here) was initially described by 
Federle et al. (63). They investigated the contribution of this system to the transcription of 
virulence genes encoding the M protein, C5a peptidase, SLO, SLS, hyaluronic acid capsule, 
and streptokinase by a mutagenesis approach, but did not find any significant differences 
between wildtype and mutant. Up to date, the streptococcal virulence factors or other genes 
under direct or indirect regulatory control of this system remain unknown. However, a high 
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expression of Irr/Ihk during acute pharyngitis has been reported (218). Furthermore, the 
activity of this regulatory system seems to be important for the mechanism by which 
intracellularly located S. pyogenes evade killing by human PMNs. This was shown by an 
upregulation of this system during the encounter with human PMNs and the failure of Irr/Ihk 
deficient mutants to survive within PMNs (219). Additionally, Irr/Ihk expression seems to be 
positively influenced by the TCS CsrRS (80). 
1.3.1.4. Lantibiotic-associated TCS 
Lantibiotics are antimicrobial peptides produced by some gram-positive bacteria and are 
active against closely related species. Their name derived from the presence of the modified 
amino acid lanthionine. Lantibiotics are synthesized as propeptides and posttranslationally 
processed (84). The biosynthesis of lantibiotics is depending on the presence of an inducer 
molecule, which is sensed by the corresponding lantibiotic-associated HK, subsequent 
transcription is induced by the RR-activity.  
Salivaricin is described as a lantibiotic produced by Streptococcus salivarius, but is however 
found in many S. pyogenes strains of different serotypes (214). The TCS SalRK lies within 
the salivaricin gene cluster that comprises six other genes involved in the production, 
processing and transport of this lantibiotic. In S. pyogenes strain SF370, the gene encoding the 
salivaricin precursor is transcriptionally inactive due to a deletion within the gene cluster 
(214). In a Streptococcus salivarius strain that harbours the complete salivaricin cluster, the 
involvement of SalRK in salivaricin synthesis, as well as its auto-regulation by external 
salivarcin concentrations has been demonstrated. Additionally, it was speculated that an 
additional, unknown regulator might be involved and the role of salivaricin as intra- and 
interspecies signalling molecule between S. salivarius and S. pyogenes has also been proposed 
(214). 
The TCS SrtRK lies within the srt-gene cluster, which encompasses five other genes involved 
in streptin synthesis, transport, and in so far unknown functions. Similarly to the genes coding 
for the lantibiotic salivaricin, S. pyogenes strain SF370 harbours an incomplete srt-locus due 
to a deletion of streptin processing- and transport genes, therefore resulting in lack of the 
active lantibiotic (222). Although the gene for streptin (srtA) is widespread among S. 
pyogenes strains of many serotypes, only few of them are able to produce the active 
lantibiotics (222). Neither the role played by the SrtRK system in the biology of S. pyogenes, 
nor its environmental signal is known.  
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1.3.2. Regulation by “Stand-alone” regulators 
In addition to the typical TCS, other regulatory systems which seem to function without a 
cognate histidine kinase have been described. These “stand-alone” regulators have been 
shown to regulate a number of virulence genes of S. pyogenes. Some of them are similar to 
response regulators of TCS and may in fact be associated with so far unidentified sensory 
elements; others are unrelated transcriptional regulators. 
1.3.2.1. Multiple gene regulator of GAS (Mga) 
Of all GAS regulators, Mga is by far the best characterized. It was originally described by 
Simpson et al. (198) and named vir. Mga can be found in all GAS serotypes and contains 
sequence similarities with and features of response regulators, such as a phosphorylation 
acceptor motif (168). For this reason, it was proposed that Mga might represent the response 
regulator of a two-component regulatory system. However, the putative sensor protein that 
responds to environmental signals and activates Mga remains unidentified. Mga is auto-
regulated and additionally influenced by elevated temperatures and CO2-levels, as well as iron 
limitations (31, 147) and it positively regulates several GAS virulence factors, including M 
protein, C5a peptidase, serum opacity factor, and SIC protein (121). The Mga-regulated genes 
have been identified by direct Mga-binding studies to the corresponding promotor sequences 
(150), therefore this regulator seems to directly influence gene expression of these virulence 
factors, which are expressed during mid- to late exponential growth phase (149). In vivo 
transcriptional analysis using swabs from patients with acute pharyngitis revealed a high 
expression rate of Mga, underlining its role for the regulation of virulence factors active 
during in vivo infection (218).  
1.3.2.2. Regulator of F (RofA) and Negative regulator of GAS (Nra) 
Due to the 62% sequence identity shared by RofA and Nra, they were grouped together in a 
family called RALP (RofA-like protein family of regulators) (121). Despite high similarity on 
the sequence level, they have different regulatory functions. The fibronectin-binding protein 
of GAS, SfbI/protein F, as well as RofA itself is under regulatory control of RofA, as shown 
by DNaseI protection assays (81). Furthermore, it has been suggested that RofA also regulates 
SLS, SpeB, and the regulator Mga (14). A reduced transcription of the rofA gene could be 
observed at reduced temperatures (199).  
Similar to RofA, Nra seems to regulate expression of colonization factors such as Cpa, a 
collagen-binding protein, and another fibronectin-binding protein of S. pyogenes, SfbII (175). 
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Additionally, Nra can repress the expression of other virulence genes, including speB, speA, 
sagA (SLS), and mga (121).  
1.3.2.3. Rgg  
Rgg, also known as RopB, was first identified as a regulator for SpeB expression (33). 
Microarray transcriptome analysis of an Rgg mutant in comparison with the wildtype strain 
has identified a large number of genes transcriptionally affected by this regulator. These 
include the genes encoding the M protein, C5a peptidase, hyaluronic acid synthetase, SLO 
and SLS, as well as a variety of known two-component-, and stand-alone regulators, such as 
Mga, SagA CsrRS, Irr/Ihk, SalRK, and FasBCA (34). Additionally, decreased temperature 
has been found to increase transcription of this regulator (199). Independently, an unusual 
utilization of nutrients such as arginine and serine instead of glucose, accompanied by an 
upregulation of enzymes needed for this utilization, was also observed in the mutant strain 
(35). The complexity of bacterial regulatory circuits can clearly be seen by the abundance of 
genes influenced by this single regulator. Genes under direct control of Rgg, however, have 
not yet been identified.  
1.3.2.4. Other Regulators 
RocA (Regulator of csr) is a membrane-associated regulator without known DNA binding 
motif, which lead to the assumption that it is not a regulator on the transcriptional level. 
However, deletion of this gene leads to an elevated level of CsrR transcript, resulting in a 
mucoid phenotype of the mutant (22), and therefore implying a potential role of this regulator 
in streptococcal virulence.  
LuxS is a regulator known for its role in quorum-sensing and cell density-dependent gene 
expression in other bacteria, such as S. mutans, where it responds to a secreted pheromone 
named autoinducer-2 (154). Deletion of the homologue in S. pyogenes has been shown to 
result in a media-dependent growth defect, as well as an increased expression of SLS, and a 
lower secretion level of the SpeB precursor (136). Functionally, LuxS might be involved in 
invasion of epithelial cells, since the lack of this regulator increased the internalization rate of 
S. pyogenes (143).  
Deletion of the sagA locus, encoding SLS, has also been shown to influence the expression of 
several virulence genes. Li et al. (130), who named this locus pel for pleiotropic effect locus 
found that this deletion reduced the expression levels of streptokinase and SpeB. In addition, 
SLS mutant strains have been shown to be more attenuated than the wildtype strain in a 
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mouse model of GAS infection (20). Whether the observed reduced virulence was due to lack 
of this important virulence factor in the SLS mutant, or to the missing regulatory activity of 
SLS on other virulence genes remains to be elucidated.   
1.4. Objectives of this work 
The extend to which pathogenic bacteria are able to percept and adapt to changes within their 
host is an important attribute with respect to bacterial virulence, and it greatly influences the 
outcome of infection. Most Group A streptococcal two-component systems are so far poorly 
investigated and little is known about their role in gene regulation and virulence.  
Within the scope of this dissertation, the role of two-component systems in streptococcal 
virulence was to be investigated. Therefore, the objectives of this work were the identification 
of such systems involved in streptococcal virulence, as well as the elucidation of underlying 
mechanism responsible for this involvement. This was to be achieved by (i) the construction 
of a number of stable TCS knock-out mutants, (ii) a closer characterization of the mutants’ 
virulent behaviour in a mouse model of infection, and (iii) identification of virulence factors 
regulated by the corresponding TCS.  
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2. Results 
The first part of this section addresses two-component systems in strain KTL3, the generation 
of deletion mutants in 5 of these systems, and their investigation as contributors to bacterial 
virulence. The second part focuses on the closer characterization of two of these systems with 
corresponding mutants, which showed impairment in their virulence behaviour.  
2.1. Two-component systems in S. pyogenes strain KTL3  
Screening of the annotated genome of S. pyogenes strain SF370 (66) for putative two 
component systems revealed a total number of 13 TCS present in this strain. In most cases, 
the genes for TCS lie adjacent to each other on the bacterial chromosome and are transcribed 
as an operon. The systems present in SF370 were named according to their order in this 
genome, except already characterized ones, for which given names were retained. 
Additionally, some systems were named due to their homology to other TCS. Homology 
searches by BLAST and comparison of the molecular designs of these systems allowed their 
classification into the described four families (LytTR, OmpR, AraC, LuxR; see section 1.2.), 
except for TCS07. This system shows the closest homology to the LytTR (AgrA) family, 
however can be grouped into a newly described family called CitAB (156).  
 
Tab. 3: Two component systems present in S. pyogenes strain SF370.  
No. Name ORF 
designation 
Accession 
number 
TCS-family Gene organization Reference 
1 FasBCA Spy 
0243/0244/0245 
AE006491 LytTR  120 
2 CsrRS  
(= CovRS) 
Spy 0336*/0337 AE006498 OmpR  129 
3 VicRK Spy 0528/0529 AE006510 
AJ012051 
OmpR   
4 TCS04 Spy 0874/0875 AE006537 OmpR   
5 TCS05 Spy 1061/1022 AE006550 AraC   
6 SrtRK Spy 1081/1082 AE006552 OmpR  116 
7 TCS07 
(DpiAB) 
Spy 1106/1107 AE006553 CitAB   
8 TCS08 Spy 1237/1236 AE006563 OmpR   
9 TCS09 Spy 
1555**/1556 
AE006558 AraC     
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10 TCS10 Spy 1587/1588 AE006590 AraC   
11 TCS11 Spy 1621/1622 AE006593 LuxR   
12 SalRK Spy 
1908/1909** 
AE006616 LuxR  186 
13 Irr/Ihk 
(TCS13) 
Spy 2026/2027 AE006624 OmpR  63 
 
Histidine kinases are displayed in blue, response regulators in yellow. * This gene has not been annotated and 
therefore not named in the SF370 genome.** This gene has not been annotated and named due to a frameshift 
mutation in the SF370 genome. 
 
For identification of TCS involved in streptococcal virulence, S. pyogenes strain KTL3 (179), 
which had been used before in an established murine skin- infection model (213) was chosen 
for disruption of these systems. Since the number of TCS systems, especially those associated 
with the expression of lantibiotics (see section 1.3.1.4.) may vary from strain to strain, the 
total number of TCS present in strain KTL3 had to be determined. Oligonucleotides were 
chosen on the basis of the SF370 sequence, and KTL3 was screened for the presence of TCS 
by PCR. Figure 4A shows the amplified DNA fragments of the corresponding TCS in strain 
SF370, Fig. 4B displays the TCS-fragments of KTL3, revealing that all systems are present in 
this particular strain.  
 
 
 
 
 
 
 
 
 
 
Figure 4: Agarosegel of the PCR analysis showing TCS present in strains SF370 (A) and KTL3 (B). Numbers 
refer to the corresponding ones in Tab. 3, representing all 13 TCS. Fragment sizes are indicated as kb on the 
left.  
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2.2. Generation of TCS-deletion mutants in S. pyogenes strain KTL3  
For assessing a possible role of TCS in streptococcal virulence, deletion mutants for FasBCA, 
TCS07, TCS09, TCS11, and TCS13 were generated in strain KTL3. These particular systems 
were chosen for the following reasons. (i) The FasBCA system has already been shown to 
play a role in the regulation of virulence factors (120), and therefore a regulatory mutant 
deficient at this locus would allow further insight into the system’s role in bacterial virulence. 
(ii) TCS13 has been chosen due to its chromosomal neighbourhood (2.4.2.1.), which is mainly 
composed of characterized virulence factors (Fig. 28 page 54). (iii) TCS 07 (recently named 
DpiAB by Banks et al., (12)) and 11 have been chosen based on their gene organization, in 
which the histidine kinase precedes the response regulator (Tab. 3). Most of the TCS involved 
in nutrient perception and metabolism belong to the OmpR family of TCS (see section 1.2.), 
which are typically for theses systems arranged in the opposite way (Tab. 3). Therefore, these 
systems were neglected for mutagenesis studies, except for TCS09.  
2.2.1. Construction of plasmids used for electroporation 
For disruption of the corresponding TCS in strain KTL3, a promotor-containing 
spectinomycin resistance cassette (145) was inserted into the first gene of the corresponding 
system, which was either the histidine kinase or the response regulator depending on its gene 
arrangement (Tab. 3). As exception, in the FasBCA system, which is composed of two 
histidine kinases and one response regulator (Tab. 3), the insertion was introduced within the 
second histidine kinase, therefore leaving the first kinase intact upon chromosomal 
integration. As result of the insertion, a frameshift mutation is introduced into the targeted 
gene and due to a transcriptional stop inserted at the 3’-end of the spectinomycin cassette, the 
second TCS gene will no longer be co-transcribed. 
An overview of the plasmid construction, as well as following transformation- and 
incubations steps is given in Fig. 5 on page 23. Constructs for gene inactivation were partially 
obtained by overlap extension PCR (see section 5.6.3.3.). Three sets of primers were used for 
each construct and PCR products were amplified from the appropriate template DNA. The 
first set of oligonucleotides was used to amplify the homologous fragment 1, corresponding to 
the 5' end of the gene to be inactivated; the second set was used to amplify the spectinomycin 
cassette, and the third set was used to amplify the homologous fragment 2, corresponding to 
the 3' end of the gene to be inactivated. PCR-derived fragments 1 and the spectinomycin 
cassette were purified (5.6.4.), mixed in a ratio of 1:1, and reamplified in a second run with 
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the external primers. The resulting fragment was ligated into the pCR2.1 cloning vector 
resulting in pCR2.1-F1-spc, the same was performed with the homologous fragment 2, giving 
rise to pCR2.1-F2 (Fig. 5, step 1). Fragment 2 was then excised from the vector using the 
vector-harbouring restriction site XhoI in combination with the primer-harbouring site AvrII, 
and ligated into the AvrII/XhoI restricted pCR2.1-F1-Spc, resulting in pCR2.1-F1-Spc-F2 
(Fig. 5, step 2 and 3). 
For transformation of S. pyogenes, the thermosensitive shuttle vector pJRS233 (170) was 
used, which is a derivative of pG+host4 (139). In E. coli, this vector can autonomously 
replicate at 37°C, but in S. pyogenes only at 30°C. Therefore, upon raise of temperature to 
37°C under selective pressure, only chromosomal integrates of the plasmid are recovered in S. 
pyogenes. The above constructed F1-Spc-F2 fragment was excised from pCR2.1 using vector 
harbouring restriction sites HindIII or SpeI, in combination with the vector harbouring site 
XhoI, and ligated into the shuttle vector pJRS233, resulting in pJRS233-RR/HK::Spc (Fig. 5, 
step 4), which was then used for transformation of KTL3. All plasmids used for 
electroporation are listed in Tab. 4.  
 
Tab. 4: Plasmids generated in this work used for electroporation of S. pyogenes strain KTL3 
 
*The fragment positions correspond to the GenBank accession numbers NC_03737 (S. pyogenes SF370, 
complete genome) and M69221 (aad9). 
Plasmid Selection Cloned DNA-fragments* 
pJRS233_fasC::spc Spc (80 µg/ml) fasC(1): 211495-211946 
aad9 
fasC(2): 211995-212461 
pJRS233_hk07::spc Spc(80 µg/ml) hk07(1): 907423-906990 
aad9 
hk07(2): 90694-906485 
pJRS233_hk09::spc Spc (80 µg/ml) hk09(1): 12821138-1281712 
aad9 
hk09(2): 1281629-1281136 
pJRS233_hk11::spc Spc (80 µg/ml) hk11(1): 1347919-1344476 
aad9 
hk11(2):1344458-1344007 
pJRS233_irr::spc Spc (80 µg/ml) irr(1): 1691848-1691361  
aad9  
irr(2) : 1691323-1690860 
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2.2.2. Electroporation of S. pyogenes  
For electroporation of S. pyogenes strain KTL3, a method adapted from McLaughlin and 
Ferretti (151) was applied. Using the recommended TH-Broth with glycine however did not 
yield any transformants; only exchange of the medium to TSB with glycine resulted in 
successful transformation. Since transformation with at –70°C stored bacteria was inefficient, 
cells were freshly prepared before each transformation and resuspended in the electroporation 
buffer described by Caparon and Scott (30). Additionally, the suggested amount of DNA (1-2 
µg) was raised to up to 8 µg, amounts below 5 µg did not yield any transformants.  
After electroporation of S. pyogenes strain KTL3 with the pJRS233-derivatives (Tab. 4 and 
Fig. 5 step 5), the cultures were maintained in selective medium (0.5 µg/ml Erm) at 30°C for 
allowing autonomous replication of the plasmid. Verification of the presence of the plasmid 
was achieved by PCR using oligonucleotides M13 Universal and Reverse (for priming sites in 
the plasmid refer to Fig. 5B). Subsequently, clones were subjected to a temperature shift to 
37°C, selecting for chromosomal integration of the plasmid into the corresponding TCS by a 
single cross-over event (Fig. 5 step 6). This genetic setup can only be reliably maintained 
under constant selective pressure, preventing reversion to the wildtype situation by 
homologous recombination within the identical copies of the internal gene fragment 
concomitant with the excision of the plasmid (Fig. 5 step 7). However, for animal infection 
experiments, occurring in the absence of selective antibiotics, stable, non-revertible double 
cross-over mutants were required. Therefore, clones were passaged between 30°C and 37°C 
(Fig. 5 step 7). The shifts back to 30°C permit the autonomous replication of the plasmid and 
favour the excision of the plasmid from the chromosome. Excision of the plasmid from the 
chromosome results either in reversion to the wildtype situation or in replacement of an 
internal gene fragment by the spectinomycin resistance cassette, depending on the exact 
position of homologous recombination. Transformants were selected on spectinomycin for 
this second genetic setup and repeatedly analyzed until complete loss of the plasmid and 
integration of the spectinomycin cassette into the genome was confirmed (Fig. 5 step 8). This 
transformants were resistant to spectinomycin and, due to the loss of the plasmid, sensitive to 
erythromycin. 
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Figure 5: Schematic overview illustrating the construction of the pJRS233-derivatives used for transformation of 
KTL3 and the process of transformation and integration of the plasmid into the streptococcal chromosome, 
yielding stable insertion of the spectinomycin cassette into the targeted gene. Additionally, priming sites for 
oligonucleotides used for PCR analysis of KTL3 transformants are indicated. F1 and F2 correspond to the two 
internal fragments of the TCS; Spc refers to the spectinomycin resistance cassette, and RR/HK represent the 
chromosomal location of the targeted gene. Priming sites are indicated as arrows. (B) Priming sites of Universal 
and Reverse on the pJRS233-derivatives for step (i) described in 2.3.1; (C) Priming sites of oligonucleotides for 
verification of the chromosomal integration described in step (ii) of 2.3.1; (D) Final verification of the double-
cross-over described in step (iii) of 2.3.1. For further descriptions refer to the text. 
2.3. Verification of TCS deletion mutants 
2.3.1. PCR analysis of KTL3 transformants 
A fast screening of the mutants by PCR was achieved in three independent reactions. (i) 
Using vector-priming oligonucleotides M13 Universal and Reverse (Figure 5 B); a negative 
PCR result indicated the loss of the free form of the plasmid. (ii) Loss of the plasmid from the 
chromosome was confirmed by negative PCR using oligonucleotide M13 Universal in 
combination with a TCS-specific one (Fig. 5 C). (iii) The final verification of the double 
cross-over event and integration of the spectinomycin resistance cassette into the locus was 
obtained by using oligonucleotides C1 and C2, which prime outside of the site of 
recombination (Fig. 5 D). Due to the inserted resistance cassette, the resulting PCR products 
were larger when compared to the wildtype (Fig. 6). 
    
 
 
 
 
 
 
 
 
 
  
 
 
 
     Fas               
wt        mt
 TCS07               
 wt        mt 
TCS09               
 wt      mt 
TCS11               
 wt        mt 
TCS13               
 wt        mt 
2.5 kb -
1.0 kb -
1.5 kb -
Figure 6: Verification of the double cross-over by PCR. Oligonucleotides C1 and C2 for the corresponding 
TCS were used, wt refers to the parental strain KTL3, mt stands for the knockout strains. Fragments amplified 
from the mutants are larger due to the insertion of the spectinomycin resistance cassette. 
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2.3.2. Sequence analysis of the integration site in the TCS mutants 
Sequence analysis of the regulatory mutants was performed as final proof for verification of 
the correct integration of the spectinomycin cassette into the corresponding TCS loci. As seen 
in Fig. 7, fasC has the cassette integrated at position 326, corresponding to the glutamine at 
position 109 of the histidine kinase. HK07 has the cassette integrated after position 404, 
which corresponds to the lysine in position 134, RR09 after amino acid 88 (tyrosine), HK11 
after amino acid 137 (alanine) and RR13 after amino acid 142, which is a glutamine. These 
results confirm the correct integration of the spectinomycin cassette into the corresponding 
TCS. Integration sites of the spectinomycin cassette determine the size and putative remaining 
activity of the residual mutant protein, i.e. the N-terminal part of the protein might be 
expressed up to this position in the mutant strain. All inactivated histidine kinase genes are 
disrupted upstream of the encoded crucial histidine residue, resulting in loss of the functional 
kinase domain. For RR09 and RR13, a residual protein will only cover the phosphorylation 
domain, but will lack the DNA-binding domain. The insertion leads to a frameshift mutation 
within this gene, resulting in a premature mRNA-termination due to the transcriptional stop 
present at the 3’-end of the spectinomycin cassette. Therefore, the second gene of the TCS 
will not be cotranscribed, as well as other genes located within the same operon. 
 
 
 
 
 
  
 
 
 
Figure 7: Sequence analysis of the spectinomycin cassette integration site within the different GAS mutants. 
Black letters refer to the sequence of the corresponding streptococcal gene, red letters indicate the integrated 
aad9 gene, restriction sites are underlined, and the start codon of aad9 (Spc-cassette) is indicated in bold 
letters. Numbers correspond to the base pair position within the targeted gene. 
FasC   300 GCTGTCTTAGGATTTAGCATTGGTCAACCCGGCAATTGCCCGGATCGATTTTCGTTCGTGAATACATGTTAT
HK07   404 ATGGCGGTTCCCGTGTTTAGGAAAGTCCCCGGCAATTGCCCGGATCGATTTTCGTTCGTGAATACATGTTAT
RR09 266 CGTTCTAGATGCGGTGTCAGGCTATCGCCCGGCAATTGCCCGGATCGATTTTCGTTCGTGAATACATGTTAT
HK11   386 TAAAACAAGAGCGCAAACGAATTGCAACCCGGCAATTGCCCGGATCGATTTTCGTTCGTGAATACATGTTAT
RR13   223 GAGACCGAACATAGCGTCTATTGGCAACCCGGCAATTGCCCGGATCGATTTTCGTTCGTGAATACATGTTAT
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2.3.3. Southern Blot analysis 
The high sequence similarity between TCS required verification of a single insertion of the 
construct within the streptococcal chromosome, guaranteeing disruption of the targeted 
system alone. Therefore, mutants were analysed by Southern blot for multiple integrations of 
the spectinomycin cassette into the chromosome. Chromosomal DNA digested with BamHI, 
HindIII, and EcoRI was hybridized with a probe specific for the spectinomycin cassette. In all 
cases, only a single band could be detected on the Southern blot (Fig. 8). This corresponds to 
a single integration of the cassette into the streptococcal chromosome.   
 
 
 
 
 
 
 
  
 
 
 
 
 
2.4. Growth rate of the regulatory mutants 
A prerequisite for a successful assessment of the role played by the TCS in bacterial virulence 
is the same growth behaviour of the regulatory mutants in comparison to the parental strain. 
Otherwise, a slower growth rate cannot be distinguished from a higher susceptibility of the 
mutants to host immune responses; both would result in lower bacterial counts in infection 
experiments when compared to the wildtype. Therefore, the growth behaviour of the mutants 
under standard laboratory conditions was investigated and compared to the parental strain 
KTL3. Representative growth curves of all mutants are displayed in Fig. 9. Under regular 
laboratory conditions, no obvious differences in their growth rate could be detected. Bacterial 
doubling times during exponential growth phase are given in Tab. 5. 
    1              2             3                4                       5    6      7 
2027 -
2322 -
10 kb -
Figure 8: Southern Blot analysis of the KTL3 regulatory mutants using a probe specific for the 
spectinomycin cassette. 1: KTL3 wildtype; 2: ∆FasCA; 3: ∆TCS11; 4: ∆TCS13, chromosomal DNA triple-
digestion with BamHI, EcoRI, and HindIII; 5, 6, and 7: ∆TCS07, DNA digested with BamHI (4), EcoRI (5), 
and HindIII (6). 
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Tab. 5: Doubling times of a representative growth curve during exponential phase of wildtype and regulatory 
mutants. 
 
 
 
 
 
2.5. Lancefield Bactericidal Assay  
The ability to survive and to grow in whole human blood in the presence of immune-relevant 
cells like macrophages and polymorphonuclear leukocytes (PMNs) is a prerequisite feature of 
S. pyogenes (126). During infection, this property can lead to spreading of S. pyogenes once it 
enters the bloodstream. There are several bacterial factors mediating this phagocytic 
resistance (see section 1.1.2.), and the ability to upregulate their expression during the 
encounter with host immune cells is a major virulence attribute. Consequently, when 
investigated in vitro, this ability to withstand phagocytosis can be used as indication for 
Strain Doubling time 
        [min] 
KTL3 wildtype 74.53 
KTL3 ∆FasCA 71.46 
KTL3 ∆TCS07 75.34 
KTL3 ∆TCS09  66.65 
KTL3 ∆TCS11 78.77 
KTL3 ∆TCS13 74.53 
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Figure 9: Representative growth curves of KTL3 wildtype and regulatory mutants. 
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streptococcal virulence. Therefore, in order to investigate the antiphagocytic ability of the 
regulatory mutants in comparison to the wildtype, bacteria were incubated in whole human 
blood as described by Lancefield (126). Impairment in the ability to survive indicated a loss 
of virulence and therefore a potential role of the regulatory system in regulation of 
antiphagocytic factors.  
After three hours of incubation in fresh human blood, bacterial counts were determined and 
compared to the initial inoculum. Results presented in Fig. 10 show the percentage of bacteria 
isolated after 3 hours in comparison to 100% initial inoculum. Survival and growth of the 
wildtype strain within the incubation period corresponded with an increase of its number by 
48 %. The TCS11 mutant was also able to grow as seen by a bacterial increase of 37.5 %. 
This clearly shows that their ability to resist to phagocytosis and killing is not altered. On the 
other hand, the bacterial number of all other mutants was reduced, the FasCA mutant by 23 
%, and the TCS09 mutant by nearly 55 %. Strikingly, the Irr/Ihk- and the TCS07 mutant were 
almost completely eliminated, indicating a strong impact of the mutation on expression of 
antiphagocytic factors, leading to an impaired ability to grow and resist to phagocytosis and 
killing by human immune cells.  
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Figure 10: Bacterial counts after the Lancefield Bactericidal Assay. Results refer to 100% initial inoculum. 
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The Lancefield Bactericidal Assay allowed the identification of four out of five TCS which 
are involved in resistance against phagocytosis by host immune cells, as shown by the 
inability of the corresponding mutants to grow and survive when compared to the wildtype 
strain. The mutants deficient in TCS07 and TCS13, showing the clearest reduction within this 
assay were characterized in more detail regarding (i) their virulent behaviour in a murine skin 
infection model, and (ii) the underlying molecular mechanisms responsible for their 
attenuation.  
2.6. Characterization of streptococcal TCS involved in virulence 
Within the following sections, the molecular structure of TCS07 and TCS13 will be addressed 
and compared to similar TCS of other bacterial species. Additionally, results obtained from 
the characterization of the corresponding mutants regarding their virulent behaviour in 
different animal models, as well transcriptional, expressional, and functional analysis will be 
presented.  
2.6.1. Characterization of the TCS07 of S. pyogenes strain KTL3 
2.6.1.1. Genetic organization and structural analysis of TCS07 
TCS07 is present in all so far sequenced genomes of S. pyogenes, i.e. M3 (15), M18 (199), 
M6 (12), and SSI-1 (160) (where the genes refer to SpyM3_0768/0769, SpyM18_1068/1069, 
M6_Spy828/829 (dpiAB), and Sps_0968/0969, respectively). As depicted in Tab. 3 (page 19), 
the histidine kinase HK07 is encoded upstream of the response regulator RR07, between these 
two genes, a non-coding region of 19 basepairs is located. Structurally, this system belongs to 
the CitAB-subfamily of two-component systems (156), which include the citrate-responsive 
CitAB and CitST systems from Klebsiella pneumoniae and Bacillus subtilis, as well as other 
C4-dicarboxylate-responsive systems, such as DcuRS and YufLM of E. coli and B. subtilis, 
respectively.  
2.6.1.1.1. Structural analysis of the response regulator RR07 
The response regulator RR07 consists of 221 amino acids, encompassing all highly conserved 
active residues described for response regulators. In RR07, these are two aspartates at 
positions 8 and 9, the phospho-accepting aspartate at position 53, a lysine residue at position 
103, and finally a serine located at position 81. 
Prediction of the Helix-Turn-Helix (HTH) DNA-binding motif within RR07, as well as 
sequence alignments to known HTH motifs of other response regulators identified to 100 % a 
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HTH motif in RR07 starting at amino acid 175 (phenylalanine) and ending at position 199 
(glutamine).  
Searches for other response regulators sharing sequence homologies with RR07 revealed a 
large number of RRs within other bacterial species. Fig. 11 shows alignments of selected 
similar response regulators with RR07. All of them belong to the CitAB subfamily of two-
component sensor-regulators (156) (see section 2.1.). For the response regulators CitB of 
Klebsiella pneumoniae and E. coli, as well as CitT of B. subtilis, the involvement in citrate 
metabolism has been demonstrated (23, 229).  In B. subtilis, CitT controls the expression of 
the citrate transporter CitM (229), while in K. pneumoniae, it is essential for the expression of 
citrate fermentation genes under anoxic conditions, allowing this bacterium the growth on 
citrate as sole carbon source (24). In both cases, genes needed for regulation, uptake, and 
catabolism of citrate lie in a cluster on the bacterial genome.  
The YdbG response regulator of Bacillus subtilis regulates transport systems for C4-
dicarboxylic acids such as fumarate and succinate (6). The same function has been 
demonstrated for DcuR in E. coli (77, 232). YufM of B. subtilis also plays a role in the 
utilization of a C4-dicarboxylic acid, its influence on the expression of malate transporters 
MaeN and YflS could be demonstrated; furthermore, it activates the transcription of the malic 
enzyme gene ywkA in response to malate (52, 210).  
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2.6.1.1.2. Structural analysis of the histidine kinase HK07 
The sensor kinase HK07 is composed of 513 amino acids comprising three functional 
domains. Due to characteristic patterns found within its homology boxes, it can be grouped 
into the HK5 subfamily of histidine kinases (82). Structurally, HK07 shows all the 
characteristics for sensors of the CitAB-subfamily of TCS. It has two membrane-spanning 
helices in the N-terminal region, the first one ranging from amino acid 11 to 27, the second 
one from amino acid 173 to 192, resulting in an extracellularly located sensing domain of 146 
amino acids. Comparisons of this domain with protein databases did not identify homologies 
to known proteins; therefore no predictions about putative signals could be made. 
Additionally, protein family scans revealed the presence of a PAS domain (PFAM: PF00989), 
encompassing amino acid 211 through 243 in HK07. These domains, which are often present 
in histidine kinases, mediate the sensing of intracellular signals, such as oxygen levels, 
   1 -----MNVLIIEDDPMVDFIHRNYLEKLNLFDRIISSDSMKAVQSILT--DYAIDLILLDIHITDGNGIQFLEKWRTQHIPCEVI RR7 Spy 
   1 -MTAPLTLLIVEDETPLAEMHAEYIRHIPGFSQILLAGNLAQARMMIER-F-KPGLILLDNYLPDGRGINLLHELVQAHYPGDVV CitB Eco 
   1 -MDS-ITTLIVEDEPMLAEILVDNIKQFPQFDVIGIADKLESARKQLRL-Y-QPQLILLDNFLPDGKGIDLIRHAVSTHYKGRII CitB Kpn 
   1 ----MIEVLVVDDDTRVARVNAAYVEKVPGFHVAAEAHSALEALDAVER-LPRLDLILLDHYLPDRTGLEVVQEMRRRGRQTDVI CitB Sco 
   1 ----MIHIAIAEDDFRVAQIHERLIKQLDGFKIIGKAANAKETLALLKE-H-KADLLLLDIYMPDELGTALIPDIRSRFPEVDIM CitT Bsu 
   1 ----MINVLIIDDDAMVAELNRRYVAQIPGFQCCGTASTLEKAKEIIFNSDTPIDLILLDIYMQKENGLDLLPVLHNARCKSDVI DcuR Eco 
   1 MARKEWKVLLIEDDPMVQEVNKDFITTVKGVTVCATAGNGEEGMKLIKE-E-QPDLVILDVYMPKKDGIKTLQEIRKQKLEVDVI YdbG Bsu 
   1 ----MINVLIVEDDPMVGELNKRYLSQIDGFQLKGIASSFQSALHILG--EHHIDLILLDIYMPGKNGLELLTELRAQNEAVDVI YufM Bsu 
 
  79 IISAANDGNIIRDGFHLGIIDYLIKPFTFERFQESIQQFVTHREHLANQQ-LEQAQIDQLKCLTSKKDTKNKQLLEKGLSESTFQ RR7  Spy 
  83 FTTAASDMETVSEAVRCGVFDYLIKPIAYERLGQTLTRFRQRKHMLESIDSASQKQIDEMFNAYARG--EPKDELPTGIDPLTLN CitB Eco 
  82 FITADNHMETISEALRLGVFDYLIKPVHYQRLQHTLERFARYRSSLRSSEQASQLHVDALFNIQAREQTEPASAPLRGIDESTFQ CitB Kpn 
  81 MVTAARDVSTVQATMRQGALQYLVKPFAFAGLRAKLEAYAELRRTLDGGGEAEQAEVDRIFG--ALS-APSEPGLPKGHSPTTAE CitB Sco 
  80 IITAATETRHLQEALRAGIAHYLIKPVTADKFRQVLLQYKEKRKLLMSQPEVSQSMIDHIFGNGVKT-ALPAEDLPTGINSITLR CitT Bsu 
  82 VISSAADAATIKDSLHYGVVDYLIKPFQASRFEEALTGWRQKKMALEKHQYYDQAELDQLIHGSSS-NEQDPRRLPKGLTPQTLR DcuR Eco 
  84 VVSAAKDKETISLMLQNGAVDYILKPFKLERMRQALEKYKQYKQKIEANDTLSQEQLDAILN--IPQ--QAVQDLPKGLNHFTMN YdbG Bsu 
  80 VISAASELDVIKKTLRYGAVDYLIKPFEFERFQTALSDYRRKQKVYSTHRNMSQKELDAELFQKK--EATEKVQLPKGLTKSTLK YufM Bsu 
 
 163 WIMENIKVF-DQPFTIQELASACHLSHVSVRKYIAYLEENKQLNSQQIFTKVGRPYRVYW                          RR7  Spy 
 166 AVRKLFKEP-GVQHTAETVAQALTISRTTARRYLEYCASRHLIIAEIVHGKVGRPQRIYHSG                        CitB Eco 
 167 RVLQLFADP-TVVHTADSLARILGSSKTTARRYLEQGVKNDFLEAEISYGKVGRPERIYHGKQTYPEQR                 CitB Kpn 
 163 LVRQCLLKA-DGPLSAQEIAERTGVSRQTAQRYLKLLERTGRAVLTLKYGEAGRPEHRYAWVTRA                     CitB Sco 
 164 KIKEALQTA-SEGLTAEELGEKMGASRTTARRYAEYLVSKEEARAELEYGIIGRPERKYYLAAD                      CitT Bsu 
 166 TLCQWIDAHQDYEFSTDELANEVNISRVSCRKYLIWLVNCHILFTSIHYGVTGRPVYRYRIQAEHYSLLKQYCQ            DcuR Eco 
 165 EVTAFLKQQ-TASLSAEEVAKALGIARVTARRYLDYLEKTGIIKLDVQYGGVGRPVNRYVLKG                       YdbG Bsu 
 163 LIWSSIQSFENESFTTEDLAKHTEISQVSIRKYLKFLEDIQVLNVEMAYGTIGRPVFQYNVNNSNINGIKQYL             YufM Bsu 
       HELIX-TURN-HELIX MOTIF 
Figure 11: Sequence alignment of RR07 of S. pyogenes strain SF370 with similar response regulators of 
other bacterial species. Spy = S. pyogenes; Eco = E. coli; Kpn = K. pneumoniae; Sco = S. coelicolor; Bsu = 
B. subtilis. Conserved residues are indicated in red, HTH-DNA-binding motifs are shaded in grey. 
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temperature, or acidic conditions (212). In the CitA-like histidine kinases of gram-negative 
bacteria, they have been shown to act as a periplasmatically located sensor for tri- and/or 
dicarboxylates (112, 166, 181). Therefore, besides the extracellularly located domain, the 
PAS domain of HK07 might play an additional role in signal perception. The transmitter 
domain of HK07, facilitating the transfer of the phosphoryl group to the cognate response 
regulator, is located from amino acid 327 to 513. 
Scans for the typical histidine kinase signature sequences clearly identified four out of the five 
homology boxes. The H-Box of HK07 ranges from amino acid 327 to 346, harbouring the 
crucial phospho-accepting histidine at position 333. The conserved asparagine lies within the 
N-Box (amino acid 423-434) and is located at position 429 of HK07. The α-helical X-region 
ranges from amino acid 372 to 395, however the lysine within this region is missing in HK07. 
This residue can be found in members of the HK5 subfamily, in other HK-subfamilies it is 
often absent and therefore its function remains unclear (82). The D-Box with its conserved 
aspartate (amino acid 462) ranges from position 457 - 462, whereas the phenylalanine-
containing F-Box spans the regions from amino acid 469 through 471. The G-Box of HK07 is 
partly missing; only two residues are present, represented by two glycines at position 505 and 
506. Therefore, HK07 could exhibit an impaired ability or an alternate mechanism for ATP 
binding, since the G-Box in involved in this process. Sequence comparisons of HK07 
revealed the same incomplete G-Box within the other sequenced S. pyogenes strains, therefore 
sequencing errors in HK07 of strain SF370 can be excluded. All homology boxes, as well as 
the X-region are indicated in Fig. 12, an additional overview is given in Tab. 6. 
 
Table 6: Positions of homology boxes found in HK07 with and conserved residues. 
Homology box / region Amino acid positions Conserved residue and position 
H-Box 327 – 346 Histidine 333 
X-Region 372 – 395  Lysine missing 
N-Box 423 – 434 Asparagine 429 
D-Box 457 – 462 Aspartate 462 
F-Box 469 – 471 Phenylalanine 471 
G-Box  Partly missing Glycine 505 and 506 
 
Homology searches of HK07 with bacterial genome databases identified the cognate histidine 
kinases to the in 2.6.1.1.1. described response regulators of the CitAB-subfamily, as well as a 
similar HK of unknown function in the closely related species Streptococcus agalactiae. 
Sequence alignments of HK07 with these histidine kinases are displayed in Fig. 12, HK-
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specific signature sequences, as well as PAS- and transmembrane domains are indicated. The 
partly missing G-Box of HK07 is however present in the homologues.  
   1 -----------MKKP------LRLWASLSLILVSMIVVTTSLFYGIMLHDTHQS-----IKNQETHLLTSTGKMLASHQA HK07 Spy 
   1 -------MLQLNENKQFAFFQRLAFPLRIFLLILVFSIFVIAALAQYFTASFED----YLTLHVRDMAMNQAKIIASNDS CitA Eco 
   1 -----MSIYPMYTRKITHWFARRSFQNRIFLLILFTSTIVMLAMSWYLTDITEE----RLHYQVGQRALIQAMQISAMPE CitA Kpn 
   1 MPPAPRTVMAMSSTPPVRR-LRLGLPRRVFSQVLLMQLAIAAGVAVLATGLFLAPLGDQLDDQAMRRALAIAQTTAQQPQ CitA Sco 
   1 ----------MVKKR-----FHFSLQTKIMGLIAALLVFVIGVLTITLAVQHTQ----GERRQAEQLAVQTARTISYMPP CitS Bsu 
   1 --MRHSLPYRMLRKR------PMKLSTTVILMVSAVLFSVLLVVHLIYFSQISD----MTRDGLANKALAVARTLADSPE DcuS Eco 
   1 ----------MNKKK-----LSIRWKITILSYILVIFSFLIGGIVLIGNIQHT------EERELKKRLMNTARTVSEMTE YdbF Bsu 
   1 -----------MKKT-------LKLQTRLTIFVCIVVLIALLITFFTVGAQTTK----RIRDQEKATALQTAEMVAEAPM YufL Bsu 
         Transmembrane I 
 
  59 IKELLLNNQPNAK--TTAYTNSIASIYNLDYVVVMNMKGIRLTHPNPKNIGKPFQGGDEE-AVLAGKKVISTAKGTLGKS HK07 Spy 
  70 VISAVKTRD-YKR--LATIANKLQRDTDFDYVVIGDRHSIRLYHPNPEKIGYPMQFTKQG-ALEKGESYFITGKGSMGMA CitA Eco 
  72 LVEAVQKRD-LAR--IKALIDPMRSFSDATYITVGDASGQRLYHVNPDEIGKSMEGGDSDEALINAKSYVSVRKGSLGSS CitA Kpn 
  80 VVRDLRTTRPTANGPVQREAERVREATRAEYVVVMDRQGVRWSHTDPERIGEVVSTDPGQ--ALAGREVMEIDDGTLGRS CitA Sco 
  62 VKELIERKDGHAA--QTQEVIEQ-MKEQTGAFAIYVLNEKGDIRSASGKSGLKKLERSRE-ILFGG-SHVSETKADGRRV CitS Bsu 
  69 IRQGLQKKPQESG--IQAIAEAVRKRNDLLFIVVTDMQSLRYSHPEAQRIGQPFKGDDIL-KALNGEENVAINRGFLAQA DcuS Eco 
  60 VKEALARKKQTEA--VRHAVEEIRMINEADYIVVMDMNHIRYTHPVSTSIGKKSEGADEE-AAFAEHIYFSEAKGEIGTA YdbF Bsu 
  59 TAAALESGKKQKE--LQSYTKRVQKITGTEFVVVMDMNGIRKTHPDPSKIGKKFRGGDES-EVLKGHVHISTASGTLGKS YufL Bsu 
 
 136 LRYLVPVFDGD----KQIGAIAVGIKLTTLNDVALTSKRNYTLSLLLCLLISLLVTSFISFRLKRQLHQLEPSEIYQLFE HK07 Spy 
 146 MRAKTPIFDDD---GKVIGVVSIGYLVSKIDSWRAEFLLPMAGVFVVLLGILMLLSWFLAAHIRRQMMGMEPKQIARVVR CitA Eco 
 149 LRGKSPIQDAT---GKVIGIVSVGYTIEQLENWLSLQISSLLIPMAIMLLLLLFCARRFSLHIKKQMLNMEPQQLSQLLI CitA Kpn 
 158 ARGKVPLRDGD---GEIVGAVSVGIAYDSVRARLIHAIPGLFAYAGGALAVGALASWIISRRVQRQTRDLAFSDIAGLLA CitA Sco 
 137 IRGSAPIIKEQKGYSQVIGSVSVDFLQTETEQSIKKHLRNLSVIAVLVLLLGFIGAAVLAKSIRKDTLGLEPHEIAALYR CitS Bsu 
 146 LRVFTPIYDEN---HKQIGVVAIGLELSRVTQQINDSRWSIIWSVLFGMLVGLIGTCILVKVLKKILFGLEPYEISTLFE DcuS Eco 
 137 VRAFYPVKDQD---LNQIGVVLVGKTLPGIADILLHLKRDIAFIVVLTLGFGLAGSFLLARHIKKQMFQLEPHEIVRMYE YdbF Bsu 
 136 QRAFVPVYAEN---GKQVGAVAVGITVNEIDEVISHSLRPLYFIICVSIFVGVIGAVIVARTVKNIMYGLEPYEIATLLE YufL Bsu 
            Transmembrane II 
 
 212 ERNAMLDQIEAAVFVVDKAGILQLCNQAGQKLIARKCQ-----LGKPTGNSFNYLFPDFPKLSLQEGHEQLFRYGEEDYL HK07 Spy 
 223 QQEALFSSVYEGLIAVDPHGYITAINRNARKMLGLSSPGR-QWLGKPIVEVVRPADFFTEQIDEKRQ-DVVANFNGLSVI CitA Eco 
 226 QQSVLFESVFEGLIAIDSDYKITAINQTARRLLNLSQPEP-TLIGKRISSVISQEVFFYDAPQTNKK-DEIVTFNQIKVI CitA Kpn 
 235 EREAMLHGIREGVVALDRGGRVRLLNDEAQRLLGIGGE----AVGRSPDEALGAGRTADVLAGRVTGTDLLTVRGQRVLV CitA Sco 
 217 ERNAMLFAIREGIIATNREGVVTMMNVSAAEMLKLPEP----VIHLPIDDVMPGAGLMSVLEKGEMLPNQEVSVNDQVFI CitS Bsu 
 223 QRQAMLQSIKEGVVAVDDRGEVTLINDAAQELLNYRKSQDDEKLSTLSHSWSQVVDVSEVLRDGTPRRDEEITIKDRLLL DcuS Eco 
 214 ERTATFHSMNEGVIAIDNRLVITIFNEKAKQIFEVQGD----LIGKVIWEVLKDSRLPEIVERNKAVYNEEIRVSGKVIM YdbF Bsu 
 213 ERSAMLESTKEGILAVDEHGKIKLANAEAKRLFVKMGIN-TNPIDQDVDDILPKSRLKKVIETKKPLQDRDVRINGLELV YufL Bsu 
          PAS-Domain 
 
 287 LAISPICVKNDHRGHIIFMREAVKAIDTLDQLAYTTAYASALQAQTHKFMNQLHVIYGLVDIAYYDQLKIYLDSILEPEN HK07 Spy 
 301 ANREAIRSGDDLLGAIISFRSKDEISTLNAQLTQIKQYVESLRTLRHEHLNWMSTLNGLLQMKEYDRVLAMVQGESQAQQ CitA Eco 
 304 ASRMAVILNNEPQGWVISFRSKDDINTLSLQLSQVQQYADNLRAVQHEHRNLISTIAGLLFLKRYNQALELIQQQSESHQ CitA Kpn 
 311 ANRMPTDDG----GAVATLRDRTELEQLGRELDSTRGLIDALRAQDHEHANRMHTLLGLLELEMYDDAVEFVGEVVGDHR CitA Sco 
 293 INTKVMNQGGQAYGIVVSFREKTELKKLIDTLTEVRKYSEDLRAQTHEFSNKLYAILGLLELGEYDEAIDLIKEEYAIQN CitS Bsu 
 303 INTVPVRSNGVIIGAISTFRDKTEVRKLMQRLDGLVNYADALRERSHEFMNKLHVILGLLHLKSYKQLEDYILKTANNYQ DcuS Eco 
 290 SSRIPIVMKKKVIGAVAIFQDRTEAAKMAEELTGVRNFVEALRVQNHEHMNKLHTIAGLIQLGKSEKALQLAFQASTEQE YdbF Bsu 
 292 FNEVPIQLKGQTVGAIATFRDKTEVKHLAEQLSGVKMYANALRAQSHEFMNKLHVILGLVQLKEYDDLGDYIKDIAIQQK YufL Bsu 
                  H-Box 
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2.6.1.2. Chromosomal neighbourhood of the TCS07 
Compared to adjacent lying genes, TCS07 is transcribed in the opposite direction and 
therefore insertion of the spectinomycin cassette will not have any influences on the 
transcription of downstream-located genes. Fig. 13 gives a more detailed overview of the 
chromosomal neighbourhood of TCS07, which is identical in all so far sequenced S. pyogenes 
strains, but different in closely related species such as S. agalactiae. Downstream of rr07 - 
and transcribed in opposite direction - a putative ABC-transporter of the spermidine-
/putrescine family (75) is located. In E. coli, this type of system mediates the transport of 
polyamines (75, 112). A putative malate permease and malic enzyme (EC 1.1.1.39) are 
encoded upstream of the histidine kinase hk07, of which homologues in S. bovis have been 
 367 EILTSLSVLVKEPLLASFLIGEQEKYQELNVHLKIDVLSEIPHSATKNQLNNGLMIYRFIHTNLLTTLRPKS-----LVL HK07 Spy 
 381 QLIDSLREAFADRQVAGLLFGKVQRARELGLKMIIVPGSQLSQLPPGLDS----TEFAAIVGNLLDNAFEASLRSDEGNK CitA Eco 
 384 KVIDFIARNFQDNHLAGLLIGKYYRAKELGLELIFDPACFVDRLPTALSH----NEWISIVGNLLDNAYNASLRQPQGSK CitA Kpn 
 387 VTAEQITERIHDPLLAALLVGKATVAAERGVALRVSDRTRLPDR—LVDP-----RGLVTIVGNLVDNALDAAAGTA--HA CitA Sco 
 373 EQHDLLFHNIHSQQVQAILLGKISKASEKKVKLVIDENSSLAPLPAHIG----LSHLITIIGNLIDNAFEAVAEQS--VK CitS Bsu 
 383 EEIGSLLGKIKSPVIAGFLISKINRATDLGHTLILNSESQLPDSGSED----QVATLITTLGNLIENALEALGPEP--GG DcuS Eco 
 370 NVTEFLHRSIQNDAAAGLLLSKIRRGRELGIAVHIDENSSLQQFPEHV----DQHDIVVLLGNLIENAFGSFETVQSEDK YdbF Bsu 
 372 SETSEIINDVKSSVLAGFLLGKQSFIREQGANLDIECNGVIPNAADPSV----IHELITIIGNLINNGLDAVADMP--KK YufL Bsu 
     X-Region                  N-Box 
 442 SIQHDQNHLISHYTLTDNWIDLERVQ------PIFDLPYFQQLLTDTNSQFHQHQTVT-ELQFSVTTPYVGGQHERFNH        HK07 Spy 
 461 IVELFLSDEGDDV--VIEVADQGCGVPESLRDKIFEQGVSTRADEPG-EHGIGLYLIASYVTRCGGVITLEDNDPCGTLFSIYIPK CitA Eco 
 464 QIECLINSDGQE--VIIEIADQGCGIDEALRDRIFERGVTSSASK---DHGIGLWLVRSYVEQAGGSIVVENNIPFGTIFTLYIPL CitA Kpn 
 463 RVEVELRAEGRA--ATLTVRDTGPGIAADHRELVFAAGWSTKEPPAHRERGIGLPLVRRLAERQGGSATVGEAYGGGAEFVVVLPE CitA Sco 
 451 EVLFFITDMGHD--IVIEVSDTGPGVPPEKIEAVFERGYSS-KGM---RRGYGLANVKDSVRELGGWIELANQKTGGAVFTVFIPK CitS Bsu 
 461 EISVTLHYRHGW--LHCEVNDDGPGIAPDKIDHIFDKGVSTKGSE----RGVGLALVKQQVENLGGSIAVESEPGIFTQFFVQIPW DcuS Eco 
 450 RIDISIEQTDD--ILAILIEDNGCGIEPTHMPRLYDKGFTVNKTG---GTGYGLYLVKQIIDKGSGTIEVDSHAGQGTSFSIVFPM YdbF Bsu 
 450 QITMSMRFHNS--ILDIEITDTGAGMSEEDQAKVFEQGYSTKGKN----RGFGLYFTQQSIENLKGQMILTSEKNEGTTFSIRIPY YufL Bsu 
               D-Box                       F-Box                  G-Box 
 
 540 VKP-----------NDSSINPIDR                                                              CitA Eco 
 541 TRD-----------EHHG                                                                 CitA Kpn 
 543 ALTEAAPEPALTVPVTTAAEEESR                                                               CitA Sco 
 527 EKQRGNPF-----DSHRDCGG                                                                  CitS Bsu 
 537 DGE----------RSNR                                                                      DcuS Eco 
 527 KGE----------EAQHGS                                                                    YdbF Bsu 
 526 EPK----------EENHD                                                                     YufL Bsu 
 
Figure 12:  Sequence alignment of HK07 of S. pyogenes strain SF370 with similar histidine kinases from other 
bacterial species. Spy = S. pyogenes; Eco = E. coli; Kpn = K. pneumoniae; Sco = S. coelicolor; Bsu = B. 
subtilis. Conserved residues are indicated in red, signature sequences, transmembrane helices, and PAS 
domains are shaded. 
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investigated in more detail (114, 132). There, the malic enzyme catalyzes the oxidative 
decarboxylation of L-malate, as well as the reductive carboxylation of pyruvate. L-malate 
permease, on the other hand, is cotranscribed with the malic enzyme, and functions as L-
malate specific permease that is highly active at low pH (114, 115).  
2.6.1.3. Growth characteristics of the TCS07 mutant 
In 3.1., it was demonstrated that the TCS07 mutant does not show any difference in its growth 
rate when compared to the parental strain. Nevertheless, a different growth phenotype was 
observed, i.e. altered sedimentation behaviour. Additionally, due to the described regulatory 
functions of similar TCS in other species, the effects of different C-sources and other 
variations of growth parameters were analysed.  
2.6.1.3.1. Sedimentation behaviour 
During growth in standard broth, differential sedimentation behaviour of the ∆TCS07 strain 
was observed in comparison to the wildtype. Once reaching early- to mid-logarithmic growth 
phase, the parental strain formed aggregates and started to sediment, the mutant strain 
however did not (Fig. 14). Frick et al. (73) investigated sedimentation behaviours of different 
GAS serotypes and identified a conserved region of 19 amino acids present in the 
streptococcal M- and M-like protein H. They concluded that homophilic protein-protein 
interactions between neighbouring proteins of S. pyogenes containing this region caused 
sedimentation in liquid medium. Additionally, aggregation of S. pyogenes was accompanied 
with an increased ability to survive in whole human blood. (73). The lack of sedimentation 
observed in TCS07 mutant cultures may therefore be due to a lower expression of M-protein 
or other AHP-containing surface proteins. The analysis of M protein expression on the surface 
of wildtype and TCS07 mutant will be presented in 2.6.1.5.3. 
hk07rr07potDpotCpotBpotA malP malE
Streptococcal chromosome
Figure 13: Chromosomal neighbourhood of tcs07. PotA-D refer to structural genes of the ABC transporter, 
malP and malE encode the malic enzyme and -transporter.  
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2.6.1.3.2. Exchange of the C-Source 
Due to the close relationship of the TCS07 system to other regulatory systems involved in the 
utilization of citrate, malate, succinate, and fumarate, the ability of wildtype and ∆TCS07 
strain to grow on these compounds (as well as pyruvate) was addressed. However, neither 
wildtype, nor mutant were able to grow in medium containing these compounds as sole C-
source, except when glucose was supplemented in addition. Growth on lactose as sole carbon 
source occurred after an extensive lag phase of approximately 3.5 hours, but again, no 
detectable differences could be observed between parental and mutant strain.  
Interestingly, no phenotypic difference in the sedimentation behaviour of wildtype and TCS07 
strain cultures could be observed when grown in medium containing glucose and malate. 
Neither Wildtype, nor mutant cultures showed aggregative behaviour and sedimentation (Fig. 
15). This stands in contrast to observations made in regular growth medium (Fig. 14), or in 
medium supplemented with other C-sources, where the wildtype invariably sedimented, but 
the mutant did not.  
 
WT    ∆TCS07 
Figure 15: Sedimentation behaviour of KTL3 wildtype and isogenic 
TCS07 mutant in CDM-glucose, supplemented with malate. 
WT    ∆TCS07 
Figure 14: Sedimentation behaviour of KTL3 and its 
isogenic mutant ∆TCS07. 
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2.6.1.3.3. Dependency of pH on growth ability 
After phagocytosis by cells of the host’s immune system, bacteria are enclosed in 
phagosomes, which is followed by a fast drop in pH (54). The inability to survive within the 
Lancefield Bactericidal Assay could be directly linked to an incapability to respond to such 
changes in pH. Therefore, in order to investigate the possible role of HK07 in sensing and 
responding to an increased level of protons or ions, the ability of wildtype and TCS07 mutant 
to grow at different pH levels was investigated. Results summarized in Tab. 7 demonstrate 
that bacterial growth required a minimum pH of 5.5, at all other investigated pH levels, no 
difference between wildtype and TCS07 mutant was observed. These results demonstrate the 
equal ability of both strains to grow at low or high pH. 
 
 
Table 7: Influence of pH on bacterial growth.  
 
 
 
 
 
 
 
 
 
 
 
           +++ represents very good growth; ++ good growth; + poor growth; - no growth. 
 
 
Taken together, growth analysis of wildtype and ∆TCS07 strain in the present of diverse C-
sources, as well as varying pH levels did not show any significant differences, even though 
structural similarities to other TCS involved in the utilization of C4-compounds exist. The 
only striking observation was a lack of sedimentation in the wildtype strain when malate was 
supplemented, a phenotype that so far has been a characteristic for the ∆TCS07 strain. 
pH WT ∆TCS07 
pH 5.0 - - 
pH 5.5 + + 
pH 6.0 ++ ++ 
pH 6.5 +++ +++ 
pH 7.0 +++ +++ 
pH 7.5 +++ +++ 
pH 8.0 ++ ++ 
pH 8.5 ++ ++ 
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2.6.1.4. Contribution of the TCS07 to bacterial virulence in a mouse model of infection 
As already shown in 2.3.2., the mutant exhibited an impaired ability to survive in whole 
human blood. However, in vitro experiments do not necessarily reflect the situation occurring 
during in vivo infections, where the interactions of bacteria with their host are more complex. 
Therefore, the virulence of the TCS07 mutant was investigated in a mouse model of 
subcutaneous infection and compared to that of the wildtype strain.  
2.6.1.4.1. Survival time of infected animals 
One method to assess bacterial virulence is to monitor the animal’s survival after infection.  
Therefore, mice were subcutaneously infected either with KTL3, or with the ∆TCS07 
isogenic mutant strain and the survival time of individual animals was determined over time. 
A Kaplan-Meier Plot of one representative experiment is shown in Fig. 16. By day three, 
about 50 – 60 % of wildtype-infected animals succumbed to infection, by day five, 100% 
mortality was observed within this group. In contrast, mice infected with an equal amount of 
∆TCS07-bacteria survived over the whole investigated time-period, clearly showing the 
attenuation of the regulatory mutant in comparison to the wildtype strain. 
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Figure 16: Survival of mice infected with either KTL3 wildtype or ∆TCS07. 
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2.6.1.4.2. Determination of the lesion sizes 
In order to estimate the virulent behaviour of wildtype and mutant at the local site of 
infection, the sizes of the skin lesions were measured 48 hours postinfection. Animals 
infected with the wildtype developed lesions of about 3.1 cm2, whereas in mice inoculated 
with the ∆TCS07 strain only very small lesions of about 0.2 cm2 were observed. Therefore, 
the mutant has a decreased ability to induce lesions in infected animals.   
2.6.1.4.3. Dissemination of bacteria from local infection foci to systemic organs and 
bloodstream.   
The possibility that the observed attenuation of the mutant could be due to a reduced bacterial 
ability to spread from the local site of infection through the bloodstream and to establish a 
systemic infection was further investigated. For this purpose, bacterial loads of wildtype and 
mutant were determined in blood, as well as in systemic organs of infected mice. Mice were 
infected with either wildtype or ∆TCS07, and 24, 48, and 72 hours after subcutaneous 
infection, liver, spleen, and blood samples were taken, serially diluted in PBS and plated in 
order to determine the exact bacterial number.  
During the infection period, bacterial loads increased steadily in systemic organs of wildtype-
infected mice (Fig. 17). After 24 hours, no bacteria were detectable in the bloodstream; most 
bacteria were located in liver and spleen (log10 3.29 and log10 2.68), respectively. After 48 
hours, bacterial counts within systemic organs increased in the wildtype, reaching log10 6 in 
liver and spleen, and log10 4.2 in blood (Fig.17). By day 3, all wildtype-infected animals had 
died, indicating an inability of these animals to control the infection.  
In contrast, mice infected with the TCS07 mutant had fewer bacteria in blood and systemic 
organs at all time-points investigated. After 48 hours, an increase of bacteria could be 
observed, but never exceeded log10 3. By 72 hours, all bacteria were eliminated from blood 
and systemic organs of infected animals. These results show the ability of mice infected with 
the TCS07 mutant to clear the infection from bloodstream and systemic organs at 72 hours 
postinfection. 
 
Over all, the outcome of the animal infection parallel results obtained from the Lancefield 
Bactericidal Assay (2.5). Animals infected with ∆TCS07 showed a reduced virulence in a 
mouse model of skin infection. This could be observed by survival of animals during the 
monitoring-period, as well as by the development of smaller skin lesions and a rapid clearing 
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Figure 17: Distribution of KTL3 wildtype and ∆TCS07 bacteria to mouse organs and blood at 24, 48, 
and 72 hours postinfection. KTL3 is displayed in blue, ∆TCS07 in red. (A) Bacteria isolated from 
spleen. (B) Bacteria isolated from liver. (C) Bacteria isolated from blood.  
 
of the mutant from blood and systemic organs. 
  
 
2.6.1.5. Identification of differentially expressed proteins and virulence factors  
Reduced virulence in the Lancefield Bactericidal Assay (2.5.), as well as in in vivo infections 
can have a variety of reasons. Streptococcal knock-out mutants missing M-protein have been 
shown to exhibit loss in virulence (168). Such high attenuation in animal models as observed 
for the ∆TCS07 strain has only been reported in the absence of major virulence factors, such 
as the hyaluronic acid capsule, M protein, and to some degree SpeB (8, 223). Thus, to 
understand and identify the molecular basis of the reduced virulence in the TCS07 mutant 
strain, the expression levels of these important virulence factors was investigated in ∆TCS07 
and compared to the wildtype strain.  
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2.6.1.5.1. Hyaluronic acid capsule 
The amount of cell-associated capsule can be determined by an unspecific staining method in 
combination with measurement of photometric absorbance. Capsule is usually upregulated 
during early exponential growth phase; its expression reaches a peak in logarithmic growth, 
and decreases towards stationary phase (45).  
Blood passage of S. pyogenes can result in increased capsule expression, visible by highly 
mucoid colonies (178, 180). The same observation could be made for KTL3 after subjection 
to blood-passage or when isolated from the liver of infected animals. ∆TCS07-colonies rising 
from organs of infected animals, as well as from mouse- or human blood were 
unencapsulated, observable by a missing mucoid phenotype (Fig.18 D). For quantification, 
the amount of cell-associated capsule was determined from those colonies. The parental strain 
KTL3 showed a capsule expression that was 6.8 fold higher than in ∆TCS07 (89 fg/cfu to 13 
fg/cfu, respectively), in which only minor amounts of capsule could be detected (Tab.8). This 
difference was not visible under standard culture conditions (Fig. 18 A and 18 C), but only 
when bacteria were isolated from blood or systemic organs. 
Mouse-passages often result in selection of spontaneous mutants in the capsule synthesis 
regulating gene locus, CsrRS, accompanied by isolation of S. pyogenes strains with a highly 
mucoid phenotype (59). For excluding the possibility that the mucoid phenotype of the 
wildtype strain was due to mutation, encapsulated wildtype GAS were subjected to several 
broth-passages. Loss of the capsule was achieved after 2-5 passages, confirming this 
phenotype to be revertible and therefore not due to a spontaneous mutation. These results 
clearly show than in the wildtype strain, an upregulation of hyaluronic acid capsule occurs 
within blood and organs. This upregulation is absent in the TCS07 mutant, i.e. the mutant is 
no longer able to respond to an environmental stimulus present in blood or organs. 
Consequently, TCS07 is involved in either positively activating capsule transcription directly, 
or in regulating genes essential for efficient expression of this virulence factor under stress 
conditions.  
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Tab. 8: Amount of hyaluronic acid capsule of bacteria isolated from mouse blood and subsequently grown on 
blood agar plates.  
 Hyaluronic acid capsule 
[fg/CFU] 
KTL3 WT 89 ± 0.71 
KTL3 ∆TCS07 13 ± 2.83 
 
2.6.1.5.2. Streptococcal inhibitor of complement (sic) 
For detection of differences in the pattern of secreted proteins from wildtype and TCS07 
mutant, precipitated supernatants of stationary grown cultures were separated on a 1-
dimensional SDS gel. As seen in Figure 19, three bands are visible in the wildtype strain 
KTL3, of which two are absent from the supernatant of the TCS07 mutant. The first missing 
protein has a molecular mass of ~ 100 kDa, the second one is about 45 kDa in size. Isolation 
of the respective bands from the SDS gel and subsequent Maldi-TOF analysis could not 
identify the 100 kDa proteins, but the ~ 52 kDa-sized proteins present in both strains were 
identified as a putative secreted protein, corresponding to SF370 gene number Spy0019. The 
Figure 18: KTL3 (A) and ∆TCS07 (C) colonies on blood agar plates grown under standard conditions.   
Mucoid KTL3 (B) and non-mucoid ∆TCS07 isolated from mouse liver and subsequently grown on blood 
agar plates..   
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45 kDa proteins lacking in the ∆TCS07 strain, on the other hand, were found to be the well-
known streptococcal virulence factor SIC. This protein is a GAS secreted protein that 
interferes with complement-mediated lysis and is predominantly present in S. pyogenes of 
serotypes M1 (2; see section 1.1.2.3).  
These results clearly show the absence of the virulence factor SIC in the TCS07 mutant. 
 
 
 
 
 
 
 
 
 
2.6.1.5.3. Detection of M1-Protein  
Besides capsule, M-protein is one of the major and best described streptococcal virulence 
factors (68; see section 1.1.2.2.). Since the regulatory mutant exhibited a significant loss in 
phagocytic resistance and in murine virulence, a putative impact of the missing TCS on the 
amount of M1-protein was investigated. For preventing M protein degradation by SpeB, 
bacteria were grown in standard broth in the presence of a cysteine protease inhibitor. 
Subsequently, M1 extraction from the surface of KTL3 and ∆TCS07 and Western analysis 
with anti-M1 serum could detect slightly degraded M protein in the wildtype, but none in the 
mutant (Fig. 20). Hence, besides the incapability to upregulate capsule in blood and organs, 
the TCS07 mutant’s attenuation is additionally linked to the lack of the M1 protein. Likewise, 
these results go conform to the slower sedimentation exhibited by stationary-grown ∆TCS07 
(2.6.1.3.1.), since low expression rates of M-protein have been associated with this phenotype 
(21, 73). 
 
Figure 19: Analysis of precipitated secreted proteins in 
KTL3 and ∆TCS07. SDS gel with supernatants from 
wildtype (lane 1) and TCS07 mutant (lane 2). Maldi –TOF 
identified protein SIC is indicated by an arrow. Sizes are 
indicated on the left in kDa. 
SIC 
100
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To further prove this hypothesis, field emission electron microscopy (FESEM) for detection 
of surface-located M protein was performed. Purified anti-M1 antibody, which was 
subsequently gold-labeled, was incubated with wildtype and ∆TCS07. FESEM photographs 
displayed in Fig. 21 show images of wildtype (A) and ∆TCS07 (B). Due to the gold-label, 
surface-localized M proteins appear as white dots. As already seen by Western analysis, the 
wildtype expresses adequate amounts of M protein. In contrast, ∆TCS07 produces only little 
or none of this virulence factor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The ability to bind to human fibrinogen is a streptococcal attribute that has not only been 
ascribed to the M1-protein, but to many other streptococcal proteins such as FnBP54, serum 
Figure 20:  Western blot analysis of the expression of M1-
protein in wildtype and TCS07 mutant, detected by incubation 
with polyclonal anti-M1 serum. 1. HCl-extraction of KTL3 2. 
HCl-extraction of ∆TCS07. 3. Recombinant M1 protein. Sizes  
are indicated on the left in kDa. 
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Figure 21: FESEM picture of surface-localized M1 protein on KTL3 (A) and ∆TCS07 (B). Bar corresponds to 
0.5 µM.  
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opacity factor (SOF), and protein F (see section 1.1.1.2). For strain KTL3 it was reported that 
fibrinogen binding is solely due to the M1-protein (179). Therefore, it was investigated 
whether the lack of M1-protein in ∆TCS07 impairs the mutant’s ability to bind to 
radiolabelled human fibrinogen. As seen in Fig. 22, a clear reduction of the capability to bind 
to human fibrinogen was observed for the TCS07 mutant, which was only able to bind 23.6 % 
of the added fibrinogen. In the parallel experiment, the parental strain KTL3 bound 94.1 % of 
deployed labelled protein (Fig. 22). Therefore, the lack of the M1-protein in the regulatory 
mutant clearly reduces its ability to bind to human fibrinogen. 
 
 
 
 
 
 
 
 
 
 
2.6.1.6. Transcription analysis of streptococcal genes 
2.6.1.6.1. Virulence factors emm, sic, and hasA 
For further elucidating the nature of the difference seen for the M1-protein and SIC in the 
TCS07 mutant, transcriptional analysis of these virulence factors was performed by Northern 
blot. For emm1, as well as for sic no transcript was detected in the TCS07 mutant (Fig. 23 A 
and B, lane 2). In contrast, strong signals were detected in KTL3 (Fig. 23 A and B, lane 1). 
Reprobing of both blots with a specific probe for the house-keeping gene rpsL confirmed 
loading of equal amounts of RNA (Fig. 23C). Consequently, the lacking expression of M 
protein and SIC in ∆TCS07 were due to absent transcripts. Both virulence factors are under 
positive regulatory control of Mga (149), thus the observed effects could be caused by an 
influence of TCS07 on the transcription of mga. Northern analysis of this single regulator 
however did not yield any signals in both, wildtype and mutant. Likewise, at no time-point 
 
Figure 22: Binding of radiolabelled human fibrinogen to wildtype and ∆TCS07 shown 
as percentage of the total amount of deployed protein. 
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was a signal detectable for hasA, representing the capsule gene cluster, which was probably 
due to amounts of transcripts below detection limits. Therefore an indifferent transcription of 
hyaluronic acid capsule, as well as mga could not be shown.  
The obtained results demonstrate that the observed differences in protein level seen for M 
protein and SIC (see section 2.6.1.5.2. and 2.6.1.5.3.) are due to a lack of transcription in the 
TCS07 mutant, and not to post-translational modifications. Consequently, TCS07 is directly 
or indirectly involved in the transcription of these streptococcal virulence factors. An indirect 
influence of the transcriptional regulator Mga on the observed results, however, cannot be 
excluded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional transcription analysis was performed to assess amount of emm1-transcript as 
possible reason for the lost sedimentation of the wildtype strain that was only observed in 
malate-containing medium (2.6.1.3.2.). In the wildtype strain, a repression of emm1 
transcription mediated by TCS07 in the presence of malate and consequently lower levels of 
M protein – as factor inducing sedimentation by homophilic protein interactions (2.6.1.3.1) - 
could explain this observed lack of sedimentation. However, Northern analysis of KTL3 
grown in the presence of malate showed a detectable emm1-transcript (Fig. 24), and therefore 
indicating the presence of M1-protein under malate-containing conditions. 
2.6.1.6.2. Neighbouring genes of TCS07 
The wildtype exhibited the same sedimentation phenotype as the TCS07 mutant only in CDM 
supplemented with malate. Consequently, it seemed tempting that the regulatory circuit 
1,5
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Figure 23: Transcriptional analysis of virulence factor genes emm1 (A) and sic (B) in KTL3 (lane 1) and 
∆TCS07 (lane 2) by Northern blot. Loading of equal amounts of RNA was confirmed by reprobing the 
Northern blot with an rpsL-specific probe (C). Transcript sizes are indicated on the left. 
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leading to this phenotype might be similar in wildtype and mutant under these conditions. The 
involvement of malic- enzyme and permease in malate uptake and catabolism has been shown 
in S. bovis (114, 115), and the corresponding genes malE and malP are located adjacent to 
TCS07 on the GAS chromosome (Fig. 13). Thus, the regulation of these malate-associated 
genes was investigated by Northern analysis with RNA isolated from bacteria grown in the 
presence of this C4-compound. However, no transcript of the calculated size of 1.3 kb was 
detectable. The same results were obtained for transcriptional analysis of the TCS-
neighbouring ABC putrescine-/spermidine transport system (potA-D). In summary, the 
growth in malate-containing medium did neither induce detectable levels of malic enzyme 
and L-malate permease, nor of the downstream located ABC-transporter. 
 
 
 
 
 
 
 
 
WT TCS07
Figure 24: Northern blot analysis of emm1 in KTL3 and TCS07 mutant 
grown in CDM supplemented with malate (4.1.3.2.). An arrow indicates 
the emm1 transcript.  
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2.6.2. Characterization of the TCS13 (Irr/Ihk) of S. pyogenes strain KTL3 
2.6.2.1. Genetic organization and structural analysis of TCS13 
TCS13 has been named Irr/Ihk (isp-adjacent histidine kinase/response regulator) by Federle et 
al. (63), who partially characterized a TCS13 deletion strain in an M6 background with 
respect to transcription of the virulence factors M protein, C5a peptidase, SLO, SLS, 
streptokinase and capsule synthetase, as well as the regulator Mga. However, they neither 
found any differences between wildtype and mutant strain, nor did not test the mutant for 
attenuated virulence in animal models.  
In the annotated streptococcal genome SF370, TCS13 has been assigned as Spy2026/2027. It 
is present in all annotated Group A streptococcal genomes (corresponding genes: 
SpyM3_1732/1733 (15), M6_Spy 1724/1725 (12), SpyM18 2083/2084 (199), and 
SPs_1729/1730, respectively (160), and shares 99 - 100 % identity on the protein level. 
Structurally, TCS13 belongs to the OmpR family of two-component systems and has the 
response regulator located upstream of the histidine kinase, as it is typical for this family of 
TCS. A Shine-Dalgarno sequence is located prior to the start codon of RR13, and displayed 
Figure 25, –10 and –35 regions as probable binding sites for the RNA-polymerase are also 
indicated. The region in between the stop-codon of the response regulator and the start-codon 
of the histidine kinase encompasses merely 3 bp. In the region downstream of HK13, scans 
revealed no putative inverted repeats as transcriptional terminators. However, by extending 
scans to the downstream located gene isp, an incomplete palindrome could be identified (Fig. 
25). The resulting stem-loop would be composed of 11 basepairs, with 2 imperfect matches of 
guanine with uracil. However, due to this weak terminator structure, it cannot be excluded 
that the transcription of the succeeding gene isp is influenced in the TCS13 mutant.  
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2.6.2.1.1. Structural analysis of the response regulator RR13 
Sequence analysis of the response regulator RR13, which consists 218 amino acids, revealed 
all five characteristic conserved residues (see section 1.2.) to be present in RR13. The 
conserved asparagines in the N-terminal receiver domain are located at amino acid positions 9 
and 10 of RR13, the phospho-accepting aspartate at position 52, whereas within the C-
terminal regulatory domain, the conserved threonine is located at position 79, and the lysine at 
position 101. The sequence of RR13 with all its five conserved residues is represented in Fig. 
26. 
Homology searches and comparisons of the C-terminal region of RR13 revealed the 
affiliation of this response regulator to the OmpR family. OmpR itself has been characterized 
in great detail and shown to control the porin expression system in E. coli (204). The crystal 
structure of the C-terminal domain has been resolved resolved and revealed a ‘winged helix-
turn helix motif’ as DNA binding motif (144). It has been demonstrated that response 
regulators of this family are crucial for a broad range of regulatory functions, like antibiotic 
resistance (VanR of Enterococcus faecalis (61), phosphate regulation (PhoP of B. subtilis; 
193), as well as regulation of secreted virulence factors (ArlR of S. aureus; 72) 
Searches for response regulators sharing sequence homologies to RR13 identified RRs 
belonging to the OmpR family, as well. These include a so far non-characterized response 
regulator in S. suis, as well as a number of regulators of the Bacillus genera, with yet 
Figure 25:  Abbreviated sequence of the TCS13: “start RR13 ” corresponds to the beginning of the 
response regulator, “stop HK13 ” to the end of the histidine kinase, and “start isp” refers to the beginning 
of the following gene. Shine-Dalgarno (SD), -10, and –35 region are underlined, inverted repeats (IR) as 
putative transcriptional terminator are displayed in red, mismatches within the IR in bold letters.  
                                     -35 
ATTGCGATTTGAATAATCAACCAAACAAGCATAAAAGTCAAAAAGGATGACCCTTTGATGTCATCCTTAGCTGCTTG 
 
        -10           SD                   → Start rr13 
ATACACTAAACGCCAATCTAGAAAGGGAAGTTATGTTTAAAATATTAGTAGTTGAAGATGATGA......TCATGACGAT 
 
    ← Stop hk13                 IR 
TGATCCATACTAGTAGGACGACAAAAGTCATCAATCATTAACCAAGCCTTGACCTTTACCCATCATTGTTTAGGCAA 
 
                                                                                 → Start isp 
GTATAAAAAAGAGGAGAGAAATCATATATGAAGAAAAGGAAATTGTTAGCAGTAACACTATTAAGTACCAT 
 
     IR 
ACTCTTAAACAGTGCAG.... 
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unknown functions. VanR of Enterococcus faecalis is with 49 % identity the most similar 
response regulator with known functions. It has been shown to bind to a promoter region 
within the vancomycin resistance gene cluster of E. faecalis, leading to a change in the 
expression of genes required for this bacterium to grow in the presence of the corresponding 
antibiotic (61). A sequence alignment of RR13 with these response regulators is given in Fig. 
26. 
2.6.2.1.2. Structural analysis of the histidine kinase HK13 
The histidine kinase HK13 is composed of 463 amino acids and can be grouped into the 
HK2a subfamily of histidine kinases, to which EnvZ as one of the most thoroughly 
characterized histidine kinase belongs (57, 211). Prediction by hydrophobicity scans revealed 
the presence of two membrane-spanning regions, the first one ranging amino acid 7 to 28, and 
the second one from amino acid 154 to 173. Therefore, HK13 harbours an extracellular, 126 
amino acid long sensing domain starting at position 29 (alanine) and ending at position 153 
(aspartate). In order to identify putative signal molecules, the sequence of this sensing domain 
was compared with entries of protein databases; however, no similarities were found.  
Sequence analysis of HK13 identified four out of five for histidine kinases characteristic 
homology boxes (see section 1.2 and Tab. 9). The H-Box harbouring the phospho-accepting 
histidine (position 252) is located from amino acid 243 to 261. The X-region ranges from 
Figure 25: Sequence alignment of RR13 of S. pyogenes strain SF370 with similar response regulators of 
other bacterial species. Spy = S. pyogenes; Bce = Bacillus cereus; Fear = Enterococcus faecalis; Lmo = 
Listeria monocytogenes; Ssu = Streptococcus suis. Conserved residues are indicated in red.  
   1 -MFKILVVEDDDTISQVICEFLKANNYDPDCVFDGQAALDKWQTTSYDLIILDIMLPSLSGLEVLKTIRKTSDVPIIMLT Spy RR13 
   1 -MTHILVIEDNPDIQELIREFLMAQNFTVDVVGAGTEGILLFQKNSYDLVLLDVMLPDIDGYSICKIMRGQSDVPIIMLT Bce vanR 
   1 MSIRILLVEDDDHICNTVRGFLAEAGYQVDACTDGNEAYTKFYENTYQLVILDIMLPGMNGHELLREFRAKNDTPILMMT Efa vanR 
   1 -MEKILIAEDDSAILGVITAFLTEAGYQVMTAKNGIEAYHLFQKETFDLIIMDIMMPSMDGYTLTELIRSTSTTPILMMT Lmo phoP 
   1 -MSRILVVEDDIVISQVVCEFLKEHGYQVESVFDGKVALERFQEEQFDLIVLDIMIPSMTGLEVLKEIRKTSQIPILMLT Ssu 
 
  80 ALDDEYTQLVSFNHLISDYVTKPFSPLILIKRIENVLRV---STPDEK-----RQIGDLLVDETEHSVYWQGTLVKLTKK Spy RR13 
  80 GLHNEESEIKGFELGIDDYITKPFHYTVFIKRVEAVLRR---AATKEAEAATILQFHELMLNSTAYAAYVHGNQIELTTK Bce vanR 
  81 ALSDDENQIRAFDAEADDYVTKPFKMQILLKRVEALLRR---SGALAK----EIRVGRLTLLPEDFTVLCDGTELPLTRK Efa vanR 
  80 ALSEEDDELKGFDLGADDYIQKPFSYLVLLKRVQVLLRRVNQSETKKQ----ILRCGNISVDTETFEVISAGETIELTKK Lmo phoP 
  80 AMGDEYTQLISFNQIISDYVVKPFSPTILVKRIENILRG---KGETDS-----IEIGTILIQPTSGAVYMEEEEVQLTKK Ssu 
 
 152 EYDIIDYLAKRHQKIVTRDQLMDDIWGYSEL-DTRVLDNHIKNLRKKMTGIPLKTITGMGYLLGERE              Spy RR13 
 157 EFEIIHTLLQNRGKVLSRSDLLNKIWGYEHYGDVRVIDTHIKNLRKKLGIPYIKTVKGIGYKIES                Bce vanR 
 154 EFEILLLLVQNKGRTLTHEIILSRIWGYDFEGDGSTVHTHIKNLRAKLPENIIKTIRGVGYRLEESL              Efa vanR 
 156 EFDILVLLIKNQKKVITREMILSQAWDFAAIVDTSIINTHMKNLRKKLHTEKIQTIRGAGYKMDE                Lmo phoP 
 152 EYEVLLYLAKRRGKIVSRDNLMMGIWGYTEL-DSRVLDNHIKNIRKKLPSLPLKTIVGRGYQIEGT               Ssu 
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amino acid 285 to 305, and secondary structure prediction could confirm the characteristic α-
helical form (82) within this region. The conserved asparagine is located at position 362; the 
N-Box itself is ranging from amino acid 352 through 371. One of the homology boxes that 
could not be identified is the D-Box, which is usually located between the N- and F-Box and 
contains a conserved aspartate as part of the nucleotide-binding domain. The predicted 
location of this residue is position 380; it is lacking in HK13 of strain SF370, as well as in the 
other sequenced S. pyogenes genomes. Fig. 27 depicts all conserved residues of the D-box as 
grey shades, however this signature sequence has not been named due to the absent aspartate. 
The F-Box, which succeeds the D-Box, is present again; the conserved asparagine after which 
this region has been named is positioned at amino acid 405 within HK13. Ranging from 
amino acid 420 through 426, the G-Box involved in ATP-binding is located.  
 
Table 9: Positions of homology boxes found in HK13 with and conserved residues. 
 
Searches for histidine kinases sharing sequence homologies with HK13 revealed a number of 
similar kinases, of which the best characterized one is the HK VanS of E. faecalis strain V583 
(accession number Q47745). VanS is the corresponding sensor to the response regulator 
VanR mentioned in 2.6.2.1.1., and is involved in the sensing process of vancomycin. A 
similar kinase named VncS involved in adaptive responses to vancomycin as well is described 
in S. pneumoniae (163, 184). Besides these two histidine kinases, HK13 shares similarities to 
a yet uncharacterized kinase in Streptococcus suis (Acc. No. ZP_00333076), and Bacillus 
cereus (Acc. No. NP_977908). An alignment of HK13 with all named histidine kinases is 
illustrated in Fig. 27. Transmembrane domains, as well as homology boxes with their 
conserved residues are indicated in shades and red. Interestingly, all similar histidine kinases 
also lack the in HK13 absent D-Box. Additionally, the extracellular sensing domain located in 
between the two transmembrane helices does not share any sequence homologies between the 
compared kinases, as seen by long stretches of non-alignable amino acids.  
Homology box / region Amino acid positions Conserved residue and position 
H-Box 243 - 261 Histidine 252 
X-Region 285 - 305 none in HK 2a 
N-Box 352 - 371 Asparagine 362 
D-Box absent 
F-Box 402 - 409 Phenylalanine 405 
G-Box  420 - 426 none 
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   1 MR---LIKKTFLVINGLIIVVVTSILLVLYFAMPIYYTKVKDKEVKCEFDQTSKQIK--GKTVTEIR----DILTKK--- Spy HK13 
   1 MG---IARKNFIIVAAMISFISVTLLGLLYYAMPIYYNQVKKQELRHDYMTVAKQLD--GMPEAKIIS---EIDDFD--- Ssu 
   1 MKRTGLFAKIFIYTFSIFSVLVICLHLAIYFLFPSTYLSHRQETIGQKATAIAQSLE--GKDRQSIE----QVLDLY--- Spn VncS  
   1 MERKGIFIKVFSYTIIVLLLLVGVTATLFAQQFVSYFRVMELQQTVKSYQPLVELIQ--NSDRLDIQ----EVAGLF--- Efa VanS 
   1 MKNRSIVFKLFLLTSTLFTIIFLLFFLGQSLFLEKFYINKKVKTVQTAFEKFVDTYEKSGKTYEEIRKLKQEFHDKTNAD Bce 
      Transmembrane I 
 
  69 ---------INKDN-IWYSLVDSDNQLLYPS----------LQLLDGVSESKDSQN-------------VNIVTTF---- Spy HK13 
  70 ---------IKTPN-IIISLFSSDRKIIYP------------DPNDEMAKKHENEY-------------LE--------- Ssu 
  72 ---------SQTSDIKGTVKGEMTEDKLEVK--------------DSLPLDTDRQT------------------------ Spn VncS 
  72 ---------HYNNQSFEFYIEDKEGSVLYAT--------------PNANTSNSFRP------------------------ Efa VanS 
  81 MQFLNTNGIIKSDNNYYIDVFNPKNNETYSIPLNNLLTPEEYKKFENLGLKKDDVINVVGLLQNKTITPIKLTTNYNRWQ Bce 
 
 112 ----DNSYSNVK-----------------------------VMSQKVTLR------------------------------ Spy HK13 
 106 ----NGDFDEIG-----------------------------SWGAEITSA------------------------------ Ssu 
 105 ------TSLFIE-------------------------------EREVKTQ------------------------------ Spn VncS 
 105 ------DFLYVV-------------------------------HR----D------------------------------ Efa VanS 
 161 NEYTNSDFSSINGNPSKNRLTNRYKTVTQIEFTGTISKLQLPSKAEVRLANDIETLQAVQYFAELIRNGTANSQQLNTYI Bce 
 
 129 ----DGKKMTLLGQ---------------SSLQPVTDASKVLLDLYPSLLIFSVTVGSIVAYLYSRTSSRRILSMSQTAK Spy HK13 
 123 ----EGVTYYLLFN---------------YGFHSLSDVSQTLVTFYPFILLLIIVLAVSVAFVYSRLSTRRIARISETTR Ssu 
 118 ----DGGTMILQFL---------------ASMDLQKEAEQISLQFLPYTLLASFLISLLVAYIYARTIVAPILEIKRVTR Spn VncS 
 114 ----DNISIVAQSK---------------AGVGLLYQGLTIRGIVM---IAIMVVFSLLCAYIFARQMTTPIKALADSAN Efa VanS 
 241 IDSGENIKNSIFVKPIIENGEITEYAFAIASLQPVNEAMLVLKDYYVYALIIVFLVIILLSFYYSKIIVKPLIKMNRVTK Bce 
                                                    Transmembrane II 
 190 KMVNLEPNLTCTIHGKDEIAMLASDINRLYASLSTSIK-------SLQKEYEKASDSEREKSEFLRMTSHELKTPITSVI Spy HK13 
 184 RMQSLESGISCAVAGTDEITILAQDINSLYSKLLSSID-------ELRTENERAMAREKEKSDFLRITSHELKTPIASML Ssu 
 179 RMMDLDSQVRLRVDSKDEIGNLKEQINSLYQHLLTVIA-------DLHEKNEAILQLEKMKVEFLRGASHELKTPLASLK Spn VncS   
 172 KMANLK-DVPPPLERKDELGALAHDMHSMYVRLKETIA-------RLEDEIAREHELEETQRYFFAAASHELKTPIAATS Efa VanS 
 321 KMANFDFSEKLPVTADDEIGGLSGSINTLSVNLKDRIDRLNVANTKLQQDIERERQLEKTRKEFISGVSHELKTPLSVIR Bce 
                    H-Box 
 263 GMIDGMLYNVGDFADRDKYLRKCRDVLEGQAQLVQSILSLSKIET-LASQNQELFSLKSSLEEEMEVFLVLSELKHLKVT Spy HK13 
 257 GLVEGMIYNVGPFKDHDTYLKKCKEILQEQSELVHSILEATNLDM-ALKESREQIRLDQLIDSSLASYQSLAEVKGYQFE Ssu 
 252 ILIENMRENIGRYKDRDQYLGVALGIVDELNHHVLQILSLSSVQELRDD--RETIDLLQMTQNLVKDYALLAKERELQID Spn VncS 
 244 VLLEGMLENIGDYKDHSKYLRECIKMMDRQGKIISEILELVSLNDGRIVPIAEPLDIGRTVAELLPDFQTLAEANNQRFV Efa VanS 
 401 SFAEGIKDGVS--KDTTYYTDVILEETENMNRLIVEMLELAKLESGTYKLDMTTFSIGELIQQVYTKLLFSMEEKHLQVN Bce 
          X-Region 
 342 INLEE-QFVKANKVYLLKAIKNIIDNAFHYTKSGGQVMIQLKDN----QLVIKNEAETLLTQQQMKQLFQPFYRPDYSRNR Spy HK13 
 336 VELSP-VLIEANPVYFLKAIKNILDNAFRYSCKEAIIRVVLR----QNQLIIENQVERVLSDEELDQVFRPFYRPDYSRDK Ssu 
 330 NSLTHQQAYLN-PSVMKLILSNLISNAIKHSVPGGLVRIGEREG----ELFIENSCSSEEQEKLAQS----FS--DNA-SR Spn VncS 
 324 TDIPAGQIVLSDPRLLQKALSNVILNAVQNTPQGGEVRIWSEPGAEKCRLFVLNMGVHIDDTALPRL-FTPFYRIDQARSR Efa VanS 
 479 IDVDPSIFVKANRSRIEQVVVNLLSNAIRYTPDGEKIQVSVMEMEDTVKVEIENTGNPIPEESLEKI-WDRFYRLDASRSR Bce 
    N-Box        F-Box 
 418 KDGGTGLGLFITHQILDQHHLAYRFVVLDQRWMVFTIDFPSHHDD                                    Spy HK13 
 412 KDGGIGIGLFIIQKILEKHGFPYTFYASDTQTMRFMIHLQSQSTANSNELI                              Ssu 
 399 KVKGSGMGLFVVKSLLEHEKLAYRFEM-EENSLTFFIDFPKVVQD                                    Spn VncS 
 404 KSGRSGLGLAIVQKTLDAMSLQYALEN-TSDGVLFWLDLPLTSTL                                    Efa VanS 
 559 HTGGTGLGLSIVKNILDLHHAEYGVYN-TTNSVVFYFNLQKVKEVK                                   Bce 
 G-Box 
Figure 27:  Sequence alignment of HK13 of S. pyogenes M1 with homologue histidine kinases from other 
bacterial species. Spy = S. pyogenes; Ssu = Streptococcus suis; Spn = Streptococcus pneumoniae; Efa = 
Enterococcus faecalis; Bce = Bacillus cereus. Conserved residues are indicated in red, signature sequences 
and transmembrane helices are shaded. The missing D-Box is indicated between the N- and F-Box.  
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2.6.2.2. Chromosomal neighbourhood of the TCS13 
TCS13 was chosen for mutagenesis studies due to its interesting chromosomal 
neighbourhood, which comprises a number of well-characterized streptococcal virulence 
genes. A more detailed overview of the chromosomal neighbourhood, including putative 
transcriptional terminators is given in Fig. 28. In the other so far sequenced S. pyogenes 
genomes, the neighbourhood of this two-component system is nearly identical. Upstream of 
rr13 lies an ABC transporter, which shows homologies to a transporter with unknown 
functions from Streptococcus cristatus. Downstream of the histidine kinase hk13, the gene isp 
is located, which encodes the immunogenic secreted protein, and probably lies within the 
same operon as TCS13. The biological function of Isp is yet unknown, however McIver et al. 
(148) have demonstrated that inactivation of the gene had no effect on the transcription of M-
protein. Nevertheless, it is expressed and exposed to the host during infection, since serum 
isolated from a patient suffering from streptococcal infection recognized forms of this protein. 
Additional analysis of Isp using protein family searches (PFAM) revealed the presence of a 
CHAP (cysteine, histidine-dependent amidohydrolases/peptidases) domain within this 
protein. These domains are found in many uncharacterized proteins for which a function in 
peptidoglycan hydrolysis has been proposed (13). Consequently, Isp might have a similar 
function in S. pyogenes. 
Downstream of isp, the gene for the multiple gene activator Mga is located, which influences 
expression of a number of virulence factors (see section 1.3.2.1). Downstream of mga, sic, as 
well as an uncharacterized open reading frame of 84 amino acids, and scpA, encoding C5a 
peptidase precursor, are located.  
Figure 28: Chromosomal neighbourhood of tcs13 (response regulator rr13 in yellow, histidine kinase hk13 in 
blue). Isp refers to the structural gene of immuno-secreted protein, mga encodes the single regulator Mga, 
emm1 the M1 protein, orf represents an uncharacterized open reading frame, and sic the streptococcal inhibitor 
of complement. Downstream of tcs13 three structural genes encoding an ABC transporter are located. Putative 
transcriptional starts are indicated as arrows, terminators as loops.  
hk13rr13
Streptococcal chromosome
isp mga emm1 sicorfABC transporter
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2.6.2.3. Growth characteristics of the TCS13 mutant 
In regular culture broth, the TCS13 mutant did not show any altered growth rate (see section 
2.4.), and therefore met the requirements needed for further studies. However, the TCS13 
mutant showed different sedimentation behaviour in comparison to the wildtype. In mid-
exponential to stationary phase, the wildtype showed strong aggregative behaviour, however 
the mutant did not (Fig. 29). This phenomenon has already been observed with the TCS07 
mutant, where it was related to the lack of M protein expression on the bacterial surface 
(2.6.1.5.3). Therefore, this observation might again be directly linked to a reduced expression 
of this virulence factor on the surface of the TCS13 mutant. Results related to transcription of 
emm1 and presence of M-protein on the surface of the TCS13 mutant will be presented in 
section 2.6.3.7.1. 
.  
 
                                                                 
 
 
 
 
 
 
 
2.6.2.4. Contribution of the TCS13 to bacterial virulence in a mouse model of infection 
Although the role of the TCS13 in resistance to killing by phagocytic cells has already been 
demonstrated within the Lancefield Bactericidal Assay, its contribution to bacterial virulence 
during in vivo infection remains unknown. Using two different mouse models of infection 
(213), the contribution of TCS13 to streptococcal virulence was evaluated in terms of (i) 
survival times of infected mice; (ii) bacterial dissemination to systemic organs; (iii) resistance 
to phagocytosis by PMNs and macrophages.  
2.6.2.4.1. Survival time of infected animals  
In a first approach, the survival times of mice subcutaneously infected with 2.5 × 108 cfu of 
either wildtype or mutant was monitored over a period of seven days. Results depicted in Fig. 
30 show that while 100 % of animals infected with the wildtype strain died between day 2 and 
three postinoculation, 80 % of mice infected with the mutant survived until day 7. The 
∆WT ∆TCS13 
Figure 29: Sedimentation behaviour of KTL3 and its isogenic 
mutant ∆TCS13. An arrow indicates sedimented wildtype 
bacteria. 
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extended survival of ∆TCS13-infected animals suggests a loss of virulence associated with 
the knock-out of this regulatory system. However, the severeness of the skin lesions was 
comparable in both groups of mice, indicating a similar capacity of wildtype and mutant to 
survive and proliferate at the local infection site. 
 
2.6.2.4.2. Dissemination of bacteria from local infection foci to systemic organs and 
bloodstream.   
The possibility that an impaired ability of the mutant to spread from the local site of infection 
to the bloodstream and systemic organs might be responsible for the increased survival 
observed in ∆TCS13-infected mice was evaluated. Mice were infected subcutaneously with 
either wildtype or mutant, and the bacterial load at 24, 48, and 72 hours postinfection in blood 
and the whole systemic organs was determined. Because of the short survival times, bacterial 
loads in mice infected with the wildtype were only determined 24 hours postinfection (Fig. 
31). At this time of infection, between groups of mice infected with wildtype and mutant 
significant differences were found in the number of bacteria per organ. Thus, while wildtype-
infected animals exhibited 5.6 log10 bacteria in liver, 5.8 log10 in spleen, and 5.5 log10 in 
blood, bacterial counts in ∆TCS13-infected mice were lower with only 3.0 log10 bacteria 
detected in the liver, 1.57 log10 in spleen, and none in the blood. The number of bacteria was 
stabilized between 24 and 48 hours postinfection with a sharp decrease observed at 72 hours 
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Figure 30: Kaplan-Meyer plot showing the survival times of mice subcutaneously infected with 2.5 × 108
cfu of either KTL3 wildtype or ∆TCS13. 
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(Fig. 31). When bacterial counts in the skin of mice were determined, no significant 
differences were found between the wildtype- and mutant-infected animals.  
These results suggest that the TCS13 mutant is either impaired in the ability to spread from 
the local site of infection to the bloodstream and systemic organs, or it is more readily killed 
than the parental strain once it reaches the bloodstream; both possibilities can explain the 
lower bacterial count found in blood and organs of mice infected with ∆TCS13. The 
regulatory system seems does not play a role in the bacterial capability to survive and 
proliferate at the local infection site since the severity of the lesions were comparable for 
both, wildtype and parental strain.  
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Figure 31: Distribution of KTL3 wildtype and ∆TCS13 bacteria in mouse organs at 24, 48, and 72 hours 
after subcutaneous infection with 2.5 × 108 cfu.  KTL3 is displayed in blue, ∆TCS13 in red. (A) Bacteria 
isolated from liver. (B) Bacteria isolated from spleen. Bacterial loads in the blood of infected mice are not 
shown. 
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2.6.2.5. In vivo phagocytosis assay 
The ability of either the wildtype, or the ∆TCS13 strain to resist phagocytosis by PMNs and 
macrophages was evaluated using an in vivo phagocytosis assay developed by Goldmann et 
al. (78). This assay is based on the introduction of bacteria into the peritoneal cavity of mice 
and allows the evaluation of phagocytosis by either PMNs, which accumulate at the site of 
infection after 2-4 hours, or macrophages, which are present in the peritoneum ready to 
phagocyte bacteria immediately after inoculation.  
2.6.2.5.1. Bacterial uptake by murine macrophages 
First, bacterial uptake by murine macrophages was investigated for KTL3 and ∆TCS13. For 
that purpose, mice were intraperitoneally infected with 5 × 107 cfu of green-labelled wildtype- 
or mutant bacteria, left for 30 minutes for the phagocytic process to take place, and 
macrophages were isolated thereafter by performing peritoneal lavages. They were 
specifically labelled with a red-conjugated antibody and analysed by flow-cytometry (FACS). 
Double-positives, i.e. green and red fluorescent cells, represented macrophages associated 
with bacteria.  
The results displayed in Fig. 32 show the phagocytic activity of macrophages towards 
wildtype and ∆TCS13. Groups of mice infected with non-labelled bacteria were used as 
control (Fig. 32A and C). The percentage of macrophages associated with KTL3 and ∆TCS13 
is shown in the upper right square of Fig. 32B and D. 95.3 and 98 % of all isolated 
macrophages were associated with wildtype and mutant bacteria, respectively, indicating a 
strong phagocytic activity of these cells towards both microorganisms. 
FACS analysis has limitations, since macrophage-associated bacteria cannot be distinguished 
from intracellular-located ones. To distinguish between these two states, intraperitoneal 
infection experiments with non-labelled bacteria were performed and after isolation of 
macrophages, extracellularly attached bacteria were killed by gentamycin treatment. Cells 
were seeded onto coverslips, fixed, and for differentiation between intra- (red) and 
extracellular (green) bacteria, double immune fluorescence (DIF) was performed. 
Photographs displayed in Fig. 32 show wildtype (32E) and ∆TCS13 (32F) located mostly 
inside of macrophages, as seen by red colour. Due to the fluorescent filter, macrophages are 
only visible as shades when associated with bacteria. No differences can be detected between 
wildtype and mutant, indicating a similar ability of macrophages to phagocyte both strains.  
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Figure 32. A-D: FACS analysis of red-fluorescent-labelled macrophages associated with green-fluorescent-
labelled KTL3 and ∆TCS13. FL1-H (abcissa): relative green fluorescence (bacteria); FL2-H (vertical axis): 
relative red fluorescence (macrophages). Lower left square within each dotplot shows the non-macrophage 
population, the upper left square shows the labelled macrophage population, the lower right square 
corresponds to green fluorescent bacteria, and upper right square shows macrophages associated with 
wildtype (B) or mutant (D). Macrophages associated with unlabeled wildtype (A) or mutant (C) were used 
as control. E-F: Double-immune fluorescent photograph of wildtype (E) and ∆TCS13 (F) associated with 
macrophages. Extracellular bacteria appear in green, intracellular bacteria in red.  
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2.6.2.5.2. Bacterial uptake by murine PMNs 
The phagocytic activity of the second major phagocytic cell population (PMNs) towards 
wildtype and ∆TCS13 was investigated. For this purpose, mice were infected intraperitoneally 
with 5 × 107 cfu of either green-labelled wildtype or mutant, and left for two hours, allowing 
infiltration of PMNs from the blood to the infection foci and phagocytosis of bacteria. PMNs 
were isolated by peritoneal lavage and specifically labelled with a red-fluorescent antibody. 
Subsequent FACS analysis was performed for quantifying the percentage of PMNs associated 
with either wildtype or mutant, represented by double-positive (green and red) cells.  
The results in Fig. 33 show the phagocytic activity of murine PMNs towards wildtype and 
∆TCS13. Again, groups of mice infected with non-labelled bacteria were used as control (Fig. 
33A and C). The upper right square of Fig. 33B and D represents the percentage of PMNs 
associated with wildtype and ∆TCS13, respectively, and demonstrates that only 2.47 % of the 
wildtype, and 2.59 % of the mutant were phagocytosed. This low uptake could either be due 
to (i) a low phagocytic activity of PMNs towards both strains, or (ii) high phagocytic activity 
of macrophages, resulting in low amounts of bacteria remaining in the peritoneum after two 
hours. To further elucidate this possibility, mice were depleted of macrophages by treatment 
with carrageenan two days prior to infection, which additionally led to a significant increase 
of circulating PMNs. Carrageenan-treated mice were infected intraperitoneally with 5 × 107 
cfu of either wildtype or ∆TCS13, and PMNs were isolated by peritoneal lavage after 1 hour 
of infection. Extracellularly attached bacteria were killed by gentamycin treatment and PMNs 
were seeded onto poly-L-lysine coated coverslips to allow attachment of these usually non-
adherent cells. PMNs were fixed, and immune staining was performed for detection of intra- 
and extracellular bacteria. Photographs of PMNs associated with red-stained intracellularly 
located wildtype and mutant bacteria are displayed in Fig. 33E (wildtype) and 33F (∆TCS13), 
and show that most bacteria were situated intracellularly, independently of wildtype or 
mutant. Additionally, almost all PMNs were associated with bacteria. These results indicate 
that (i) results obtained before showing low amounts of bacteria associated with PMNs (Fig 
33B and 33D) are due to high phagocytic activity of macrophages, (ii) there are no differences 
in the ability of PMNs to phagocyte either wildtype or ∆TCS13. 
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Figure 33. A-D: FACS analysis of red-fluorescent-labelled PMNs associated with green-fluorescent-
labelled KTL3 and ∆TCS13. FL1-H (abcissa): relative green fluorescence (bacteria); FL2-H (vertical 
axis): relative red fluorescence (PMNs). Lower left square within each dotplot shows the non-PMN 
population, the upper left square shows the labelled PMN population, the lower right square 
corresponds to green fluorescent bacteria, and upper right square shows PMNs associated with 
wildtype (B) or mutant (D). PMNs associated with unlabeled wildtype (A) or mutant (C) were used as 
control. E-F: Double-immune fluorescent photograph of wildtype (E) and ∆TCS13 (F) associated 
with PMNs. Intracellular bacteria are displayed in red.  
2. Results          61 
2.6.2.5.3. Macrophage- and PMN killing assay  
The assay for bacterial uptake does not allow a differentiation between internalized live or 
dead bacteria, since dead bacteria and bacterial debris can still be detected by fluorescence. 
Since no differences could be observed between wildtype and mutant in the ability to resist 
uptake by phagocytic cells, the question remains of whether the attenuation of the wildtype 
and mutant strain seen in the animal model was due to a higher killing of these 
microorganisms after phagocytosis. To address this point, mice were intraperitoneally 
infected with non-labelled wildtype or mutant bacteria, and macrophages were isolated after 
30 minutes. For PMNs, carrageenan-treated animals were infected with wildtype or mutant, 
left for one hour, and PMNs were isolated by peritoneal lavage. Macrophages and PMNs were 
separately seeded into cell culture wells and treated with gentamycin for killing of 
extracellular located wildtype and mutant bacteria. For determining the amount of 
intracellularly located, live bacteria at time-point zero, half the wells containing PMNs and 
macrophages were treated with Triton-X-100, resulting in lysis of cells and release of 
intracellular bacteria, which were subsequently plated onto blood agar. The other wells were 
incubated for additional two hours, treated as described above, and the amount of remaining 
intracellular live wildtype and ∆TCS13 were determined by plating onto blood agar. 
Results displayed in Figure 34 show the percentage of viable wildtype and mutant bacteria 
isolated from either macrophages (34A) or PMNs (34B) after two hours of incubation and 
show that there are no differences in the killing rate of wildtype and mutant mediated by 
macrophages. Both strains are reduced by about 88 %, corroborating with the ability of 
macrophages to kill phagocytosed S. pyogenes. On the other hand, there is a clear difference 
seen in the ability of wildtype and mutant to resist killing by PMNs, the killing rate towards 
the ∆TCS13 strain is about 30 % higher than seen in the wildtype strain, resulting in nearly 
complete elimination of the mutant.  
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These results show that (i) macrophages are capable of efficiently killing wildtype and 
∆TCS13 strain to a similar degree, and (ii) that in contrast to the wildtype, the ∆TCS13 strain 
is nearly completely eliminated by PMNs. Consequently, it seems that the TCS13 confers 
high resistance against phagocytic killing, enabling bacteria a superior intracellular survival, 
as recently shown for human PMNs (219). 
2.6.2.6. Transcription analysis of virulence factors 
Results obtained from the Lancefield Bactericidal Assay (2.5.) and the Macrophage- / PMN 
killing assay (2.6.2.5.3.) indicate an altered resistance to killing after phagocytosis, since 
mutant bacteria are more readily eliminated. A number of different streptococcal surface 
proteins have been shown to be involved in resistance to phagocytosis and killing such as the 
M protein and SIC (see section 1.1.2.). 
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Figure 34: Survival of wildtype and ∆TCS13 in murine macrophages (A) and PMNs (B) after two 
hours. Results are shown as percentage of the initial number of intracellularly located bacteria at 
time-point zero, which refers to the bacterial number after gentamycin treatment. 
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For the identification of the underlying molecular factors responsible for the elimination of 
mutant bacteria, transcription levels of two main antiphagocytic proteins – M1 protein and 
streptococcal inhibitor of complement (SIC) -  were compared between wildtype and ∆TCS13 
mutant. Results shown in Fig. 35 demonstrate a strong transcription of both virulence factors 
in the wildtype strain. Transcriptional analysis of these factors in the mutant, however, 
showed comparable transcript levels. Therefore, both virulence factors are transcribed at the 
same rate, demonstrating that differences seen in the Lancefield Assay are not due to lower 
amounts of transcription of these genes in the regulatory mutant.   
 
 
 
                                                    
 
 
 
 
 
 
 
 
 
 
2.6.2.7. Expression and processing of virulence factors   
Transcriptional analysis of known main antiphagocytic streptococcal factors did not show 
differences between wildtype and mutant and could therefore not explain the differences seen 
in the Lancefield Assay. Since regulation at the posttranscriptional- and modifications at the 
postranslational level are frequently found for streptococcal surface proteins (e.g. by SpeB, 
1.1.2.5.) analysis of protein amounts and activity were performed in parallel. The hyaluronic 
acid capsule as non-proteinacious antiphagocytic factor was included. 
2.6.3.7.1. M1 protein 
In order to detect possible differences in the presence of streptococcal surface proteins 
between the wildtype and regulatory mutants, protein lysates containing cell wall fractions 
and cytosolic proteins, as well as supernatants containing secreted streptococcal proteins were 
A B 
WT ∆TCS13 WT ∆TCS13 
Figure 35: Northern Blot analysis of broth-derived KTL3 and ∆TCS13. (A) Detection of emm1 transcript (M 
protein). (B) Detection of sic transcript (SIC). 
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separated by 1-dimensional gelelectrophoresis. No differences could be seen between cell 
wall / cytosolic fraction of wildtype and ∆TCS13 (data not shown), however in TCA-
precipitated supernatants a ≈ 28 kDa sized protein was observed in the regulatory mutant (Fig. 
36A) that was absent from the culture supernatant of the wildtype. Maldi-TOF analysis of this 
28 kDa protein revealed this protein to be the N-terminal fraction of the M-protein (reliability-
score: 93), matching distinct peptides ranging from amino acid 31 to 180 of the M protein 
precursor (Acc. Nr.  AAN46657) (Fig. 36B). Western Blot analysis using KTL3 M1-specific 
polyclonal antibodies confirmed this fraction to be M protein (Fig. 36C). These results 
demonstrate that a processing of the M protein in the ∆TCS13 strain occurs, releasing the N-
terminal part of this important virulence factor from the streptococcal surface.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: (A) Coomassie stain of KTL3 (lane 1) and ∆TCS13 (lane 2) precipitated supernatants. 
Arrow indicated the truncated M protein. (B) Maldi-TOF analysis of the truncated M protein. 
Matched peptides are shown in red. (C) Western Blot analysis of the precipitated supernatant using an 
M1-specific polyclonal antibody. Lane 1: wildtype, lane 2: ∆TCS13. 
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Sequence comparisons of the released M1 protein with published structural analyses of the 
M6 protein (68), revealed the site of truncation within the variable B-repeats of the protein 
(Fig. 37).   
 
The A- and B repeats of the M protein mediate fibrinogen binding (17, 227), an attribute that 
leads to obstruction of complement binding to streptococcal cell wall structures and therefore 
protection against uptake by phagocytic cells (227). Truncation of the M protein within the B-
repeats could result in loss of the fibrinogen-binding activity, thus explaining increased killing 
within the Lancefield Bactericidal Assay, as well as the attenuation of the mutant in the 
mouse model of infection. Therefore, the M protein’s fibrinogen binding capability of 
∆TCS13 was more closely evaluated. For this purpose, fibrinogen binding of the truncated 28 
kDa fragment was investigated by Western analysis. Blotted 28-kDa fragments were 
incubated with human fibrinogen, subsequently followed by detection using an anti-
fibrinogen antibody. Results shown in Fig. 38 show a strong signal from the 28-kDa 
fragments, as well as from the recombinant M protein, which served as positive control. A 
negative control, incubating the 28-kDa fragments with the applied antibodies, gave no signal 
(data not shown). These results clearly show the fibrinogen binding capability of the truncated 
M protein.  
 
N C
A-Repeats B-Repeats C-Repeats D-Repeats Pro/
Gly
Membrane 
Anchor
Truncation
Figure 37: Schematic overview of the M protein as already shown in the introduction (1.1.2.2.). The area 
of truncation, resulting in release of the 28 kDa fragment is indicated.  
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Figure 38: Binding of immobilized M protein to human 
fibrinogen. 1. Human fibrinogen (positive control); 2. 
Recombinant M1 protein (positive control); 3. Truncated M 
protein from ∆TCS13. 
 
Loss of the N-terminal, fibrinogen-binding region of the M protein would ultimately lead to 
the inability of the ∆TCS13 strain to bind this plasma protein. Consequently, it was 
investigated whether and to what degree whole mutant streptococci were able to bind to 
radiolabelled fibrinogen. Results presented in Fig. 39 show the binding capability of KTL3 
and ∆TCS13 as percentage of the fibrinogen used in this assay. The wildtype showed a high 
fibrinogen binding ability; it bound 84.19 % of all applied fibrinogen, which corresponds to 
approximately 505 ng. In contrast, ∆TCS13 merely bound 12.56 % of the fibrinogen, 
corresponding to ≈ 75 ng, showing that the regulatory mutant bound almost 7 × less labelled 
fibrinogen that the wildtype. These results stress the importance of the M protein in 
fibrinogen binding and correlate the truncation of this protein in the TCS13 mutant with a loss 
of binding capability.  
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Figure 39: Binding of radiolabelled fibrinogen to KTL3 and ∆TCS13. Results represent the mean 
of three independent experiments and are presented as percentage of all fibrinogen used in this 
assay. 
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If a cleavage of the M protein from the surface of ∆TCS13 occurs, the approximately 27 kDa 
sized C-terminal part, composed of the last B- and the C-repeats (Fig. 37) should be 
detectable on the surface of the Streptococcus Acidic extractions of the M protein from the 
streptococcal surface were used for Western blot with polyclonal anti-M1 antiserum, raised 
against the whole protein. Maybe due to the high inspecificity and binding of the antibody to 
a number of streptococcal proteins under denaturing conditions, no band specific for a 
truncated M protein could be identified (data not shown). Another possibility to detect 
surface-located M1 protein is direct microscopic analysis using a gold-labelled M1 antibody. 
Since this method is performed under native conditions, the cross-reactivity of the antibody 
with other streptococcal proteins under denaturing conditions is minimized. Therefore, broth-
grown bacteria were incubated with purified M1 antibody, and visualized using field emission 
scanning electron microscopy (FESEM). Again, since the M1 antibody recognizes the whole 
M1 protein, the remaining cleaved fragment located on the bacterial surface should be 
detectable. Figure 40A shows wildtype bacteria incubated with anti-M1 antibody. On the 
surface, a high amount of M protein is detectable, as seen by white dots. In some regions, 
these dots appear in chains, which is probably due to multiple binding of the polyclonal 
antibody to different region of the surface protein. Figure 40B, on the other hand shows the 
∆TCS13 strain. Unexpectedly, less M protein seem to be localized on its surface. However, 
still more protein is visible than in the negative control, which in this case is the M-negative 
strain KTL3∆TCS07 (Fig. 21 page 44). The appearance of less M protein on the surface of 
∆TCS13 could be caused by: (i) comparable expression of the M protein, but instability of the 
C-terminal, surface-located part, (ii) lower expression of M protein in the mutant, or (iii) 
comparable expression, but a reduced number of binding sites for the polyclonal antibody, 
due to the shorter length of surface-located M protein. However, the C-terminal part of the 
protein is still located on the surface of ∆TCS13, and consequently the release of the 28 kDa 
fragment is with high probability due to a protease activity. The cysteine protease SpeB is 
known to mediate cleavage of the M protein from the streptococcal surface, and therefore its 
activity in wildtype and mutant was investigated in section 2.6.2.7.2. 
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2.6.2.7.2. M protein-directed proteolytic activity 
It has been described that the cysteine protease SpeB leads to degradation of the M protein 
and is mainly upregulated during late-logarithmic, to stationary growth phase (137). 
Proteolytic activity of SpeB in culture supernatants can be determined on the basis of 
degradation of azocasein, which can be photometrically detected. Analysis of the proteolytic 
activity of SpeB in culture supernatants revealed no differences between KTL3 and ∆TCS13, 
as seen in Figure 41. Wildtype supernatants exhibited an average absorbance at 366 nm of –
0.0455; the absorbance of supernatants derived from the mutant was with –0.0625 almost 
equal to the values obtained from the parental strain. Negative optical densities of both strains 
indicated no SpeB activity. In contrast, supernatants of the positive control A5448 showed an 
absorbance of 0.49. When cultures were grown in the presence of cysteine protease inhibitor 
and subjected to activity measurement, the absorbance of the positive control dropped to -
0.053, showing the efficacy of the inhibitor and specificity of this assay for SpeB. These 
results show that in both, wildtype and ∆TCS13 mutant, the SpeB activity is low and 
therefore this protease is not the responsible factor leading to the cleavage of the M protein 
from the surface of ∆TCS13.   
  
A B
Figure 40: FESEM picture of KTL3 (A) and ∆TCS13 (B), with gold-labelled anti-M1 antibody. Bar 
corresponds to 0.5 µm. 
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Figure 42: Precipitated supernatants of KTL3 wildtype (1 and 
3) and ∆TCS13 (2 and 4) grown in the presence of complete 
protease inhibitor (1 and 2) or cysteine-protease specific 
inhibitor (3 and 4). An arrow indicates the location of the 
truncated M protein. 
 
To further prove the hypothesis that not SpeB, but a different protease is responsible for the 
cleavage of the M protein from the surface of ∆TCS13, wildtype and mutant strain were 
grown over night in the presence of two different protease inhibitors, one for the complete 
inhibition of secreted proteases, the other one specific for the streptococcal cysteine protease 
SpeB. If the cleavage was mediated by a secreted protease, the truncated M protein should no 
longer be detectable. Coomassie stain of precipitated supernatants (Fig. 42) however showed 
that in both cases, the 28 kDa-sized M protein it still present.  
 
Figure 41: Analysis of proteolytic activity in culture supernatants from KTL3, ∆TCS13, and strain 
A5448 as positive control grown in THY medium after activation of SpeB by a reducing agent. 
Absorbance was measured at 366 nm. 
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Therefore, the cleavage is either not mediated by a secreted protease, or the added inhibitors 
are not long enough stable for a complete inhibition of proteolytic activities. Biswas et al. 
(2001) made the same observations of a cleaved M protein in a M6 S. pyogenes strain with a 
deletion in sagA, the gene encoding streptolysin S. This cleavage resulted in the same 28 kDa-
sized fragment and could not be inhibited by protease inhibitors. They concluded that the 
proteolytic activity was not due to a secreted protease, but to a surface-located one. To further 
address this question and to exclude the instability of the protease inhibitors, supernatants and 
cytosolic fractions of early- and mid-logarithmic, as well as stationary grown ∆TCS13 
bacteria were incubated for different time periods with recombinant M1 protein from KTL3. 
Using bacteria from different growth phases should ensure the detection of the M-cleaving 
protease, independent from growth phase-dependent expression. Probes were separated by 1-
dimensional SDS-PAGE and analysed for the 28 kDa-sized M protein. However, the cleaved 
part of the M-protein was at no point detectable. After over night incubation, a gradual 
degradation of the M protein could be observed, which occurred in all probes independently 
of the strain (data not shown). This indicates that that either the cleavage is not protease-
mediated, or the activity could not be measured under given conditions.  
2.6.2.7.3. Hyaluronic acid capsule  
In 2.6.1.5.1., the hyaluronic acid capsule is already described in more detail. The obvious 
differences in capsule expression described for the TCS07 mutant could also be observed for 
the ∆TCS13 strain. As seen in Fig. 43, wildtype colonies (43B) rising from the liver of 
infected animals have a highly mucoid phenotype when compared to broth-derived bacteria 
(43A and 43C). In contrast, colonies of the ∆TCS13 strain colonies are not mucoid (43D).  
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For quantification of the differences seen on plate, the amount of cell-associated capsule of 
colonies isolated from murine blood was measured. Tab. 10 shows the amount of hyaluronic 
acid capsule from these colonies. For the wildtype, an amount of 64.5 fg/cfu of hyaluronic 
acid capsule could be detected, whereas the ∆TCS13 strain expressed only 11.6 % of the 
amount detected for the wildtype, corresponding 18 fg/cfu, respectively.  
 
Tab. 10: Amount of cell-associated hyaluronic acid capsule isolated from blood-passaged bacteria, which were 
subsequently grown on blood agar plates.  
 
 
 
 
 
 
 
These results show that the deletion of the two-component system results in a decreased 
expression of hyaluronic acid capsule in the ∆TCS13 strain under stress conditions, since no 
differential expression could be observed under standard broth conditions (data not shown).  
 
 Hyaluronic acid capsule 
[fg/CFU] 
KTL3 WT 64.5 ± 34.6 
KTL3 ∆TCS13 18 ± 16.9 
Figure 43: KTL3 (A) and ∆TCS13 (B) isolated from mouse liver and subsequently grown on blood 
agar plates. 
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Over all, except from the hyaluronic acid capsule, transcription- and expression analysis of 
virulence factors in ∆TCS13 did not show differences in comparison to the mutant, However, 
in the mutant a processing of the M protein could be observed, resulting in release of the N-
terminal part and loss of the fibrinogen binding capability. The protease responsible for this 
cleavage is neither the known M protein-modulating cysteine protease SpeB, nor any other 
secreted streptococcal proteases, and still needs to be identified.  
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3. Discussion 
On the basis of the sequenced S. pyogenes strain SF370, thirteen two-component systems 
could be identified (66). Of these systems, three have been more closely investigated towards 
their influence on this pathogen’s virulence in vivo and in vitro. (60, 120, 219). The objective 
of this study was the identification and characterization of other bacterial TCS involved in 
streptococcal in vivo virulence. For this purpose, mutant strains of S. pyogenes deficient in the 
expression of two-component systems were generated.  
Unlike other bacterial species, Group A streptococci are not known to exhibit natural 
competence (66) and due to thick peptidoglycan layers of the cell wall and expression of 
hyaluronic acid capsule, successful bacterial transformation was a difficult task. A number of 
protocols, such as treatment with lysozyme for weakening the cell wall (128), addition of 
threonine or glycine (55) to growing cells, and the application of different DNA forms 
(plasmid- or linear DNA, transposons) and amounts (1-5 µg) have been described to improve 
the efficiency of S. pyogenes transformation (30, 197). However, some strains of S. pyogenes 
cannot be successfully transformed at all (151). Therefore, one major obstacle to overcome in 
this study was the introduction of DNA into S. pyogenes. Several strains, methods, buffers, 
and different vectors were tested, but only using an adjusted method described by 
McLaughlin and Ferretti (151) based on the use of the pJRS233 vector (Perez-Casal et al., 
1993) yielded transformants. As recipient, S. pyogenes strain KTL3 was used, which was 
prior described as transformable (179), as well as mouse-virulent in a skin model of infection 
(213).  
Another requisite for performing studies in the mouse model was the generation of stable, 
double cross-over mutant strains. Maintenance of antibiotic selective pressure during in vivo 
infection is a difficult issue and mutations introduced into genes needed for full virulence and 
bacterial survival within the host increase the selective pressure towards revertants (11). A 
selection for transformants harbouring a double cross-over would have been possible directly 
after transformation by applying selective pressure (spectinomycin) at 37°C. However, 
transformation efficiencies for KTL3 were already low and an additional selection on double 
cross-over mutants did not yield any transformants. Consequently, in this study, stable double 
cross-over mutants were generated by passaging single cross-over mutants until complete loss 
of the vector and stable integration of the construct into the chromosome. Since in the case of 
S. pyogenes, it has been observed that successive laboratory passages can lead to attenuated 
virulence (202), it was additionally necessary that the wildtype strain underwent a similar 
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number of passages for comparison studies. For subsequent virulence studies, only the 
passaged wildtype strain was used.  
An additional challenge was the generation of constructs used for transformation. Integration 
of the plasmids by double cross-over ultimately led to a frameshift within the targeted gene 
and to a transcriptional stop after the spectinomycin cassette. Therefore, downstream effects 
on genes lying within the same operon could not be prevented. Different approaches for the 
generation of TCS knock-outs have been used, such as the introduction of point-mutations, 
leading to inactivation by exchange of an active residue in e.g. the response regulator (230), 
or in-frame deletions by replacing large internal fragments without disturbing the reading 
frame and transcription (102). The aim of this study was to fully inactivate the whole TCS. 
With the introduction of point-mutations or in-frame deletions though, only a single gene of 
the whole system would have been affected by partial deletion, and the absence of cross-talk 
events as they occur between different TCS-members (217), as well as remaining functions of 
the mutated genes could not have been guaranteed.  
Within this study, five different stable mutants deficient in the two-component systems 
FasCA, TCS07, TCS09, TCS11, and TCS13 (Irr/Ihk) were generated in the KTL3 
background, which is a blood isolate of the M1 serotype (179). No mutant exhibited any 
growth deficiencies under standard conditions, indicating that none of these TCS contribute to 
the regulation of genes needed for viability of S. pyogenes. 
For elucidating the possible role of these TCS in streptococcal virulence, the classical 
Lancefield Bactericidal Assay was performed (126). This assay is based on the incubation of 
S. pyogenes in fresh human blood mainly containing PMNs, but also macrophages, and allows 
evaluation of the bacterial antiphagocytic activity. When the mutants were tested for their 
ability to resist phagocytosis, surprisingly, four out of five mutants displayed a reduced 
ability. However, the level of antiphagocytic resistance was highly variable among different 
TCS mutants, ranging from a partial resistance (23% reduction of the ∆FasBCA strain) to 
high susceptibility (92.8% reduction of the ∆TCS07 strain). A number of regulators have been 
shown to be up- or downregulated during the bacterial encounter with human PMNs, 
including single regulators such as Mga, as well as other not yet characterized (219). Except 
of the Irr/Ihk system, which was upregulated, none of the other TCS included in this work 
were found to be differentially transcribed during the encounter with human PMNs (219). 
However, this does not necessarily exclude their role in bacterial virulence, since the 
regulatory control of target genes does not occur by up- or downregulation of the TCS, but 
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rather on the state of activity, reflected by their phosphorylation level.  
In order to narrow further analysis, two mutants that exhibited the highest reduction within 
the Lancefield Bactericidal Assay were chosen for more detailed studies. These were the 
TCS07 and the TCS13 mutant, which were reduced by 76.4 % and 92.8 %, respectively. 
 
Regarding the TCS07-deleted strain, sequence alignments of the RR07 with the other known 
four families of OmpR, AraC, LuxS, and LytTR (204) did not find significant similarities, 
hindering the potential affiliation of this TCS into one of these families. Nevertheless, RR7 
shares homologies with a family of TCS (CitAB) described by Mizuno et al. (156) in E. coli. 
Closer analysis of the sequence structures of HK07 revealed aberrancies and similarities when 
compared to similar histidine kinases of the same family. One interesting feature that HK07 
shared with the other kinases was the presence of an intracellular PAS domain. These 
domains are involved in the sensing process of intracellular signals, such as pH, light, and 
oxygen (212). For other histidine kinases of the CitAB family, tri- or dicarboxylates such as 
fumarate and citrate have been identified as signals for this domain (113, 166, 181). 
Therefore, it seems conclusive that this sensor additionally or merely responds to such an 
intracellular signal, which might be identical among the similar histidine kinases. However, in 
contrast to the other kinases, HK07 did not share very close sequence homologies within the 
signature sequences, even within the HPK5 subfamily of histidine kinases (82). An additional 
striking feature was the partly absent G-Box. Therefore, it could be hypothesized that these 
aberrations are due to either mutations within the kinase, or that HK07, despite of being 
included in the same subfamily of TCS, is in fact involved in the sensing of other signals.  
For other members of the CitB-family, such as DcuR and CitB of E. coli, the involvement in 
C4-dicarboxylic acid utilization has been shown (77, 232). Due to the high homology of 
TCS07 of S. pyogenes to these two-component systems involved in C4-dicarboxylate 
metabolism, further investigations on the ability of this mutant to grow in the presence of 
different carbon sources was investigated. In the particular case of S. pyogenes, metabolic 
studies have rarely been performed and little is known about its ability to utilize a variety of 
carbon sources. In this work, neither the wildtype-, nor the mutant strain could grow in the 
absence of glucose with exchanged C4-compounds, impeding the possibility of making any 
statement about differential C4-utilization capabilities. In Streptococcus bovis and 
Streptococcus faecalis, the utilization of malate has been studied in more detail (132, 114, 
115), and S. pyogenes contains two malate utilizing genes encoding a malate permease and a 
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malic enzyme, which are located adjacent to the TCS07 on the chromosome. However, 
neither wildtype-, nor mutant strain were able to grow on malate as sole carbon source, and 
the transcript for the permease and transporter were also undetectable under malate-containing 
growth conditions (data not shown). Therefore, the involvement of TCS07 in the regulation of 
these proteins could not be shown, but cannot be excluded. The activity of TCS07 under 
malate-containing conditions though seems obvious since the presence of this C4-compound 
lead to differential sedimentation behaviour of the wildtype, which then equaled that of the 
mutant. Aggregative behaviour of S. pyogenes strains in liquid culture has been described by 
Frick et al. (73), who were able to identify a sequence present on the M protein, as well as on 
another M-like protein to be the cause for this phenotype. Therefore, the lack of the 
aggregation of the wildtype under malate-containing conditions was thought to be due to a 
lower expression of M protein on the surface of KTL3 and consequently, it was assumed that 
TCS07 functions as a positive regulator in malate-free medium, inducing transcription of e.g. 
emm1, and repressing this transcription if malate is present. However, emm1 transcripts could 
be detected in the wildtype independently of malate, and it can be concluded that the 
differential sedimentation behaviour is not due to distinct emm transcription.  
The involvement of TCS07 in bacterial virulence was investigated using an already 
established skin infection model for KTL3 (213), in which 2.5 × 108 cfu are injected 
subcutaneously. The TCS07 mutant strain was found to be highly attenuated shown by the 
less severe skin lesions, lower rate of bacterial dissemination to systemic organs, and efficient 
bacterial clearance when compared to the wildtype strain.  Therefore, the presence of an intact 
TCS07 contributes to in vivo bacterial persistence and dissemination and it is critical for 
bacterial survival in this environment.  
The basis for the reduced fitness of the mutant to survive in vivo (mouse model) or in vitro 
(Lancefield Bactericidal Assay) could have diverse reasons. From the metabolic aspect, it 
might be due to an impaired ability of the TCS07 mutant to utilize essential energy sources 
needed for survival under stress conditions and full virulence (153), as it has been 
hypothesized for an Rgg mutant (35). In this regard, a massive upregulation of hyaluronic 
acid capsule could be detected in the wildtype strain after blood- or mouse passage, but not in 
the mutant. The important role of hyaluronic acid capsule in streptococcal virulence has been 
shown extensively (104, 190, 224) and besides the M protein, the capsule represents one of 
the major streptococcal virulence factors. For accomplishing synthesis of large amounts of 
this polysaccharide, the ability to utilize alternative energy sources could play an essential 
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role. When wildtype and TCS07 mutant were grown in standard, nutrient-rich medium, no 
differences in capsule expression were observed between wildtype and ∆TCS07, both strains 
showed a moderate expression. Therefore, the reason for the mutant’s disability to upregulate 
capsule expression in vivo might be caused by a deficiency in either nutrient-utilization, 
resulting in lack of sugar availability needed for capsule expression, or in an inability to 
upregulate capsule transcription under stress-situations. A difficulty encountered for 
transcriptional- and expressional analysis using RNA and proteins from bacteria isolated from 
infected animals was that not enough material could be obtained. As an alternative approach, 
sub-cultured bacteria isolated from mice could have been used. However, due to the fast 
elimination of the mutant, this approach was not feasible for this study. Instead, 
transcriptional- and expressional analysis was performed with broth-cultured bacteria 
assuming that regulatory differences would still be detectable. Transcriptional analysis of 
broth-grown bacteria however, did not yield any detectable transcripts for genes of the 
capsule locus, and therefore the underlying reason for the poor capsule expression of the 
∆TCS07 strain in comparison to the wildtype under in vivo conditions still needs to be 
elucidated. 
The M protein is the best characterized streptococcal virulence factor, and its important 
contribution to resistance against phagocytosis, as well as virulence in animal models has 
been shown (89, 98, 169). The streptococcal protein SIC, on the other hand, has been shown 
to have an antiphagocytic effect by interfering with complement function (2) and it 
additionally inhibits host antimicrobial peptides (74). Investigations on the M- and SIC 
protein expression in the ∆TCS07 strain showed the lack of these important virulence factors. 
Northern analysis from broth-grown bacteria confirmed that the absence of these proteins in 
the mutant is not due to posttranslational events, but to lack of transcription. Consequently, 
the mutation the ∆TCS07 strain seems to affect the transcription of these two major virulence 
factors, which have both been shown to be under regulatory control of the single regulator 
Mga (121). This lead to the assumption, that TCS07 might negatively influence Mga activity, 
leading to a shutdown of genes under its control. Since Mga also controls its own 
transcription, it can be postulated that the level of Mga might also differ between wildtype 
and TCS07 mutant strain. However, the Mga-transcription rates were below detection limits 
in both, wildtype and TCS07 mutant, hampering the possibility of finding differences at this 
level. Another study, however, also investigated the transcriptional influence of a RR07 
mutant on the transcription of emm and mga. In contrast to these results, the authors did not 
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find any differences between wildtype and mutant (182). Serotype-specific regulations can be 
excluded, since they investigated this mutation in an M1- as well as an M6 serotype. The 
conflicting results between the study of Ribardo et al. (182) and this study might be caused by 
differential mutagenesis approaches. Ribardo et al. (182) introduced a mutation in the 
response regulator, and due to the organization of the TCS07, with the histidine kinase 
preceding the response regulator, a mutation does not lead to knock-out of the whole TCS. 
Therefore, remaining activity of HK07 might contribute to the differences seen in both 
studies.  
The ability to adapt the expression of virulence factors needed specifically at different sites of 
the host is a crucial virulence function for S. pyogenes. Here, the involvement of the TCS07 in 
the ability of GAS to adapt to a local skin infection (mouse model) and to survive in the 
bloodstream (Lancefield Bactericidal Assay) was investigated. In both environments, the 
mutant failed to resist the host immune defenses and was readily eliminated. The disability of 
the mutant to resist to phagocytic killing was with high probability due to the lost M protein- 
and SIC expression, as well as to the incapability to produce adequate amounts of hyaluronic 
acid capsule. In addition, the mutant strain was deficient in the ability to bind fibrinogen, 
which presents another colonization- as well as antiphagocytic factor. These streptococcal 
factors and their underlying functions are needed at nearly all sites of infection and 
consequently, it can be speculated that this TCS is critical for bacterial virulence. 
 
Regarding the TCS13, sequence homologies of the N-terminal part of RR13 showed an 
affiliation of this regulatory system into the OmpR family of regulators, which comprises a 
large number of functionally different two-component systems (204). Due to the high 
variability of regulatory tasks of different TCS within this family, it was not possible to assign 
a putative function to this streptococcal system on the basis of sequence homologies. 
Moreover, in HK13 and its homologues, the D-Box as part of the ATP-binding domain is 
absent, and this could have an impact on the phosphorylation qualities of this kinase. 
Nevertheless, the absence of D-Boxes can also be found in other histidine kinases such as 
CopS of Pseudomonas syringae (155) and PcoS of E. coli (26), both involved in copper 
resistance. These kinases, as well as others lacking this signature sequence, have been shown 
to be an active part of a regulatory system. Therefore, even though this conserved region is 
not present in HK13, it is likely that the phosphorylation-activity of this kinase may be 
functional.     
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Located downstream of TCS13 on the streptococcal chromosome, a not yet closely 
characterized protein, Isp, is encoded, which is expressed during the infections process of S. 
pyogenes (148). Protein family scans of Isp identified a CHAP domain within this protein. 
The CHAP domain is often found in association with other domains that cleave 
peptidoglycan, a process playing an important role in bacterial cell division, cell growth and 
cell lysis (13). Since investigations of the TCS13 operon structure did neither find a promotor 
with a typical consensus sequence, nor a strong palindrome as putative transcription 
terminator, the introduced mutation within this system could lead to downstream effects on 
the transcription of isp. Consequently, effects observed within the virulence studies could be 
linked to a lost expression of this protein. However, streptococcal transcriptome analysis 
during PMN encounter showed an upregulation of tcs13, but not of isp (219). Thus, since 
location of these genes within the same operon would ultimately lead to upregulation of both, 
they do not seem to be co-transcribed.   
During the infection process, S. pyogenes has to resist the host defense mechanisms, such as 
phagocytic host cells in order to survive and to disseminate (97). The contribution of TCS13 
to bacterial protection against phagocytic cells was demonstrated here in the whole blood 
Lancefield Bactericidal Assay. These results further confirmed the data from Voyich et al. 
(219), showing the involvement of this system in streptococcal survival inside human PMNs. 
To evidence that the same mechanisms occurred during the interaction of S. pyogenes with 
murine PMNs, the bacterial uptake activity was determined using PMNs that infiltrated the 
intraperitoneal cavity of mice after streptococcal i.p.-infection. The results showed that both, 
wildtype and mutant strain were phagocytosed to a comparable degree. In order to determine 
the ability of PMNs to kill the wildtype and mutant strain, mice were depleted of 
macrophages in order to increase the number of PMNs inside of the peritoneal cavity and to 
prevent bacterial uptake by macrophages, which would subsequently lead to low amounts of 
bacteria remaining for PMNs to phagocyte. The results showed that inside PMNs, the mutant 
was more readily eliminated than the wildtype strain. Therefore, this regulatory system 
contributes to the ability of S. pyogenes to resist the killing mechanisms of PMNs and confirm 
observations made by Voyich and colleagues (219) with human PMNs. When phagocytic 
uptake activity and killing of bacteria by murine macrophages was investigated, no 
differences between wildtype and mutant strain could be observed. Therefore, the TCS13 
does not contribute to streptococcal resistance against uptake and killing by murine 
macrophages. 
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The murine infection model reflected the ability of S. pyogenes to colonize the skin and to 
establish infection, as well as its capacity to disseminate from the local site into systemic 
compartments. In this model, the mutant exhibited a decreased virulence, reflected by the 
superior survival of infected animals and the lower rates of bacteria present in the systemic 
organs when compared to the wildtype. The decreased number of the mutant strain could 
result from an impaired spreading ability of these bacteria from the local site, or/and from a 
more efficient elimination of the mutant by host phagocytic cells present in the blood and 
systemic organs. The results obtained from the PMN survival assay favour that a faster 
elimination of the mutant strain takes place. 
Despite the lower bacterial counts found in the organs after systemic dissemination, the 
mutant did not display any impaired abilities to proliferate and establish infection at the local 
site, as seen by the development of severe skin lesions. These results show the importance of 
this regulatory system in conferring S. pyogenes advantages in its spreading ability, possibly 
by enabling it to survive inside PMNs. However, TCS13 does not seem to be involved in the 
ability of S. pyogenes to establish local infections.  
Although many proteins have been described involved in protecting S. pyogenes from uptake 
by host immune cells (220), little is known about how this bacterium resists the killing 
mechanisms after been phagocytosed. It has been proposed that the protein SIC plays a role in 
this process by inhibiting PMN-specific antibacterial proteins (74), and deletion of M protein 
and protein H also impaired the survival of S. pyogenes inside of PMNs (200). Additionally, 
Medina et al. (152) have hypothesized that the ability to upregulate capsule expression and to 
escape from the phagocytic vacuole into a more permissive milieu such as the cytoplasm 
might be crucial determinants. To further elucidate the mechanisms underlying the mutant’s 
lost ability to survive intracellularly, the ability to upregulate hyaluronic acid capsule, SIC, 
and M protein was investigated. The involvement of protein H was neglected, since PCR 
analysis revealed the absence of this protein in the strain used in this study. Results showed 
that the TCS13 mutant exhibited a decreased capsule expression after blood- and mouse 
passage, but not under standard broth conditions, where capsule expression was comparable 
to that of the wildtype. Consequently, the disability to upregulate capsule expression seems to 
be linked to stress conditions, as encountered in whole blood or in vivo infection. Whether 
this upregulation of capsule occurs once KTL3 is located within PMNs requires further 
investigations by e.g. electron microscopic studies.  
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The possibility that TCS13 can influence the expression of SIC and M protein, therefore 
causing the increased killing of the mutants strain by PMNs, was investigated by 
transcriptional and expressional analysis. Northern analysis of bacteria grown in laboratory 
conditions showed a high, but comparable transcription rate of both virulence factors in 
wildtype and mutant strain, indicating that ∆TCS13 does not influence the expression of these 
factors under standard conditions. These results are conform with observations made by 
Ribardo et al. (182), who saw not differential transcription of emm in a TCS13 mutant. When 
the presence of secreted proteins of wildtype and mutant were investigated by SDS-PAGE, a 
28-kDa fragment could be detected present only in culture supernatants of ∆TCS13, and was 
identified as N-terminal part of the M protein. This truncated M protein encompassed the A-, 
as well as the B-repeats, or at least parts of them, which have been shown to mediate the 
binding to fibrinogen (17). Subsequent binding studies showed the ability of this truncated 
form to bind fibrinogen, whereas the ∆TCS13 mutant itself lost almost all binding capabilities 
when compared to the wildtype strain. Since loss of M protein and fibrinogen-binding can 
lead to enhanced uptake by host phagocytic cells (98, 227), this phenomenon could explain 
the enhanced killing of the mutant. The possibility that a protease activity induced in the 
mutant, but not in the wildtype strain might be the responsible mechanism for the presence of 
the truncated M protein in ∆TCS13 culture supernatants was investigated. Two approaches 
were taken to show the involvement of a protease in the release of the 28 kDa fragment of M 
protein: (i) Detection of remaining C-terminus on the surface of the mutant by EM studies, 
and (ii) the inhibition of the M protein-cleavage by addition of protease inhibitors to growing 
cultures of ∆TCS13. In the EM studies, less protein seemed to be present on the surface of the 
mutant strain when compared to the wildtype, probably caused by either a reduced number of 
binding sites for the polyclonal antibody, due to the shorter length of surface-located M 
protein, or to instability of the C-terminal part. Addition of protease inhibitors had no effect 
on the cleavage of M protein, suggesting the involvement of a surface- or cytosol-located 
protease not accessible for protease inhibitors, rather than a secreted one. The only bacterial 
protein identified so far in degradation of the M protein has been the cysteine protease SpeB 
(17, 178). As a surface-located M protein is needed for proper activation of SpeB (39), it was 
conclusive to investigate the potential involvement of this protease in the cleavage of M 
protein in ∆TCS13. Specific inhibition of SpeB had no effect on the presence of the 28 kDa 
fragment and there was no SpeB activity in wildtype and mutant strain under this 
experimental condition. Therefore, it can be concluded that the regulatory system TCS13 
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mediates repression of an M protein-modulating protease that is different from SpeB. The 
identification and location of the protease remains to be elucidated.  
The presence of 28 kDa fragments of M protein in culture supernatants has also been 
described in a S. pyogenes mutant deficient in SLS production (21). There, the transcription of 
the emm gene was also unaffected, the mutant exhibited the same sedimentation phenotype as 
∆TCS13, showed susceptibility to phagocytosis in the Lancefield Bactericidal Assay, and the 
cleavage of the M protein was not affected by addition of protease inhibitors. The authors 
concluded that SLS or its affected downstream-located genes within the sagA operon might 
contribute to upregulation of one or more protease(s) that are either surface-associated or 
intracellularly located. Since the same effects were observed for the ∆TCS13 strain, it seemed 
probable that identical regulatory circuits occur within this strain. Differences in the SLS 
expression could however not be observed between wildtype and mutant, as seen by the 
comparable β-haemolytic behaviour on blood agar plates. Repression of the sagA locus by 
TCS13 would, however, ultimately lead to a different β-haemolytic phenotype. Consequently, 
either the proteolytic activity of a SLS mutant towards the M protein is due to polar effects on 
downstream genes of sagA, or regulation of the protease activity leading to cleavage of the M 
protein in ∆TCS13 occurs independently of this haemolysin.  
The physiological meaning behind the upregulation of an M protein-modulating protease 
during the infection process of S. pyogenes can only be speculated. Although M protein is 
needed by S. pyogenes for protection against uptake by phagocytic cells, it has also been 
demonstrated that approximately 60 min after the encounter with human PMNs, this 
important virulence factor is downregulated at the same time that TCS13 undergoes 
upregulation (219). Therefore, expression of M protein seems not to be crucial for all the 
events taken place during the infection process. Consequently, modulation of TCS13-activity 
leading to upregulation of a protease targeting this important virulence factor might be an 
additional strategy to allow S. pyogenes a fast adaptation to in vivo environments. 
 
In this study, two streptococcal regulatory systems, TCS07 and TCS13, and their role in 
bacterial virulence have been investigated. Both systems seem to contribute to resistance 
against phagocytic cells and mutation of either system lead to lost (∆TCS07) or reduced 
(∆TCS13) virulence in a mouse model of skin infections. Both TCS are involved either in 
transcription (TCS07) or posttranslational modification by upregulation of an unknown 
protease (TCS13) of the streptococcal M protein. Therefore, they also indirectly influence 
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fibrinogen-binding capabilities and resistance to phagocytosis. For the ∆TCS13 mutant, an 
additional deficiency to resist intracellular killing by murine PMNs could be demonstrated, 
which is possibly due to the inability to upregulate hyaluronic acid capsule. Since the TCS07 
mutant showed the same acapsular phenotype and additionally does not express SIC, the 
involvement of TCS07 in intracellular survival processes still needs to be evaluated.  
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4. Outlook 
Results obtained in this study gave insights into the role of the two-component systems 07 
and 13 of S. pyogenes strain KTL3. As final proof for the involvement of the investigated 
TCS in the regulation of virulence factors, a complementation attempt, i.e. expression of the 
knocked-out gene in trans from a plasmid, leading to restoration of detected effects, is under 
process. Such complementations are challenging, since equal expression from a vector is not 
guaranteed. In the case of the TCS, a plasmid harbouring the two knocked-out genes, as well 
as the promotor regions had to be generated, encompassing about 2500 bps. Generation of 
these plasmids has been performed, however, repeating transformation efforts were not yet 
successful, but will be further pursuited.  
Additionally, investigations of this study were restricted to a single streptococcal strain. Since 
it has been stated that regulators of different strains often have different regulatory actions 
(21), further experiments to show the same involvements of these TCS in other M1-, as well 
as other serotypes are needed. Additionally, elucidation of the complexity of the regulatory 
circuits, of which these systems are part of, could be achieved by microarray analysis, as 
performed with a CsrRS deletion strain (80). For identification of genes under direct 
regulatory control of these TCS however, different approaches analysing the direct interaction 
of the response regulators with their target sequences need to be taken, such as gel-retardation 
assays in combination with the construction of reporter-systems.  
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5. Material and Methods 
5.1. Chemicals  
Tab. 11: Chemicals. 
Chemical Company 
X-Gal (5-Bromo-4-Chloro-3-indolyl-ß-D-galactopyranosid) Applichem 
Acetic Acid Merck 
Acetonitrile (HPLC-grade) T.J. Baker 
Acrylamid-Bisacrylamid (Rotiphorese Gel 30) Roth 
Agarose  Roth 
Amino acids Applichem 
Ammoniumpersulfate (APS) Serva 
Ammoniumsulfate T.J. Baker 
Bacto Agar Difco 
Bacto Peptone Difco 
Bacto Tryptone Difco 
Bacto Yeast Extract Difco 
Bovine serum albumine (BSA) Applichem 
Bromphenolblue Merck 
Calciumchloride (CaCl2) Fluka 
Chloroform Baker 
D-Glucose Merck 
DEPC Fluka 
Di-potassiumhydrogenphosphate (K2HPO4) Merck 
Di-sodiumhydrogenphosphate (Na2HPO4) Merck 
dNTP-Mix Fermentas 
Ethanol T.J.Baker 
Ethidiumbromide ICN 
EDTA  Riedel-de Haën 
Ferric nitrate (FeNO3) Fluka 
Ferric sulfate (FeSO4) Merck 
Fibrinogen (human) Calbiochem 
Formaldehyde Fluka 
Formamide Applichem 
Glycerol Fluka 
Glycine Roth 
Glycogen Roche 
Guanine Applichem 
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Heparin (25000 injection units) Ratiopharm 
Hydrochloride (HCl) Fluka 
IPTG  Applichem 
Magnesiumchloride (MgCl2) Merck 
Magnesiumsulfate (MgSO4) Merck 
Manganesulfate (MnSO4) Fluka 
Methanol Baker 
MOPS Applichem 
Mutanolysin Fluka 
TEMED  Roth 
Neopeptone Difco 
N-lauroylsarcosine (sarcosine) Merck 
Phenol Applichem 
Phenol/Chloroform Applichem 
Phenol/Chloroform/Isoamylalcohol Applichem 
Ponceau S Applichem 
Potassiumchloride (KCl) Riedel-de Haën 
Potassiumdihydrogenphosphate (KH2PO4) Roth 
Proteinase K Fluka 
Riboflavine Merck 
RNase (DNase-free) Applichem 
RNase-free water Ambion 
Serva Vlue R250 Roth 
Sheep blood, defibrinated Oxoid 
Skim milk Difco 
Sodium acetate (NaH2C2OOH  ) Merck 
Sodium carbonate (NaHCO3) Merck 
Sodium Chloride (NaCl) Roth 
Sodium hydroxide (NaOH) Merck 
Sodiumdihydrogenphosphate (NaH2PO4) Merck 
Sodiumdodecylsulfate (SDS) Roth 
Sucrose Fluka 
Sulfosalicylic acid Merck 
SYBR-GreenTM Molecular Probes 
Thiamine hydrochloride Roth 
Todd-Hewitt Beckton Dickinson 
Trichloric acid (TCA) Fluka 
TriFast FL Peqlab 
Tryptic Soy Broth Beckton Dickinson 
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Tween 20 Serva 
Urea T.J.Baker 
 
All chemicals that are not listed were either purchased at Sigma, or referred to in the text.  
5.2. Bacterial strains 
5.2.1. E. coli strains 
Tab. 12: E. coli strains. 
Strain Relevant genotype Reference 
DH5α supE44, ∆(lac)U169 (Φ80∆(lacZ)M15, hsdR17, recA1, endA1, 
gyrA46, thi-1, relA1 
188 
HB101 supE44, hsdS20 (rB-, mB-), recA13, ara-14, proA2, lacY1, galK2, 
rpsL20 (Smr), xyl-5, mtl-1  
188 
M15 [pREP4] NaIS, StrS, RifS, Thi–, 
lac–, ara+, gal+, mtl–, F–, recA+, uvr+, lon+ 
Qiagen, 1994 
Top10 F-, mcrA, ∆(mrr-hsdRMS-mcrBC), Φ80∆(lacZ)M15, ∆lacX74, recA1, 
deoR, araD139, ∆(ara-leu), 7697, galU, galK, rpsL (StrR), endA1, 
nupG 
Invitrogen, 1994 
XL1-Blue recA1, endA1, gyrA96, thi-1, hsdR17, supE44, relA1, lac [F´ proAB 
lacIqZM15 Tn10 (TetR)] 
27 
 
5.2.2. Streptococcus pyogenes strains 
For mutagenesis studies, an M1 strain (KTL3) was used as representative serotype for causing 
abundant disease in North America and Western Europe (91). KTL3 is a blood isolate 
(Finnish Institute of Health) with a moderate capsule expression and was first described by 
Rasmussen et al. (179).  
For the SpeB proteolytic assay (see section 5.9), S. pyogenes strain A5448, a SpeB-expressing 
M1 isolate obtained from a patient with invasive GAS infection, was used as positive control 
(10). 
5.3. Culture media and cultivation 
5.3.1. Media for and cultivation of E. coli 
E. coli cultures were grown in LB broth at 37°C or 30°C while shaking. For plate culturing, 
LB agar plates were used. Antibiotics and other supplements were added as indicated where 
relevant. For long-term storage of E. coli strains, logarithmic-growing bacteria were mixed in 
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Kryotubes (Biozym) with sterile glycerol yielding a final concentration of 20 % glycerol and 
stored at -80°C.  
 
10 g Bacto Tryptone 
5 g Bacto Yeast Extract 
LB broth: 
10 g NaCl  
 Added up to 1L with dH2O, adjusted to pH 7.4 with NaOH, 
autoclaved. 
 
LB agar plates:    LB broth with a 1.5 % final concentration of Bacto-Agar.  
 
 
5.3.2. Media for and cultivation of S. pyogenes 
S. pyogenes strains were cultivated in either Todd-Hewitt broth (THB) supplemented with 1% 
yeast extract (THY), Tryptic Soy broth (TSB), or chemically defined medium (CDM, 215). 
For plate culturing, Columbia Blood Agar plates or D-Agar plates containing 5 % sheep blood 
were used. For long-term storage of S. pyogenes strains, bacteria were grown in THY until 
mid-logarithmic phase, mixed with sterile glycerol in Kyrotubes (Biozym) yielding a final 
glycerol concentration of 20 %, and stored at –80°C. Growth analysis of S. pyogenes in the 
presence different C-sources was performed in CDM, 1% (w/v) final glucose concentration 
was substituted with either (i) 1% (w/v) lactose, pyruvate, malate or citrate, or (ii) 0.5% (w/v) 
glucose in addition to 0.5% (w/v) lactose, pyruvate, malate, or citrate. For growth of S. 
pyogenes in the presence of protease inhibitors, 30 µM of cysteine protease inhibitor E-64 
(Sigma), or alternatively, “Complete Protease Inhibitor Mix” (Roche) at a 1 × final 
concentration was added to CDM. 
 
THY broth: 36.5 g  Todd-Hewitt (Difco) 
 10 g Yeast Extract  
 Added up with dH2O to 1L, autoclaved. 
 
 
TSB:  34.5 g  Tryptic Soy Broth (Difco) 
 Added up with dH2O to 1L, autoclaved. 
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CDM:   10 ml Solution 1 
  Amino acids (1× final) 
 100 ml  Potassium phosphate solution 
   50 ml  Vitamine solution 
 100 ml  Glucose solution 
   10 ml  Solution 5 
 100 ml  Calciumchloride solution 
   10 ml  Sodium acetate solution   
     5 ml  L-Cysteine-solution 
   40 ml  Sodium hydrogen carbonate solution 
   10 ml  Sodium phosphate solution 
 Adjusted to pH 7.4, added up to 1L with dH2O, filter-sterilized. 
   
Tab. 13: Listing of CDM solutions: 
Solution Concentration 
Solution 1 (100 ×) 
 
500 mg FeSO4 × 7H2O 
100 mg Fe(NO3) × 9 H2O 
70 g MgSO4 × 7 H2O 
500 mg MnSO4 
Added up with dH2O to 1L, autoclaved 
Potassiumphosphate solution (10 ×) 
 
2 g K2HPO4 
10 g KH2PO4 
Added up with dH2O to 1L, autoclaved 
Vitamin solution (20 ×) 
 
  4 mg p-Amino benzoic acid 
  4 mg Biotin 
16 mg Folic acid 
20 mg Niacinamide 
50 mg β-Nicotinamide adenine dinucleotide 
40 mg Panthothenate calcium salt 
20 mg Pyridoxal 
20 mg Pyridoxamine dihydrochloride 
40 mg Riboflavine 
20 mg Thiamine hydrochloride 
  2 mg Vitamin B12  
Added up with dH2O to 1L, filter-sterilized. 
Glucosesolution (10 ×) 
 
100 g Glucose 
Added up to 1L with dH2O, filter-sterilization. 
Calciumchloride solution (100 ×) 
 
100 mg CaCl2 × 6H2O 
Added up to 1L with dH2O, autoclaved 
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Solution 5 (10 ×) 
 
200 mg Adenine 
200 mg Guanine hydrochloride 
200 mg Uracil 
Dissolved at 500 × in 1N NaOH, added up with 
dH2O to 1L, autoclaved. 
Sodium acetate solution (100 ×) 45 g Sodium acetate × 3 H2O 
Added up to 1L with dH2O, autoclaved 
L-Cysteine-solution (200 ×) 100 g L-Cysteine 
Added up to 1L with 1N HCl 
Sodium hydrogen carbonate solution (25 ×) 62.5 g NaHCO3 
Added up to 1L with dH2O, filter-sterilized. 
Sodium phosphate solution (100 ×) 
 
6.32 g NaH2PO4 × H2O 
14.7 g Na2HPO4 
Added up to 1L with dH2O, autoclaved 
 
Tab. 14: Listing of CDM amino acids: 
Aminoacid Concentration 
DL-Alanine (1000 ×) 100g /L, dissolved in dH2O 
L-Arginine (1000 ×) 100 g/L, dissolved in dH2O 
L-Aspartic Acid (50 ×)    5 g/L, dissolved in dH2O 
L-Cystine (1000 ×)  50 g/L, dissolved in 1N HCl 
L-Glutamic Acid (100 ×)  10 g/L, dissolved in dH2O 
L-Glutamine (125 ×)  25 g/L, dissolved in dH2O 
Glycine (1000 ×) 100 g/L, dissolved in dH2O 
L-Histidine (400 ×)  40 g/L, dissolved in dH2O 
L-Isoleucine (300 ×)  30 g/L, dissolved in dH2O 
L-Leucine (200 ×)  20 g/L, dissolved in dH2O 
L-Lysine (1000 ×) 100 g/L, dissolved in dH2O 
L-Methionine (400 ×)   40 g/L, dissolved in dH2O 
L-Phenylalanine (250 ×)  25 g/L, dissolved in dH2O 
L-Proline (1000 ×) 100 g/L, dissolved in dH2O 
Hydroxy-L-Proline (1000 ×) 100 g/L, dissolved in dH2O 
Serine (1000 ×) 100 g/L, dissolved in dH2O 
L-Threonine (450 ×)  90 g/L, dissolved in dH2O 
L-Tryptophane (500 ×)  50 g/L, dissolved in 1N HCl 
L-Tyrosine (500 ×)  50 g/L, dissolved in 1N HCl 
L-Valine (800 ×)  80 g/L, dissolved in dH2O 
All amino acids dissolved in H2O were filter-sterilized. 
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5.4. Vectors  
Tab. 15: Vectors 
Vector Selection  Reference 
pCR2.1 Amp (100 µg/ml); Kan (50 µg/ml) Invitrogen, 1994 
pJRS233 Erm (300 µg/ml or 0,5 µg/ml*) 170 
pQE30 Amp (100 µg/ml) Qiagen, 1994 
* Refers to concentration for selection of S. pyogenes 
5.5. Oligonucleotides  
Oligonucleotides for specific S. pyogenes regions were chosen using the program Primer3 
(5.14.1.) and checked for possible mispriming sites within the S. pyogenes genome with 
NCBI Blast (5.14.1.) Oligonucleotides were ordered at MWG Biotech and diluted with 
distilled water to 100 pM/µl. A detailed listing of the oligonucleotides used can be found in 
the appendix (page 137). 
5.6. Molecular Methods for DNA and RNA 
5.6.1. Isolation of DNA and RNA 
5.6.1.1. Isolation of chromosomal DNA from S. pyogenes 
For the isolation of DNA from Streptococcus pyogenes, a modified method described by 
Pospiech and Neumann (177) was used. Bacteria were grown over night in 50 ml of THY 
broth, harvested by centrifugation (4.500 × g, 10 min., RT) and resuspended in 3 ml of TES, 
supplemented with 20 % sucrose. Lysis of bacteria was achieved by addition of 500 U 
D-Agar plates:      1 g Glucose 
    10 g Bactopeptone 
      5 g Neopeptone 
 1.25 g Yeast Extract 
      5 g NaCl 
 1.25 g Tris Base 
    13 g Bacto Agar (1.3 % final) 
 Added up to 1 L with dH2O, autoclaved. 
 
5 % of defibrinated sheep blood (Oxoid) was added to 48°C warm D-agar prior to plating, antibiotics and other 
supplements were added as indicated where relevant. 
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mutanolysin, a muramidase from Streptomyces globisporus, and incubation at 37°C for 1 
hour. RNA and proteins were digested by addition of RNase (5 mg/ml in TES) and proteinase 
K (5 mg/ml in TES) and incubation at 37°C for 15 min. 0.5 ml of SE was added and after 
several phenol-chloroform extractions (5.6.2.2), the DNA was precipitated with 0.8 volumes 
of isopropanol, washed, dried, and resuspended in 0.2 - 0.5 ml TE buffer. The DNA 
concentration was estimated by applying an aliquot onto a 0.7 % agarose gel.  
 
TES: 50 mM Tris HCl 
 5 mM EDTA 
 10 mM NaCl 
 Adjusted to pH 8, autoclaved.  
 
SE: 10 % sarcosine  
 dissolved in 250 mM EDTA 
 
TE: 10 mM Tris Base 
 1 mM EDTA 
Adjusted to pH 8, autoclaved. 
 
5.6.1.2. Isolation of plasmid DNA from E. coli 
Plasmids from E. coli cultures were isolated using the Qiagen Plasmid Mini or Midi 
Preparation Kit according to the manufacturer’s recommendations.  
5.6.1.3. Isolation of total RNA from S. pyogenes 
Bacteria were grown in 10 ml of THY broth, harvested by centrifugation (4500 × g, 5 min., 
RT), and resuspended in 250 µl of distilled water. 600 mg of glass zirconium beads (0.1 µM 
in diameter, Roth) were added and bacteria were disrupted for 60 sec. using a cell 
homogenizer (Braun Biotech). 750 µl of phenol-containing TriFastFL (Peqlab) was added 
immediately after, as well as 100 µl of 1-Bromo-3-Chloro-Propane (BCP). The suspension 
was incubated at 4°C for 15 min., and phase-separation was achieved by centrifugation 
(12.000 × g, 15 min, RT). The RNA-containing aqueous phase was precipitated by addition of 
1 volume isopropanol and 1 µl glycogen (20 mg/ml, Roche). After incubation at 4°C for 15 
min, the RNA was centrifuged like above, washed twice with 75 % ethanol, resuspended in 
RNase-free water, and stored at –80°C.  
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5.6.2. Purification of DNA and RNA 
5.6.2.1. Precipitation of DNA and RNA 
For precipitation of nucleic acids, 1/10 volume of sodium acetate, pH 4.6 was added to the 
DNA-/RNA containing solution, followed by addition of 2.5 volumes ethanol p.a. or 1 
volume isopropanol p.a. The suspension was incubated at –20°C over night, or alternatively at 
-80°C for 1 hour. The precipitated DNA/RNA was centrifuged (17.000 × g, 20 min, 4°C), 
washed twice with 70 % ethanol, the pellet was dried and resuspended in TE or distilled 
water. In order to obtain salt-free samples, instead of sodium acetate 1 µl glycogen (20 mg/ml, 
Roche) was added.  
5.6.2.2. Phenol/Chloroform extraction 
For elimination of proteins from nucleic acid-containing solutions, the DNA/RNA was 
extracted with phenol. After mixture with 1 volume phenol, phases were separated by 
centrifugation (17.000 × g, 15 min, RT). The DNA-containing, aqueous phase was 
phenolysed again using a 1:1 mixture of phenol/chloroform, and finally extracted with 
phenol/chloroform/isoamylalcohol (25:24:1). For elimination of phenolic remnants, the 
nucleic acids were subsequently precipitated (5.6.2.1). 
5.6.3. Polymerase Chain Reaction (PCR) 
5.6.3.1. Standard PCR reaction 
For in vitro amplification of DNA fragments, Taq-polymerase (Qiagen) was used according 
to the manufacturer’s recommendations. PCR-reactions were carried out using a thermocycler 
(Biometra) with the following typical solutions: 
 
10 – 100 ng  
200 µM 
0.2  µM                                                                                                                                  
250 µM 
5 µl 
0.5 µl 
ad 50 µl 
DNA (template)  
dNTPs (each 50 µM dNTP) 
per oligonucleotide 
MgCl2 (Qiagen) 
10 × Taq-Reactionbuffer (Qiagen) 
Taq Polymerase (Qiagen) 
bidistilled water 
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For amplification, the reaction was incubated in a thermocycler using the following typical 
program: 
 
Step 1: 5 min 96°C 
Step 2: 40 sec 96°C (denaturation) 
Step 3: 40 sec 58°C (annealing) 
Step 4: 1 min 72°C (extension) 
Step 2 – 4: repeating 30 × 
Step 5: 4 min 72°C (extension) 
 
The last extension step is needed for completing DNA synthesis, especially at the ends of 
amplified fragments. For verification of successful PCR reactions, aliquots were analysed by 
agarose gelelectrophoresis (5.6.9.).   
The annealing temperature in step 3 depends on the melting temperatures of the specific 
oligonucleotides and usually ranged between 52 - 63°C, whereas the duration of elongation in 
step 4 depends on the size of the amplicon (1 kb ≈ 1 min). Further aberrations of the program 
are indicated at the corresponding pages.  
A feature of the Taq polymerase is the addition of poly-adenines at the 3’end of an amplified 
DNA fragment, which allows ligation of these amplicons into vectors harbouring poly-
thymidines at their site of integration (5.6.12.1.) 
For special PCR reactions requiring high fidelity DNA sequences, proof-reading polymerases 
“AccuTherm” (Genecraft) or “Vent” (New England Biolabs) were used according to the 
manufacturer’s recommendations.  
5.6.3.2. Colony PCR 
In order to quickly analyse E. coli transformants, Colony PCR was applied. Single bacterial 
colonies were resuspended in 32.5 µl of bidistilled water, bacteria were lysed by incubation at 
96°C for 10 min, and the PCR reaction was filled up with the mentioned components 
(5.6.3.1.) to a final volume of 50 µl.  
For analysis of S. pyogenes transformants, InstaGeneTM Matrix (BioRad) was used. Colonies 
were resuspended in 1 ml of dH2O, pelleted by centrifugation (10.000 × g, 3 min, RT), 
resuspended in 100 µl of InstaGeneTM Matrix, incubated at 56°C for 20, and subsequently at 
100°C for 8 min. 5 - 7 µl of the supernatant was used as template in a PCR reaction.  
5. Material and Methods          95 
5.6.3.3. Overlap extension PCR 
In order to combine fragments without applying restriction-/ligation approaches, overlap 
extension was performed (99). This method is based on the modification of DNA fragments 
by incorporation of a specific sequence into the 5’ end of corresponding primers. Following a 
PCR reaction, any DNA fragments can be amplified that share a common sequence at one 
end. Under PCR reaction conditions, this sequence allows strands of two different fragments 
to hybridize to each other, forming an overlap. Subsequently, extension of this overlap by 
PCR yields a combined molecule. A schematic illustration of this method is given in Fig. 44.  
 
 
Figure 44: Schematic illustration of an overlap extension reaction, shown on the basis of the fusion of RR13 
(fragment 1) with the spectinomycin resistance cassette (5.6.13). 
5.6.4. Purification of PCR fragments 
For the purification of PCR products, the Qiagen PCR purification Kit was used according to 
the manufacturer’s recommendations. Determination of concentrations was performed as 
described in 5.4.6.8. 
1. PCR mit Oligonucleotides RR13_1/3 or Spc1/Spc2
Spectinomycin-Cassette
Spectinomycin-Cassette
CCCGGCAATTGCCCGG
3`
3`
5`
GGGCCGTTAACGGGCC
RR13_1
RR13-Fragment 1
RR13-Fragment 1
5`
3`
3`
5`
2. 96°C 5 min (denaturation)
3. 72°C 5 min (extension)                                       
RR13-Fragment 1
GGGCCGTTAACGGGCC
Spectinomycin-Cassette
CCCGGCAATTGCCCGG
4. PCR                                                          
Oligonucleotides
5`
RR13_3-CCGGGCAATTGCCGGG Spc2
CCCGGCAATTGCCCGG-Spc1
+ +
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5.6.5. General cloning techniques 
5.6.5.1. Restriction of DNA fragments 
Restriction of DNA fragments was performed in volumes of 10 µl – l00 µl at 37°C for 2 - 4 
hours, or alternatively over night. Restriction endonucleases purchased from New England 
Biolabs or Fermentas were used according to the manufacturer’s recommendations. 
Fragments excised from plasmids were purified using agarose gelelectrophoresis (5.6.6.) and 
eluted from the gel as described in 5.6.9.  
5.6.5.2. Ligation of DNA fragments  
Restricted DNA fragments and PCR products were covalently linked between the 3’-OH and 
5’-phosphate end using T4 Ligase (New England Biolabs). Vector- and insert DNA were 
mixed in a proportion of 1:5 in a 10 µl volume, and 1 µl of T4 ligation buffer, as well as 5-10 
U of T4 ligase were added. Incubation was performed at 16°C over night, the ligase was 
performed was inactivated at 65°C for 10 min. Ligation of PCR fragments into the TOPO 
pCR2.1 vector (Invitrogen) was performed according to the manufacturer’s recommendations.  
5.6.5.3. Addition of poly-A overhangs 
After amplification of PCR fragments with the proof-reading AccuThermTM or VentTM 
polymerases, addition of poly-A overhangs was necessary in order to ligate fragments into the 
TOPO pCR2.1 vector. Therefore, PCR fragments were incubated with 1 × Taq polymerase 
buffer, 1 µl of dNTPs (2 mM each), and 0.2 µl Taq polymerase (1 U, Qiagen) for 10 min at 
72°C.   
5.6.6. Separation of DNA- and RNA fragments using agarose gelelectrophoresis 
Depending on the size of DNA fragments, 0.7 – 2 % agarose gels (w/v in TAE) were used. 
Before application onto the gel, DNA was mixed with 1/5 volume of DNA Loading Dye. Gels 
were routinely run in 1 × TAE at 80 - 120 V in a Minigel chamber (HorizonTM58); 
“GeneRulerTM DNA Ladder Mix” (Fermentas) was used as standard size marker.  
For separation of RNA, samples were mixed 1:1 with 2 × RNA Loading Dye, incubated at 
65°C for 10 min and cooled for 5 min on ice. Routinely, 1 % agarose gels were used and run 
at 80 V, “RNA Ladder High Range” (Fermentas) served as standard molecular weight 
marker. In order to prevent degradation of the probes by RNases, all solutions were treated 
with DEPC (Diethylpyrocarbonate, 0.2 % final).  
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1 × TAE:  40 mM Tris HCl pH 7.9 
 5 mM Sodium acetate 
 1 mM EDTA 
 
5 × DNA Loading Dye 0.25 % Bromphenolblue (w/v) 
 0.25 % Xylencyanol (w/v) 
 30 % Glycerol (v/v) 
 
1 % Agarose gel for RNA separation:  0.3 g Agarose 
 23.4 ml DEPC-treated distilled water 
 Boil, cool to 50 °C 
 0.53 ml Formaldehyde solution (37 %) 
 6 ml 5 × Running Buffer  
 
5 × RNA Running Buffer: 100 mM MOPS 
 40 mM Sodium acetate 
 1 mM EDTA 
 
2 × RNA Loading Dye: 50 % Formamide (v/v) 
 20 % Glycerol (v/v) 
 2.2 M Formaldehyde 
 10 mM EDTA 
 0.5 % Bromphenolblue (w/v) 
 50 µM Ethidiumbromide   
 
5.6.7. Visualization of DNA and RNA 
After electrophoresis, DNA gels were stained with ethidiumbromide (1 µg/ml 
ethidiumbromide in H2O) for visualization of DNA, RNA gels already contained 
ethidiumbromide present in the loading dye (5.6.6). Gels were analysed using UV-light (254 
nm, UV transilluminator, Herolab) and photographed (Herolab Enhanced Analysis System). 
5.6.8. Quantification of DNA and RNA 
For quantification of DNA and RNA, UV-absorption at 260 nm was determined using a 
Pharmacia Ultrospec III. The concentrations were calculated according to Sambrook et al., 
(188), where an optical density at 260 nm of 1 corresponds to a dsDNA concentration of 50 
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µg/ml and a RNA concentration of 40 µg/ml.  
Alternatively, DNA and RNA quantities were estimated by agarose gelelectrophoresis using 
“MassRulerTM DNA Ladder, Low Range” (Fermentas) as reference.  
5.6.9. DNA isolation from agarose gels 
For elution of DNA fragments from an agarose gel, the QiaQuick Gel Extraction kit was used 
according to the manufacturer’s recommendations.  
5.6.10. DNA sequencing 
Sequencing of purified PCR fragments was performed using fluorescent “Dye-terminators”, 
which are introduced into the DNA within the sequencing reaction. This reaction was 
performed using BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) in a 
final volume of 20 µl with 4 µl of BigDye solution, 2 µl of 10 × buffer and 10-300 ng PCR 
product in a Thermocycler (Biometra) with the following program: 
 
Step 1: 20 sec 96°C (denaturation) 
Step 2: 20 sec    45 - 60° C (annealing) 
Step 3: 4 min 60° C (extension) 
Step 1 – 3: repeating 25 × 
  
The sequencing products were purified by ethanol precipitation (5.6.2.1.), resuspended in 20 
µl formamide (Applied Biosystems) and sequenced using an ABI Prism 3100 (Applied 
Biosystems), a service provided by the Microbiology Department of the GBF. Analysis of 
sequence data was performed as described in 5.14.1.   
5.6.11. Southern- and Northern Blotting 
5.6.11.1. Generation of dioxygenin-labeled DNA probes 
DNA probes were dioxygenin-labeled by addition of dioxygenin-dUTP/dTTP nucleotides 
(Boehringer Mannheim) to a PCR reaction (5.6.3.). Verification of successful labelling was 
performed by size-comparison of labeled to unlabeled DNA probe using agarose 
gelelectrophoresis (5.6.6.). 
5.6.11.2. DNA and RNA transfer onto nylon membranes 
Transfer of DNA and RNA was performed using a vacuum blotter (Appligene) as essentially 
described in Sambrook et al. (1989). In brief, after separation of the samples in a 0.7 – 1 % 
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agarose gel, DNA/RNA was visualized as described in 5.6.7. RNA gels were incubated twice 
for 20 min in 2 × SSC as preparation for the vacuum transfer, which was performed with 20 × 
SSC for 1.5 h at 50 mbar. 
DNA was denatured by incubating of the gel in Denaturizing Buffer, neutralized in 
Neutralizing Buffer, and transferred to a positively charged nylon membrane (Macherey-
Nagel) with 10 × SSC for a duration of 1 – 1.5 hours at 50 mbar. Successful transfer was 
confirmed by staining of the agarose gel in ethidiumbromide and visualization (5.6.7.) after 
the blot. The membrane was dried and the DNA/RNA was cross-linked using a Stratalinker 
1800 (Stratagene). 
  
20 × SSC: 3 M NaCl 
 0.3 M Sodium acetate, pH 7.0 
 
Denaturizing Buffer: 1.5 M NaCl 
 0.5 M NaOH 
  
Neutralizing Buffer 1.5 M NaCl 
 1 M Tris HCl pH 7 
    
5.6.11.3. Hybridization with dioxygenin-labeled probes 
Membranes were prehybridized for 1 hour in High-SDS Hybridisation solution. For Northern 
Blots, 7 % PEG 8000 was added for raising the specificity of the probe. 100 ng of DIG-
labeled DNA probe was mixed with 1 mg of sonicated Herring- (Invitrogen) or Salmon sperm 
DNA (Applichem) and denatured by boiling for 10 min. The probe was added to the 
membrane and incubated over night in a hybridization oven (Sheldon Lab) at a temperature 
suitable for the specific DNA probe (TOPT). This temperature was calculated by the following 
equation: 
TM  = 16.6 log (Mol Salts) + 0.41 (%GC) + 81.5 
  TOPT  = TM – 0.72° (% formamide) – 20° 
with TM = melting temperature. 
 
After hybridization, the membrane was washed twice with 2 × SSC, 0.1 % SDS (w/v) for 15 
min at room temperature, followed by 2 washing steps in 0.1 × SSC, 0.1 % SDS (w/v) for 15 
min at 62°C.  
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For visualization of the DIG-labelled hybrids, the membrane was treated according to the 
Roche handbook for DIG DNA labelling and detection. The signal was detected by applying 
overlaying the membrane with HyperfilmTM ECL Film (Amersham) and incubation in the 
dark for 40 min (Southern Blot) to 16 hours (Northern Blot). Development of the film was 
performed using Agfa Developer G153 and Rapid Fixer G354.  
 
1 M Sodium Phosphate Buffer (PB), pH 7 57.7 ml  1 M Na2HPO4 
 42.3 ml 1 M NaH2PO4 
 
High SDS Hybridization Solution: 7 % SDS (w/v) 
 50 % Formamide (v/v) 
 5 × SSC 
 2 × Blocking Reagent (Roche) 
 0.1 % (w/v) N-lauroylsarcosine 
 50 mM PB pH 7.0 
5.6.12. Transformation of bacteria 
5.6.12.1. Generation and transformation of chemically competent E. coli 
Chemically competent E. coli were prepared as described by Chung et al. (36). Bacteria were 
grown over night in LB medium, diluted 1/100 in fresh medium and were grown to an optical 
density of 0.3 - 0.4 at 600 nm. After pelleting by centrifugation (4500 × g, 10 min, 4°C), 
bacteria were resuspended in 1/10 of the initial volume in ice-cold TSS medium. The cells 
were aliquoted to 200 µl, immediately frozen in liquid nitrogen, and stored at –80° C. For 
transformation, 100 µl of competent cells were mixed with 100 – 200 ng Plasmid-DNA or 5 
µl of ligation mixture (5.6.5.2), incubated on ice for 30 min, and heat-shocked in a waterbath 
for 90 sec at 42°C. 1 ml of pre-warmed LB-broth was added to the suspension, and bacteria 
were incubated for 1 hour at 37°C while shaking. 100 – 500 µl aliquots were plated onto LB-
agar plates supplemented with the corresponding antibiotics, and incubated over night at 
37°C.  
Clones were picked with a toothpick and inoculated at 37°C in LB broth containing the 
appropriate antibiotics. Plasmids, as well as glycerol stocks (20 % glycerol final) (5.3.1.) for 
long-term storage were prepared from the culture.  
When the TOPO-Cloning Kit (Invitrogen) was used for ligation of PCR products into the 
pCR2.1 vector, the transformation was performed as suggested by the manufacturer.  
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TSS medium: 10 % PEG 3350 (w/v) 
 5 % DMSO (v/v) 
 20 mM MgCl2 
 Dissolved in LB broth (3.1.) 
5.6.12.2. Generation and transformation of electro-competent S. pyogenes 
Competent S. pyogenes were prepared as essentially described by McLaughlin and Ferretti 
(151). Bacteria were grown over night in THY broth with 20 mM glycine, diluted 1/15 in 50 
ml of TSB containing 20-100 mM glycine, and grown until an optical density of 0.2 at 600 
nm. Bacteria were harvested by centrifugation at 4500 × g, 10 min, 4°C, the supernatant was 
decanted and the pellet washed twice with ice-cold Electroporation Buffer 3 (EPB 3), and 
resuspended in 0.4 ml of the same buffer. 5 µg of plasmid DNA was added to 200 µl of 
electro-competent S. pyogenes; the suspension was transferred to a 2 mm electroporation 
cuvette (Equibio), and pulsed at 1.75 kV, 400 Ohm, and 25 µF (BioRad GenePulserTM). 1 ml 
of cold THY broth supplemented with 0.25 M sucrose was added, the cuvette was incubated 
on ice for 5 min, and bacteria were diluted in 9 ml of pre-warmed THY supplemented with 
sucrose as indicated above. Bacteria were incubated at 30°C for 2 hours without aeration, 
pelleted at 4500 × g, 10°C for 10 min, and resuspended in 1 ml of THY broth. A 200 µl 
aliquot of the suspension was transferred to an empty petridish and overlaid with 48°C warm 
selective agar (D-Agar containing 5 % sheep blood and 0.5 µg/ml Erm, 5.3.2.), the residual 
suspension was further diluted into 50 ml of THY broth containing erythromycin (0.5 µg/ml) 
for pre-selection and incubated over night at 30°C. The bacterial suspension was pelleted as 
described above, resuspended in 1 ml of THY broth, and aliquots of 500 µl were poured into 
still liquid selective agar. Plates were incubated for 24-48 hours at 30°C. 
Positive clones were identified by haemolysis within the blood agar, picked using a Pasteur 
pipette, and analysed for the presence of the plasmid by Colony PCR using InstaGeneTM 
Matrix (5.6.3.2.). For excluding possible contaminations by other haemolytic bacteria, the 
transformants were tested for Group A Streptococcus using the Slidex Strepto-A Kit 
(BioMerieux) as recommended by the manufacturer. 
 
EPB 3:  272 mM Glucose 
 1 mM MgCl2 
 Adjusted to pH 6.2, autoclaved. 
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5.6.13. Insertion-Deletion Mutagenesis 
For disruption of chromosomal genes within the S. pyogenes genome, an insertion-deletion 
mutagenesis approach (62) was used. Plasmids harbouring two internal fragments of the 
targeted genes were constructed. These two fragments were interrupted by a spectinomycin 
resistance cassette (aad9, Acc. Nr. NC_03737), containing an own promotor for guaranteeing 
expression of the resistance gene, as well as a transcriptional stop. The originated vector used 
for these constructs was pJRS233 (170), which is a derivative of pG+host4 (139) and has 
previously been shown to be efficient for transformation of S. pyogenes (170). Additionally, 
this vector can autonomously replicate in E. coli at 37°C, but in S. pyogenes only at 30°C. 
This allowed selection of transformants at 30°C; a raise in temperature to 37°C subsequently 
induced integration of the plasmid into the streptococcal genome by homologous 
recombination. Due to maintaining selection pressure for the plasmid, this integration 
occurred by a single cross-over event; for animal experiment however, which occur in the 
absence of selective antibiotics, a stable mutant was required. Therefore, transformants were 
repeatedly passaged between 30°C in the absence of antibiotics (favouring autonomous 
replication of the plasmid) and 37°C in the presence of spectinomycin (selection pressure for 
a chromosomally integrated resistance cassette). Once the vector was lost from the 
chromosome, the resistance cassette was integrated into the targeted gene, resulting in its 
interruption, as well as in deletion of an internal part of the gene. Therefore, this approach is 
also named insertion-deletion mutagenesis (62) 
A closer description of the construction of the plasmids, as well as transformation of S. 
pyogenes is given in 2.2. 
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Figure 45: Schematic overview of the insertion-deletion mutagenesis with pJRS233 derivatives. For further 
descriptions refer to the text. 
5.7. Protein analysis 
5.7.1. Sodiumdodecylsulfate-Polyacrylamide gelelectrophoresis (SDS-PAGE) 
In order to routinely investigate protein solutions by SDS-PAGE (124), minigels with a 10-15 
% acrylamide concentration within the resolving gel, and 5 % within the stacking gel were 
used. Protein samples were mixed with SDS-Loading Dye in a ratio of 2:1, boiled for 5 min, 
and loaded onto the gel. Electrophoresis was performed in a BioRad Mini-PROTEAN 3 cell 
applying 80 V within the stacking gel, and 140 - 200 V within the resolving gel. As protein 
standard, “Prestained Protein Ladder”, “Protein Ladder” (Fermentas), or “SDS-7B” (Sigma) 
was used. After electrophoresis, the stacking gel was discarded and the resolving gel was 
either stained with Coomassie Blue (5.7.3.1.1), or blotted onto a membrane (5.7.3.2).  
 
SDS-Loading Dye: A 0.2 M Tris/Cl pH 6.8 B -Mercaptoethanol 
  3 % SDS   
  30 % Glycerol   
  0.2 % Brompholblue   
  Prior to boiling, solutions A and B were mixed in a ratio of 5:2 
 
 erm 
pJRS233 derivative 
Response Regulator Histidine Kinase 
Chromosome 
 
Double cross-over 
Chromosome 
H1 H2 
ab-c 
H1:  homologous fragment 1  
H2 :  homologous fragment 2 
ab-c :  antibiotic resistance cassette 
Response Regulator::ab-c Histidine Kinase 
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Resolving Gel: 10 – 15 % Acrylamide/Bisacrylamide (30:0.8) 
 0.375 M Tris/HCl pH 8.8 
 0.1 % SDS 
 0.5 µl/ml TEMED 
 0.5 mg/ml Ammoniumperoxodisulfate 
 
Stacking Gel:  5 % Acrylamide/Bisacrylamide (30:0.8) 
 0.125 M Tris/HCl pH 8.8 
 0.1 % SDS 
 0.5 µl/ml TEMED 
 0.5 mg/ml Ammoniumperoxodisulfate 
 
5 × Runningbuffer: 30 g Tris 
 144 g Glycine 
 10 g SDS 
Add to 2 L with dH2O 
 
5.7.2. Preparation of protein samples 
5.7.2.1. Overexpression and purification of recombinant proteins in E. coli 
E. coli strain M15[pREP4][pQE]-emm1, harbouring a 1240 bp fragment encompassing 
positions 124 to 1363 of the emm1 gene from S. pyogenes strain KTL3 was incubated in 1.25 
L LB broth supplemented with the appropriate antibiotics until an optical density at 560 nm of 
0.7 was reached. Protein production was induced by addition of 0.1 mM IPTG. Bacteria were 
incubated at 30°C for additional 3 hours and then harvested by centrifugation (6000 × g, 15 
min, 4°C). The M15 derivative was resuspended in 30 ml of Resuspension buffer, lysed using 
a French Press (Mini Cell, SLM Aminco, SLM Instruments), and PMSF (1 mM final), as well 
as 0.2 g lysozyme was added. The suspension was centrifuged (10000 × g, 20 min, 4°C) and 
the clear lysate was applied onto a Nickel-NTA Agarose column for purification of 
recombinant His-Tag-labelled protein. Purification was performed according to the Qiagen 
protocol.  
Protein concentrations were determined as described in 5.7.3.3., for propagation of polyclonal 
antibodies, 1 mg/ml of purified protein was sent to Eurogentec for rabbit immunization. In 
order to lyse small amounts of E. coli suspensions, a sonicator (Labsonic, Braun Biotech) was 
used. Bacteria were pulsed 3 times for 30 sec, pelleted by centrifugation (10000 × g, 15 min, 
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4°C), and the clear supernatant containing soluble proteins was used for further analysis.  
 
Resuspension Buffer 50 mM NaH2PO4 
 300 mM NaCl 
 10 mM Imidazole 
 Adjusted to pH 8. 
 
5.7.2.2. Preparation of protein lysates from S. pyogenes 
Bacteria were grown in THY broth or CDM to the appropriate optical density, pelleted by 
centrifugation (4500 × g, 10 min, 4°C), washed twice in PBS, and resuspended in 300 µl of 
the same buffer. The suspension was then added to 600 mg of glass zirconium beads (Roth, 
0.1 µm in diameter). Bacteria were lysed as described in 5.6.1.3., and subsequently 300 µl of 
V-Lysis Buffer was added to the suspension. Beads were separated from the lysates by 
centrifugation (10000 × g, 5 min, RT), and the clear lysates were used for further analysis. 
 
PBS: 10 mM PB (5.6.11.3) 
 0.15 M NaCl 
 Adjusted to pH 7.4, autoclaved 
 
V-Lysis Buffer: 10 mM Tris HCl 
 100 mM NaCl 
 1 % Triton-X-100 
 
5.7.2.3. Preparation of transmembrane proteins from S. pyogenes 
For the isolation of transmembrane proteins for the 1-dimensional SDS-PAGE, S. pyogenes 
was cultured to an optical density of 0.5 - 0.6 at 600 nm (mid-logarithmic growth phase), 
harvested by centrifugation (6.000 × g, 15 min, 4°C), and the pellet was resuspended in 
Incubation buffer supplemented with 40 mM CHAPS. The suspension was incubated for 30 
min at room temperature, pelleted by centrifugation (12000 × g, 30 min, 4°C), the supernatant 
was precipitated by addition of 80 % ammoniumsulfate and incubated for 1h at 4°C. The 
suspension was centrifuged (17000 × g, 30 min, 4°C) and the pellet was resuspended in 1 – 2 
ml of PBS (5.7.2.2.). Dialysis against PBS over night using a 12 – 14000 kDa cut-off 
membrane (Sigma) was performed in order to eliminate salt remnants. For analysis, aliquots 
were loaded onto a 10 % SDS gel (5.7.1.1).  
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Incubation Buffer: 15 mM KCl 
 10 mM EDTA 
 20 % Glycerol (v/v) 
 0.1 M PB (5.6.11.3.) 
 
In order to extract the M-protein from the surface of S. pyogenes, a method described by 
Lancefield (125) was applied. Bacteria were grown to mid-logarithmic or stationary phase in 
15 – 50 ml of THY broth or CDM, harvested by centrifugation (4500 × g, 10 min, 4°C), and 
the pellet was resuspended in 0.9 % NaCl solution. After addition of 1/20 volume of 1 M HCl 
the suspension was boiled for 15 min. Cell remnants were pelleted by centrifugation (4000 
rpm, 15 min, 4°C), and the supernatant was neutralized with 1 M NaOH. Proteins were 
pelleted as described above, and the M-protein containing supernatant was precipitated with 
10 % trichloric acid (see 5.7.4.), and resuspended in 100 µl 0.1 M PB (5.6.11.3) 
5.7.2.4. Preparation of secreted proteins from S. pyogenes 
Bacteria were grown in 10 – 50 ml of CDM to the appropriate optical density, pelleted by 
centrifugation (4500 × g, 10 min, 4°C), proteins present in the supernatant were precipitated 
with 10 % trichloric acid (5.7.4.), and resuspended in 50 – 100 µl PB (5.6.11.3) 
5.7.2.5. Purification of rabbit anti-M1 IgG 
For purification of the anti-M1 IgGs, 2 ml of rabbit blood serum was applied to a Protein-A 
sepharose CL-4B (Pharmacia) column, which was equilibrated with 0.1 M Potassium 
phosphate buffer, pH 7.0. After washing steps with the same buffer, the bound IgGs were 
eluted using 0.1 M glycine, IgG-containing fractions were pooled, added up to 100 µl with 
1M PBS (5.7.2.2.), and stored at –20°C. 
5.7.3. Detection of proteins 
5.7.3.1. Staining methods 
5.7.3.1.1. Coomassie Staining 
After separation of proteins by SDS-PAGE (7.1.), the gel was stained for 30 min - 3h in 
Coomassie Staining Solution. The staining solution was exchanged by water, and the gel was 
boiled in the microwave for 3 – 5 min. Afterwards, the water was replaced by destainer 
solution and the gel was incubated for additional 1 – 3 hours. For documentation purposes, 
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the gels were scanned using a HP Scanjet 6100C/T and further processed using the program 
Irfan View (vs. 3.85).  
 
Coomassie Staining Solution:  0.25 % Serva Blue R250 
 50 % Methanol 
 10 % Acetic acid 
 
Destainer Solution: 20 % Methanol 
 7 % Acetic acid 
5.7.3.1.2. Ponceau Staining 
This method allows the reversible staining of proteins on a nitrocellulose membrane, enabling 
the verification of successful protein transfer by Western Blot (5.7.3.2). After Western Blot, 
the membrane was stained for 1 min in Ponceau staining solution, and rinsed with dH2O. 
Protein bands became visible, and the staining was completely lost upon incubation in 
Blocking buffer (5.7.3.2.). 
 
Ponceau Staining Solution: 0.2 % Ponceau S 
 3 % Trichloric acid 
 3 % Sulfosalicylic acid 
    
5.7.3.2. Western Blot 
After separation of proteins by 1-dimensional SDS-PAGE, they were transferred to a 
nitrocellulose membrane (BioRad). Transfer occurred in 1 x Blotting Buffer at 350 mA for 45 
min using a BioRad Mini Trans-Blot cell. Afterwards, the protein transfer was confirmed by 
Ponceau staining (5.7.3.1.2). Prior to detection of proteins on membranes, unspecific protein 
binding was inhibited by incubation in Blocking buffer for 1 hour. Rabbit IgGs specific for 
the desired protein were diluted 1:1000 – 1:2000 in Blocking Buffer, added to the membrane 
and incubated for 1 h. After 2 washing steps with PBS (5.7.2.2.) supplemented with 0.05 % 
Tween-20 (PBST), the secondary antibody, which was an alkaline phosphatase (AP) - or 
alternatively horseradish peroxidase (HRP)- conjugated anti-rabbit-IgG from goat (Sigma) 
was added to the blot in a dilution of 1:2000 in Blocking Buffer and incubated for an 
additional 1 h. The blot was washed twice with PBST and developed using either a 
chloronaphtol solution for HRP, or BCIP/NBT tablets (“Sigma FastTM)  for AP as substrate.  
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1 × Blotting Buffer: 50 mM Tris Base 
 40 mM Glycine 
 20 % Methanol (v/v) 
 
Blocking Buffer:  5 % Skim milk (w/v) or 3 % BSA (w/v) 
 Dissolved in PBS (5.7.2.2.)  
 0.05 % Tween 20 (v/v) 
 
Chloronaphtol Solution: 6 mg Chloronaphtol 
 Dissolved in 2 ml Ethanol 
 10 ml of PBS (5.7.2.2.)  
 
5.7.3.3. Quantification and concentration of proteins 
The method described by Bradford (1976) was used to quantify the concentrations of proteins 
in a solution. To 10 µl of a protein solution 200 µl of Bradford solution (BioRad), 1/5 diluted 
with bidistilled water, was added. The solution was incubated at room temperature for 15 
minutes; the absorption at 595 nm was measured in an ELISA-Reader (Tecan Sunrise), and 
compared to a standard of known concentrations of BSA (bovine serum albumin, Applichem). 
In order to concentrate protein solutions of low concentrations (i.e. below 1 mg/ml), they 
were applied to Centricon filters with a molecular weight cut-off of 10000 kDa (Millipore), 
centrifuged according to the manufacturer’s recommendations. 
5.7.3.4. Maldi-TOF analysis 
In order to analyse proteins using MALDI-TOF mass spectroscopy, separated protein bands 
or spots were excised from the gels, washed with distilled water, dehydrated by addition of 
acetonitrile (ACN) and by drying under vacuum. Dried gel pieces were incubated with 25 µl 
of sequencing grade trypsin (Promega, 2 ng/µl with 5000 U/mg) in 50 mM ammonium 
hydrogencarbonate at 37°C for 16 hours. Extraction of tryptic peptides was performed by 
addition of ACN and 5 % formic acid. For purification of the tryptic peptides C18 Zip tips 
(Millipore) were used. Bound peptides were eluted in 0.5 - 1.5 µl matrix solution and applied 
to a MALDI-target. MALDI-TOF MS was performed using an Ultraflex Tof Tof (Bruker) 
mass spectrometer with a 50 Hz nitrogen laser. Identified peptide masses were matched as 
described in 5.14.2.  
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Matrix solution: 10 mg α-cyano-4-hydroxy-cinnamic acid (Sigma) 
400 µl acetonitrile 
600 µl 0.1 % trifluoric acid 
 
5.7.4. Precipitation of proteins 
Proteins were precipitated by addition of ice-cold trichloric acid in acetone to a final 
concentration of 10 %. The suspension was incubated on ice for 2 hours or alternatively over 
night at 4°C. Precipitated proteins were pelleted by centrifugation (4000 × g, 15 min, 4°C), 
and washed twice with ice-cold acetone p.a. The pellets were dried and resuspended in 50 – 
200 µl of 0.1 M PB (5.6.11.3.)  
5.8. Determination of cell-associated hyaluronic acid capsule 
Hyaluronic acid capsule was determined as essentially described by Schrager et al. (1996). 
Bacteria were grown in THY medium to the required growth phase, dilutions were plated 
onto blood agar, and bacteria were pelleted by centrifugation (4500 × g, 10 min, RT), washed 
twice with distilled water, and resuspended in 500 µl dH2O. 1 volume of chloroform was 
added to the suspension, incubated for 1 h at room temperature, and the phases were separated 
by centrifugation (17000 × g, 15 min, RT). To 200 µl of the hyaluronic acid-containing 
aqueous phase 1 ml of Stains-all solutions was added, incubated for 5 min at RT, and the 
optical density was determined at 640 nm. The amount of capsule was determined by 
comparison of the optical density to known concentrations of hyaluronic acid (Sigma), and 
expressed as fg/cfu by dividing the amount of capsule by bacterial counts.  For determination 
of capsule from single colonies, bacteria grown on blood agar plates were directly 
resuspended in water and chloroform was added to the solution.  
 
Stains-All Solution: 10 ml Formamide 
 10 ml distilled water 
 4 mg Stains-All (ICN) 
 4 µl Acetic acid 
 
5.9. Measurement of cysteine protease activity 
Activity of the streptococcal protease SpeB was determined as described by Collin and Olsén 
(39). Bacteria were grown in 10 ml broth over night, pelleted (4.500 × g, 10 min, RT), and an 
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equal volume of activation buffer was added to the supernatant. The suspension was 
incubated for 30 min. at 40°C, and 20 ml of azocasein (Sigma) (2% in activation buffer) was 
added. After repeated incubation at 40°C for 30 min, the suspension was TCA precipitated 
(15 % final), centrifuged at 15.000 × g for 5 min, and the absorbance of the supernatant was 
determined at 366 nm. A higher absorbance corresponded to a higher SpeB activity. 
 
Activation Buffer: 1 mM EDTA 
20 mM DTT 
dissolved in 0.1 M NaAc-Hac Buffer, pH 5 
 
NaAc-Hac Buffer: 
 
400 ml distilled water 
3 ml Acetic acid 
4.1 g Sodium acetate 
adjust to pH 5 and add up to 500 ml. 
 
5.10. Binding of whole bacteria to radiolabelled fibrinogen 
Labelling of human fibrinogen (Calbiochem) was performed as described by Hunter and 
Greenwood (103), using the chloramine-T method. This method is based on the iodisation of 
tyrosine residues of a given protein. Fibrinogen was dissolved in PBS (5.7.2.2.) to a final 
concentration of 2 mg/ml, and 200 µl of the suspension was transferred to siliconized tubes. 1 
mCi carrier-free 125iodine (Amersham) was added and the reaction was started by addition of 
20 µl of chloramin-T (1 mg/ml in 0.2 M PB2). After incubation at RT for 1 min, the reaction 
was stopped with 20 µl of sodiumdisulfite (1 mg/ml). The solution was filled-up to 2.5 ml 
with PBST (5.7.3.2.) and excessive radioactivity was removed by filtration using a PD-10 
gelfiltration column (Amersham). Radioactively labelled protein was eluted with 3.5 ml 
PBST.  
Bacteria used in the assay were grown to stationary phase in THY, pelleted by centrifugation 
(4500 × g, 10 min, RT), washed twice with PBST (5.7.3.2.), and resuspended in 500 µl of the 
same buffer before adjusted to a transmission of 10 %, which equals a bacterial number of 
approximately 5 × 108 cfu/ml. Binding assays were conducted in triplicates with ≈ 1.25 × 108 
cfu in 250 µl PBST. Bacteria were incubated with 300 – 600 ng of 125I-labelled fibrinogen, 
incubated for 45 min at RT, washed twice with PBST, and the remaining activity present in 
the pellet was measured in a γ-counter (Wallac 1415, Perkin Elmer). Results represent the 
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percentage of retained activity compared to the initial amount added.  
Dr. Katrin Dinkla carried out the radioactive labelling, as well as binding studies.  
 
PB2, pH 7.6 15.5 ml 0.2 M NaH2PO4 
 84.5 ml 0.2 M Na2HPO4 
5.10. Phagocytosis Assays 
5.10.1. Lancefield Bactericidal Assay 
In order to assess the bacterial ability to survive in whole human blood, a standard 
bactericidal assay for S. pyogenes, described by Lancefield (126) was used. Bacteria were 
grown over night in THY broth, diluted 1/15 in fresh medium, and grown until mid-
logarithmic growth phase (OD at 600 nm of  0.5). After pelleting by centrifugation (4500 × 
g, 10 min, RT) and two washing steps with PBS (5.7.2.2.), bacteria were resuspended in 500 
µl of PBS and adjusted to approximately 105 cfu/ml. For determination of the exact initial 
inoculum size, serial dilutions in PBS were plated onto blood agar plates, and 100 µl of the 
105 suspension were added to 900 µl of fresh, heparinized human blood from non-immune 
donors and incubated at 37°C for 3 h while rotating. Afterwards, 1 ml of distilled water was 
added for lysis of human blood cells, and dilutions of the suspension were plated onto blood 
agar plates for determination of bacterial counts. Bacterial killing was determined by 
comparing the number of viable bacteria after incubation with the number of viable bacteria 
contained in the original inoculum using the following equation: 
  
cfu × ml-1 after 3h / cfu × ml-1 initial inoculum 
 
5.10.2. In vivo Phagocytosis Assay 
5.10.2.1. Determination of bacteria-associated phagocytic cells 
For determination of bacterial phagocytosis in in vivo situations, a method described by 
Goldmann et al. (78) was applied. S. pyogenes was prepared as described in 5.10.1., and 
adjusted to an inoculum of approximately 5 × 108 cfu/ml. Fluorescence-labelling of bacteria 
was performed by addition of fluorescein-isothiocyanate (FITC; Molecular Probes) to a final 
concentration of 0.2 mg/ml. The suspension was incubated for 30 min on ice; two washing 
steps in 2 volumes PBS (5.7.2.2.) were performed for removal of excessive dye, and the pellet 
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was resuspended in 5 × of the initial volume of PBS, yielding a concentration of 1 × 108 
cfu/ml. 500 µl of this suspension was injected intraperitoneally (i.p.) into 8-15 week old 
inbred C3H/HeN female mice (Harlan-Winkelmann), a control group was injected with the 
same amount of unlabelled bacteria to confirm that the association of bacteria with phagocytic 
cells was not due to an artefact caused by the labelling procedure. For assessing phagocytosis 
by macrophages, the infection was stopped after 30 min, whereas for PMN-mediated 
phagocytosis, the incubation period was extended to two hours. Then, i.p.-lavage was 
performed with 3 × 5 ml of PBS (1 % BSA) per mouse. Cells were pelleted by centrifugation 
(500 × g, 10 min, RT), resuspended in 0.5 ml RPMI medium (Difco) supplemented with 
gentamycin at 100 µg/ml for killing of extracelllular bacteria, and anti-mouse CD16/CD32-α-
FcγIII (1 µg/ml final; Becton Dickinson) was added in order to block the Fc-receptor on 
isolated cells. After 5 min incubation on ice, either RB6+ cells (PMNs) were labelled by 
addition of phycoerythrin-conjugated mouse anti-Ly6G (clone RB6-8C5); 1 µg/ml final, 
Becton Dickinson), or F4/80+ cells (macrophages) were labelled with phycoerythrine-
conjugated mouse anti-F4/80 (1 µg/ml final, Serotec). After additional incubation on ice for 
30 min, flow-cytometric analysis was performed with a FACScan (Becton Dickinson) using 
CellQuest Pro Software of the same company, phagocytic cells were gated according to their 
F4/80 or RB6 expression (red fluorescence), macrophages/PMNS associated with bacteria 
were gated according to the additional presence of FITC (green fluorescence).  
5.10.2.2. PMN- and Macrophage Killing Assay  
In order to assess survival of bacteria located within phagocytic cells, six C3H/HeN female 
mice were treated with 1 mg carrageenan in PBS (Sigma, type IVλ), which was injected i.p. 
two days prior to infection, leading to depletion of macrophages and increase of PMNs within 
the intraperitoneal cavity (78). For infection, bacteria were prepared as described above, but 
no fluorescence labelling was performed. Three macrophage-depleted animals, as well as 
three non-treated mice per group were infected i.p. with 5 × 107 bacteria, the incubation 
period for macrophage-associated phagocytosis was 30 min, for PMN-mediated phagocytosis 
1 hour, since due to the macrophage depletion PMNs were already present in the 
intraperitoneal cavity. Lavage was performed as described above, cells from all animals per 
group were pooled, pelleted, resuspended in 3 ml of RPMI medium, the amount of 
macrophages and PMNs was quantified by counting using a Neubauer chamber (Assistent), 
and cells were transferred to a poly-L-lysine coated (100 µg/ml) flat-bottomed 4-well cell 
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cultivation dish (Nunc) with approximately 5 × 106 cells per well. For killing of extracellular-
located bacteria, gentamycin (100 µg/ml final) was added to each well and incubated for 1 
hour at 37°C and 5 % CO2 atmosphere. In order to assess the amount of intracellularly 
located, viable bacteria at time-point zero, half of the wells were washed twice with PBS and 
cells were lysed by addition of 250 µl PBS (0.025 % Triton-X-100). Serial dilutions of this 
suspension were plated onto blood agar. After additional incubation for 2 hours, the other half 
of the wells were treated as described above, bacteria were plated and the survival rate was 
determined using the following equation: 
 
cfu × ml-1 after 2h / cfu × ml-1 after gentamycin treatment 
 
5.11. Double-immune fluorescence 
For visualization of intra- and extracellularly located bacteria, cultivation of cells obtained 
from infected mice was performed on sterile cover slips (Nunc) that were either non-treated 
(for macrophages) or in the case of PMN-cultivation, poly-L-lysine-treated (100 µg/ml; 
Sigma). Cells were seeded and incubated as described in 5.10.2.2., washed twice with PBS, 
and fixed by addition of 3.7 % formaldehyde (Sigma) in PBS. For double immune-fluorescent 
staining, coverslips were rinsed twice with 500 µl PBS per well, and unspecific binding of 
antibodies was blocked by incubation in 200 µl PBS (10 % FCS) for 30 min. Extracellular 
bacteria were labelled by a 30 min. incubation period at RT with an rabbit anti-GAS 
polyclonal antibody (1:100 in PBS/10 % FCS; Molinari et al., 1997), followed by 2 washing 
steps with PBS and addition of goat anti-rabbit IgGs, Alexa-green conjugated (1:300 in 
PBS/10 % FCS, Sigma), which was incubated for 45 min at RT. Cells were washed twice 
with PBS and permeabilized for 5 min by addition of PBS/FCS with 0.1 % Triton-X-100. 
After two additional washing steps with PBS, intracellularly located bacteria were labelled by 
a repeated incubation with the anti-GAS antibody, followed by an 1 hour incubation with goat 
anti-rabbit IgGs, Alexa-red conjugated (1:200 in PBS/10 % FCS, Sigma). Cells were 
repeatedly washed with PBS and the coverslips were embedded in Moviol (Sigma), 
supplemented with anti-fade reagent N-propyl-gallate (Sigma) in a ratio of 2:1. The 
fluorescent images were obtained with a confocal laser-scanning microscope (Bio-Rad). 
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Moviol: 20 g Moviol  
80 ml PBS, pH 7.3; dissolve over night 
40 ml glycerol; dissolve over night 
Centrifuge 1h  at  20000 × g 
add 0.01M Sodiumazide to supernatant, store at 4°C. 
 
N-propyl-gallate: 
 
0.1 M N-Propyl-Gallate  
dissolved in glycerol:PBS in a ratio 9:1 
5.12. Mouse model of infection 
5.12.1. Preparation of the inoculum 
For mouse infections, a model described by Toppel et al. (213) was used. Bacteria were 
grown over night in THY broth, diluted 1/15 in fresh medium, and grown to an optical density 
of 0.3 – 0.4 at 600 nm (early logarithmic growth phase). After pelleting by centrifugation 
(4500 × g, 10 min, RT) and two washing steps with PBS, the inoculum was adjusted to 2.5 × 
109 cfu/ml in PBS (7.2.2.). Since the bacterial number in this inoculum is higher than in 10 % 
transmission suspension (5 × 108 cfu/ml), the inoculum had to be prepared from the 
concentrated bacterial suspension using the following calculation: 
 
 
 
 
 
For each single animal experiment, the initial inoculum was determined by plating dilutions 
onto blood agar plates.  
5.12.2. Mouse infection  
For the infection, 8-15 week-old inbred C3H/HeN female mice (Harlan-Winkelmann) were 
shaved on their backs using an Akku shaver 8000 AD (Albrecht GmbH & Co), and inoculated 
with 100 µl of the inoculum (referring to 2.5 × 108 bacteria per mouse), which were injected 
subdermally. For determination of the survival time, 5 - 10 mice per group were monitored 
for a period of 8 days.  
In order to assess the dissemination of bacteria to systemic organs as well as bacterial growth 
within the animals, 15 mice per group were infected and blood, liver, and spleen from 5 
animals per group were taken at 24, 48, and 72 hours postinfection. Liver and spleen were 
x µl suspension/3 ml PBS = Transmission 10 % = 5 × 108 cfu/ml 
therefore: 
            (x µl/3) × 5 = 2.5 × 10
9 cfu/ml 
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homogenized in 5 ml PBS using a Polytron Handdispenser PT1200 (Kinematica), and serial 
dilutions of organs and blood were plated onto blood agar plates.  
Lesion sizes were measured according to the following equation described by Bunce et al. 
(1992): 
  
 A = pi (L × W) / 2 
   With A = area; L = length; W = width 
 
All animal infections were approved by the animal committee of Lower Saxony (Animal 
permit No. 509.42502/07-06-01)  
5.13. Field-emission scanning-electron microscopy (FESEM) 
For electron-microscopic imaging, bacteria were incubated in 2 ml THY to a mid-logarithmic 
growth phase, washed twice with PBS (5.7.2.2.), and the pellets were resuspended in 180 µl 
PBS. 20 µl of protein A purified rabbit anti-M1 IgGs (1.8 mg/ml; refer to 5.7.2.1) were added, 
incubated at 30°C for one hour, bacteria were centrifuged at 4500 × g, and washed 3 × in 
PBS. Subsequently, the pellet was resuspended in 190 µl PBS, and colloidal protein A gold 
solution was added (15 nm in diameter, British BioCell, Cardiff), followed by a 30 min 
incubation period at 30°C. Cells were centrifuged (4500 × g, 10 min, RT), repeatedly washed 
with PBS, and fixed with 3 % formaldehyde in PBS.  
Coverslips (12 mm in diameter, Nunc) were coated for 10 min with poly-L-lysine solution 
(100 µg/ml, Sigma), washed with water and air-dried. 25 µl of fixed probes were dropped 
onto the coverslips, allowed to attach for 10 min at RT, and transferred to a 24 well plate 
(TPP) containing 800 µl of a fixing-solution. After 5 min, probes were washed twice with TE-
Buffer, and dehydrated on ice by 10 min incubation in a raising series of acetone (10, 30, 50, 
70, 90, 100 %). Probes were warmed to RT and critical-point dried using liquid CO2 
(CPD030, Balzers). Coverslips were fixed on aluminium-plates and covered with a thin layer 
of coal (MED020, Balzers). Probes were analyzed in a Zeiss field emission scanning electron 
microsope (DSM982 Gemini) at 5 kV using the Everhart-Thornley SE detector and the in-
lens secondary electron (SE) detector in a 50:50 ratio. Digital pictures were subsequently 
edited using Adobe Photoshop 6.0.  
Dr. Manfred Rohde performed all electron microscopic studies. 
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Fixing Solution: 2 % Glutaraldehyde in  
2 × TE-Buffer (5.6.1.1.), pH 6.9 
 
5.14. Computer-based data analysis 
5.14.1. DNA analysis 
S. pyogenes DNA sequences were obtained from the annotated genomes for S .pyogenes M1, 
M3, and M18 (http://www.ncbi.nlm.nih.gov/genomes/MICROBES/Complete.html). For 
editing sequences, the program Edit Sequence, and for analysing sequences SeqManII, both 
from DNA STAR, were used. Determination of the percentage of guanines and cytosines 
within a DNA sequence was conducted using the program GEECEE 
(http://bioweb.pasteur.fr/seqanal/interfaces/geecee.html), possible transcriptional stops 
characterized by inverted repeats were predicted using the program Palindrome 
(http://bioweb.pasteur.fr/seqanal/interfaces/palindrome.html). Oligonucleotides were selected 
with the program Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/ primer3_www.cgi; 187). 
DNA sequences were compared to other databases using the National Center for 
Biotechnology Information’s (NCBI) program BLAST 
(http://www.ncbi.nlm.nih.gov/BLAST; 4). A six-frame translation of DNA sequences into 
protein sequences was performed with the program Sixframe at BCM searchlauncher 
(http://searchlauncher.bcm.tmc.edu/seq-util/Options/sixframe.html). All cloning experiments, 
as well as prediction of restriction sites within DNA sequences, were planned using Clone 
Manager version 6 (Sci Ed Central).  
5.14.2. Protein analysis 
For the prediction of possible transmembrane domains within histidine kinases, the program 
TM-predict at http://www.ch.embnet.org/software/TMPRED_form.html was used (94). 
Scanning of proteins for helix-turn-helix motifs was accomplished using “Helix-turn-helix 
predictor”, which is accessible at http://www.es.embnet.org/Services/ MolBio/hth.html; 53). 
Multiple protein sequence alignments were conducted using the program Multi-align 
accessible at BCM search launcher (http://searchlauncher.bcm.tmc.edu/multi-align/multi-
align.html). For identification of proteins according to their mass, the program Mascot 
(Matrix Science) was used, and for prediction of secondary protein structures,  
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5.14.3. Statistical analysis 
For comparison of multiple independent experiments and determination of significant 
differences, the student’s t-test and R-squared test was performed using the program 
STATGRAPHICS PLUS. Results where p ≤ 0.05 were considered statistically significant. 
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7.1. Oligonucleotides 
Tab. 15: Oligonucleotides for amplification of two-component system regions  
Name Access. No. Position 
 
Length 
(Bases) 
Sequence 5’→3’ 
FasA/1 fwd AE006491 4703-4726 23 CGTGGTATCGGCCTTTCTAATGC 
FasA/2 rev AE006491 5669-5645 24 GAAGTTGCCGATTGCTGAATAACC 
FasA/3 rev AE006491 5154-5128 43 CCGGGCAATTGCCCGGGTTGACCAATGCTA
AATCCTAAGACAGC 
FasA/4 fwd AE006491 5203-5235 47 GCCGCGCCTAGGCGCCCAATATTTTATCTG
TTTAGCTACATTTTCAG 
FasBCA_chr_fwd2 AE006491 4534-4557 23 TTTTTGTGATAACGCCATTGAGG 
FasBCA_chr_rev2 AE006491 5898-5878 20 AGGACGTCTACTGCCTTTGG 
CovR/1 fwd AE006498 2595-2624 29 TTTCTGGGAGAAAAAGATAGATTAAGAGG 
CovR/2 rev AE006498 3546-3520 26 AAATTAGAGTCCACCTCAGAAAGACG 
VicR/1 fwd AE006510 3873-3900 27 TCATTGTCAATTAGGCTGAATTTTTGG 
VicR/2 rev AE006510 4917-4888 26 CCATTAACTCAATGTCTGCTTTTTCG 
RR04/1 fwd AE006537 2897-2921 24 TGATGTTACCATGCAAACCATTCG 
RR04/2 rev AE006537 3993-3969 24 GCCTTTTTCTTCCCCAGACTTAGC 
HK05/1 fwd AE006550 8467-8496 29 AGACTTGTTTTGATGAAAAACGTAGTAGC 
HK05/2 rev AE006550 9461-9434 27 CGAGAGATCGCACTCATATCTCTAACC 
SrtR/1 fwd AE006552 2725-2749 24 AAAGAAATGATTCCTGCCGCTTAC 
SrtR/2 rev AE006552 3752-3725 27 TTCTTTAGATAAATATTTTCCTTCCATAGC 
HK07/1 fwd AE006553 13537-
13513 
24 AAGCTAGCAGGTCATTTCTTATCG 
HK07/2 rev AE006553 12557-
12580 
23 AAATAATATGGCCTCGGTGATCG 
HK07/3 rev AE006553 13063-
13085 
38 CCGGGCAATTGCCGGGGACTTTCCTAAAGT
GCCCTTGG 
HK07/4 fwd AE006553 13041-
13017 
39 GCCGCGCCTAGGCGCGTTTGACGGTGACAA
ACAGATTGG 
TCS07_chr_fwd2 AE006554 111-86 26 TGAAACAACCTCCTTTAGTGATAAGG 
TCS07_chr_rev3 AE006553 12284-
12309 
25 ATTCTTGGTATTTCTCTTGCTCTCC 
RR08/1 fwd AE006564 44-15 28 TCCATAGTTTAATTCAAAAGGAGATTGC 
RR08/2 rev AE006563 9404-9425 21 AACGCCAAACCGCATAATCTG 
HK09/1 fwd AE006588 3912-3889 23 GGCAAGCTATTGGAAGCTTACGG 
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HK09/2 rev AE006588 2910-2930 20 GCGGTTCTCCTGTCACAACG 
HK09/3 rev AE006588 3467-3447 36 CCGGGCAATTGCCGGGGCATAGCCTGACAC
CGCATC 
HK09/4 fwd AE006588 3403-3381 37 GCCGCGCCTAGGCGCTGAAGTGGCCTATGA
TGCGAAC 
TCS09_chr_fwd AE006588 4096-4071 25 TTGGTGTTCAATCTGTCTATCAACC 
TCS09_chr_rev AE006588 2699-2723 24 AAGCTATTGATGCAGTAACGAAGG 
HK10/1 fwd AE006590 9664-9641 23 CGGAGCTCTAGTCTTTTGCTTGG 
HK10/2 rev AE006590 8615-8635 20 ACAAATCGCCTGCTGCAACC 
HK11/1 fwd AE006593 10533-
10511 
22 ACTATTGCCGGAAATGTTGAGG 
HK11/2 rev AE006593 9621-9648 27 CCATAACTCAAATCCCTTACCTGATCC 
HK11/3 rev AE006593 10090-
10112 
38 CCGGGCAATTGCCGGGTTGCAATTCGTTTG
CGCTCTTG 
HK11/4 fwd AE006593 10072-
10048 
39 GCCGCGCCTAGGCGCGTCAGTCAAGAGCTA
TTCGCTTCG 
TCS11_chr_fwd1 AE006593 10921-
10900 
21 CAAAAAGAAGAATCGCTTTGC 
TCS11_chr_rev2 AE006593 9504-9524 22 TCGTCATCTCCCTTCACTATCG 
SalK/1 fwd AE006616 2531-2508 23 TGACATTGCGGTTAGTGACATCC 
SalK/2 rev AE006616 1583-1607 24 CACTAGACAAAACAACGTGCTTGC 
RR13/1 fwd AE006624 9496-9472 24 TGACCCTTTGATGTCATCCTTAGC 
RR13/2 rev AE006624 8508-8531 23 GGAGCTGCAAGGAAGGATAGAGC 
RR13/3 rev AE006624 9009-9031 38 CCGGGCAATTGCCGGGTTGCCAATAGACGC
TATGTTCG 
RR13/4 fwd AE006624 8971-8944 42 GCCGCGCCTAGGCGCTTATTGATTATTTAG
CAAAACGTCACC 
TCS13_chr_fwd1 AE006624 9731-9710 21 TTGCTAGGTGGTGTGATAGGG 
TCS13_chr_rev2 AE006624 8355-8376 21 CGGGTTGAAGTGAAGATTGCC 
* Complementary overhangs are underlined once, integrated restriction sites are double-underlined. 
 
Tab. 16: Oligonucleotides used for amplification of DIG-labeled DNA probes  
Name Access. 
No. 
Position 
 
Length 
(Bases) 
Sequence 5’→3’ 
hasA_1 (long) AE006637 617-636 20 TCGAAACGTTATCGTTCACC 
hasA_2 (long) AE006637 1193-1214 20 AGTCCATAAGGCAACGATGG 
sic1_long AE006624 1121-1140 20 CATCACGCAATTTTGACTGG 
sic2_long AE006624 323-343 21 CGTTGCTGATGGTGTATATGG 
malP1_long AE006554 151-170 20 CTGAGCATTCAAAAGCATGG 
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malP2_long AE006554 837-856 20 TTAACCAGTTGCCCTTGACC 
rpsL long fwd AE006493 8546-8570 25 CAATTAACCAGTTGGTACGTAAACC 
rpsL long rev AE006493 8933-8952 20 TTATCCTTTTGGACGTTTCG 
rpsB 1  AE006629 7715-7734 20 AGAGCGTAACGGTATCCACG 
rpsB 2 AE006629 8295-8314 20 GCAACGTCTGCATCTTCACC 
Spc_1 (fwd) M69221 1-21 38 CCCGGCAATTGCCCGGATCGATTTTCGTTC
GTGAATAC 
Spc_2 (rev) M69221 1100-1121 37 GCGCCTAGGCGCGGCCCAATTAGAATGAAT
ATTTCCC 
Emm1_Bam AE006624 2745-2766 22 CGGGATCCAACGGTGATGGTAATCCTAGGG 
Emm2_Sal AE006624 1527-1556 30 CACCTGTTGAGTCGACCTGTCTCTTAGTT 
MalE FOR AE006554 1940-1959 20 TGTTTTCCATGACGATCAGC 
MalE REV AE006554 2437-2458 21 CCCCTAAAAATACCTGGAAAGG 
* Complementary overhangs are underlined once; integrated restriction sites are double-underlined. 
 
Tab. 17: Oligonucleotides used for sequencing studies 
Name Access. 
No. 
Position 
 
Length 
(Bases) 
Sequence 5’→3’ 
FasA/1 fwd AE006491 4703-4726 23 CGTGGTATCGGCCTTTCTAATGC 
HK09/1 fwd AE006588 3912-3889 23 GGCAAGCTATTGGAAGCTTACGG 
HK11/1 fwd AE006593 10533-10511 22 ACTATTGCCGGAAATGTTGAGG 
irr_Seq AE006624 9312-9332 21 CAAGCTGCCTTAGACAAGTGG 
pQE fwd   21 TTTGCTTTGTGAGCGGATAAC 
rr7_Seq AE006553 133350-
13331 
20 AAATCAGGAAACCCATTTGC 
 
Tab. 18: Oligonucleotides used for amplification of overexpression-constructs 
Name Access. No. Position 
 
Length 
(Bases) 
Sequence 5’→3’ 
Emm1_Bam AE006624 2745-2766 22 CGGGATCCAACGGTGATGGTAATCCTAGGG 
Emm2_Sal AE006624 1527-1556 29 CACCTGTTGAGTCGACCTGTCTCTTAGTT 
* integrated restriction sites are double-underlined. 
 
Tab.19: Oligonucleotides used for amplification of inserts in vectors 
Name Length (Bases) Sequence 5’→3’ 
pQE fwd 21 TTTGCTTTGTGAGCGGATAAC 
M15 Universal 22 GTAAAACGACGGCCAGTGAATTG 
M15 Reverse 27 CAATTTCACACAGGAAACAGCTATGAC 
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7.2. Abbreviation/Acronym list 
 
ACN Acetonitrile 
Amp Ampicillin 
AP Alkaline phosphase 
ATP Adenosine-5’-triphosphate 
BCIP 5-Bromo-4-Chloro-3-Indoxyl-Phosphate 
bp Basepair 
BSA Bovine serum albumin 
CD Critical determinant 
CDM Chemically defined medium 
cfu Colony-forming units 
DEPC Diethylpyrocarbonate 
dH2O Distilled water 
DIG Dioxygenin 
DMSO Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DNase Desoxyribonulcease 
dNTP Desoxyribonulceotide-5’-phosphate 
ds Double-stranded 
EDTA Ethylenediamine-tetra-acetic acid 
Erm Erythromycin 
FACS Fluorescence-assisted cell sorting 
FITC Fluorescein-isothiocyanate 
h Hour 
HK Histidine kinase 
HRP Horseradish peroxidase 
i.p. Intraperitoneal(ly) 
Ig Immunoglobulin 
IPTG Isopropyl-β-D-thiogalactopyranoside 
Kan Kanamycin 
LB Luria-Bertani 
MALDI Matrix assisted laser desorption/ionization 
min Minute 
MOPS 4-Morpholinepropanesulfonic acid 
NBT Nitrobluetetrazoliumchloride 
OD Optical density 
PAGE Polyacrylamide gelelectrophoresis 
PBS Phosphate-buffered saline 
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PCR Polymerase Chain Reaction 
PEG Polyethylenglycol 
PMN Polymorphonuclear leukocyte 
PMSF Phenylmethansulfonylfluorid 
RNA Ribonucleic acid 
RNase Ribonuclease 
RR Response regulator 
RT  Roomtemperature 
SDS Sodiumdodecylsulfate 
sec Second 
SLO Streptolysin O 
SLS Streptolysin S 
Spc Spectinomycin 
TCA Trichloric acid 
TCS Two-component system 
TEMED N,N,N’,N’-Tetramethylendiamin 
TOF Time-of flight 
Tris Trishydroxymethylaminomethan 
U Units 
UV Ultraviolett light 
v/v Volume per volume (volume percentage) 
w/v Weight per volume (weight percentage) 
WT Wildtype 

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